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vi 
Abstract 
 
In 2006, Baker reported the isolation of palmerolide A (14), a polyketide 
derived marine macrolide, from the Antarctic tunicate Synoicum adareanum 
collected in the shallow waters surrounding Anvers Island. This unique 
macrolide displayed potent levels of cytotoxic activity in the human 
melanoma cell lines (UACC-62, LC50 = 18 nM and M14 LC50 = 76 nM), 
while also inhibiting V-ATPase with an IC50 of 2 nM. There have been eight 
further palmerolides isolated from Synoicum adareanum, which have been 
shown to possess cytotoxicity activity. The synthetic route devised 
(Scheme A), was a convergent approach synthesising palmerolide A (14) 
from three key subunits (91, 92 and 93), which could be coupled via a Horner-
Wadsworth Emmons to give the C1-C14 subunit 94 followed by a Julia-
Kocienski olefination and formation of the macrolcycle 90. This approach 
offers both flexibility and convergence as alterations to the subunits would 
give access to other members of the palmerolide family and their analogues; 
as using the C15-C23 subunit (95) instead of the C15-C24 subunit (93) would 
give rise to palmerolide E (18). This thesis details the synthesis of these key 
fragments and efforts towards their coupling. The C1-C14 subunit synthesis is 
detailed in chapter 2; chapter 3 and 4 detail the synthesis of thr C15-C23 
subunit (95) for palmerolide E (18) and the C15-C24 subunit (94) for 
palmerolide A (14) respectively. Chapter 5 describes the unsuccessful Julia-
Kocienski olefination between the C1-C14 subunit (94) and the C15-C24 
subunit (95) 
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viii 
Compound Numbering 
 
All compounds intended towards the total synthesis of palmerolide A (14) 
will be numbered according to the carbon chain of the natural product. This 
numbering is given on the structure. 
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The naming of the compounds in the experimental chapter uses IUPAC 
convention. 
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1 
Introduction 
 
1.1: Natural products in drug discovery 
 
Nature has proven to be an extensive resource of structurally diverse 
secondary metabolites that can be isolated from both terrestrial and marine 
sources. Many of these secondary metabolites possess important functions 
directed to their host organism’s continual survival by acting as a defence 
against predators, parasites, diseases and also facilitating their reproductive 
processes.1 Due to this, secondary metabolites often exhibit unique and potent 
biological properties such as antibiotic, antifungal, cytotoxic and pesticidal 
activity, which can provide an extremely large library of potential lead agents 
for both pharmaceutical and agrochemical development.2 
 
The use of natural products in the search for biologically active compounds is 
a powerful method for the identification of lead compounds in the drug 
discovery process. To date 60–70% of pharmaceuticals in clinical use have 
natural product origins, from the pain killing drugs of morphine (1) and 
aspirin (2) to various anticancer agents of which 47% originate from natural 
products, with one of the most well known being Taxol (3) (Figure 1.1), 
which was isolated from the bark of the Pacific yew tree, Taxus brevifolia.3,4,5 
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Figure 1.1: Structures of morphine (1), aspirin (2) and Taxol (3).  
 
Biologically active natural products can arise from many different sources. 
One area playing an ever-increasing role are compounds isolated from marine 
extracts.6 Two of the first notable discoveries from marine extracts were 
spongouridine (4) and spongothymidine (5), isolated by Bergmann from the 
Caribbean sponge Crypotheca crypta in the early 1950s (Figure 1.2).7 These 
showed that for a nucleoside to have biological activity it did not require 
ribose or deoxyribose as the sugar unit and the base also could contain 
differing heterocycles.  
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Figure 1.2: Structure of spongouridine (4) and spongothymidine (5). 
 
Due to the low abundance of many of these natural products, extraction from 
natural sources is often not practical, and as a result total synthesis remains 
the most viable option. Synthesis of natural products began in 1828 with the 
synthesis of urea (6) by Wöhler.8 Total synthesis has developed since then, 
through the continual development of new technologies and techniques for the 
 
3 
determination of compound structures and with the development of new 
reaction methodology. Now it is possible to synthesize highly complex 
molecules with many different stereocentres and functional groups such as 
dictyostatin (7) and erythronolide B (8, Figure 1.3).9,10 
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Figure 1.3: Structure of urea (6), dictyostatin (7) and erythronolide B (8) 
 
1.2: Classification of marine macrolides 
 
Polyketides are secondary metabolites, which often display anticancer, 
antibiotic, antifungal, immunosuppressant and other biological properties. 
They have a generic 1,3–hydroxyl motif containing alternating carbonyl and 
methylene groups and are commonly biosynthesized via decarboxylative 
condensation of malonyl-CoA extender units via a Claisen condensation.11 
The polyketide chains are assembled by multi-domain polyketide synthase 
enzymes (PKS’s).  
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One of the most prominent classes of polyketides are the macrolides. 
Macrolides are a class of compounds characterized by a macrocyclic lactone 
ring acting as a conformational constraint, which can be adorned with many 
stereocentres and a range of functional groups.12 These compounds can be 
isolated from a variety of sources and possess a diverse range of biological 
properties. Many marine macrolides, such as the spongistatins (9-13, Figure 
1.4) have been shown to be potent against cell growth in numerous cancer cell 
lines, which has led to their development as possible lead structures in the 
discovery of new anticancer agents.13  
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Figure 1.4: Structure of spongistatins 1-6 (9-13) 
 
The study of how these macrolides interact with their corresponding protein 
targets could help provide many new opportunities in finding novel cancer 
treatments. As there is a low natural abundance of these macrolides, large 
scale harvesting is neither practical due to the associated financial costs nor 
ecologically acceptable.14 Therefore practical synthetic routes, in principal, 
have the most potential for supplying sufficient quantities of natural products 
to further investigate their activity and mode of interaction with their 
corresponding proteins. Due to their complex structures, synthesis still 
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presents a formidable challenge; in some cases the structure possesses in 
excess of thirty stereocentres, they can contain many di- or tri- substituted 
double bonds, and unusual structural motifs.  
 
Total synthesis is also important for confirming, or in some cases determining 
the absolute and relative configuration of the target natural product. The 
common spectroscopic and crystallographic methods used to determine 
natural product structure may not have been able to fully assign the molecule 
or may have mis-assigned the relative and absolute configuration. The 
synthetic strategy devised must also be able to deliver sufficient quantities of 
pure material to enable further preclinical testing and biological evaluation, 
while also being flexible enough to allow access to structural analogues.  
 
1.3: The palmerolides 
 
1.3.1: Isolation of the palmerolides 
 
Antarctica is one of the least accessible marine environments, due to its 
extreme isolation and severe climate. Predation and competition are the 
dominant forces that determine the species composition and distribution of 
such an ecosystem. Antarctica is home to many distinct organisms that 
produce novel secondary metabolites, possessing unique molecular structures 
with distinctive biological properties, essential for survival in this harsh 
environment. Its seas sustain a largely unexplored indigenous population of 
fauna and algae, due to the Antarctic polar front isolating this marine 
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ecosystem, for over 20 million years.15 During this time the Antarctic biota 
has evolved in a relatively stable system without the influence from other 
habitats. Due to this isolation, the Antarctic seas offer a unique collection of 
compounds, isolated from fauna that have evolved differently to organisms 
from more temperate climates. These species flourish in cold seas and have 
also developed unusual chemical defences to combat predators. Antarctic 
organisms are therefore of great interest in the search for novel compounds.16 
 
In 2006, Baker and co-workers isolated the palmerolide family from the 
circumpolar tunicate Synoicum adareanum, which is found in the shallow 
waters near Palmer station on Anvers Island.17 This family consists of nine 
polyketide-derived macrolides termed palmerolide A-H and K (14-22, Figure 
1.5).18 
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Figure 1.5: Palmerolide A-H and K (14-22) 
 
Structurally each of the nine palmerolides A-H and K (14-22), are similar, 
each bearing a 20-membered macrolide, containing four E-olefins and four 
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stereocentres. Palmerolide A (14) bears an unsaturated N-acyl dienamide side 
chain bearing another stereocentre attached at C-19, whereas palmerolide E 
(18) supports a truncated C-19 enal side chain. The gross structure of 
palmerolide A (14) was assigned using a number of analytical techniques, 
including MS, and NMR spectroscopy.  
 
Palmerolide D-G (17-22) are all presumed to have the same relative and 
absolute configuration as palmerolide A (14), assuming a common biogenesis. 
Palmerolide D (17) has been shown to bear an extended enamide side chain 
with the same macrolide core as palmerolide A, whereas palmerolide F (19) is 
a tautomer of palmerolide A (14) bearing the C29-C30 olefin at the C30-C32 
terminus. Palmerolide G (20) is a geometric isomer of palmerolide A (14) 
with the (Z)-C23-C24 olefin. Palmerolide B (15) and H (21) both contain a 
carbamate moiety at C7 and a sulfonate at C11. Palmerolide K (22) contains 
the same structural variations as palmerolide C (16) in the macrolide core with 
hydroxyls at C8 and C9 and the carbamate at C10, but like palmerolide E (18) 
it lacks the enamide side chain while supporting a C19 enal side chain. 
 
1.3.2: Structure of palmerolide A 
 
Baker and co-workers attempted to establish the configuration of the C7 and 
C10 stereocentres through Mosher ester analysis,19 where the (R)- and (S)-
MTPA esters of palmerolide A showed both the C7 and C10 to convey the (R) 
configuration which was later shown to be incorrect. The C11 stereocentre 
was then assigned based on the C10 Mosher ester analysis. This was achieved 
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using J-coupling based conformational analysis of the C10/C11 coupling 
constants which showed a gauche relationship between H10 and H11 based 
on the small 3JHH and large 2JCH for both H10/C11 and H11/C10 relationships 
(Figure 1.6).20  
 
C10/C11
3JHH (Hz) 2JCH (Hz)
H11
C12 O
H10O
C9
2.2
C11/H10: 5.5
C10/H11: 4.2
 
Figure 1.6: J-coupling based conformational analysis 
 
This method, developed by Murata and co-workers, is based on heteronuclear 
spin-coupling constants (2,3JCH) as well as homonuclear (3JHH) coupling 
constants (Figure 1.7).20 In systems with conformational flexibility, the 
observed coupling constants exist as a weighted average for each conformer, 
so the most favourable conformer will govern the result. The dihedral angle 
dependence of proton to proton coupling constants (3JHH) and the Karplus 
relationship is frequently used to aid conformational analysis. This alone is 
inadequate for confident relative stereochemical determination, as two gauche 
rotamers cannot be distinguished, thus determination of the 2,3JCH coupling 
constants is necessary for stereochemical assignment. 
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Figure 1.7: Coupling constants size dependence on dihedral angle 
 
The remote C19 and C20 stereocentres were assigned on the basis of nOe and 
ROESY correlation experiments, which was achievable due to the constraints 
placed in the macrolide by the four olefins.17  
 
The relative and absolute configuration of the five stereocentres, which was 
proposed by Baker and co-workers, was subsequently proved to be incorrect 
by De Brabander in 2007 (Figure 1.8).21 Total synthesis of the proposed 
diastereoisomer (23) showed that the synthetic compound’s 1H and 13C NMR 
spectra did not match the natural isolate. De Brabander then synthesised the 
diastereoisomer with inversion of the C19 and C20 stereocentres, which he 
believed to be the most tenuous assignments to give (24). This isomer was 
shown to have an identical NMR with the natural isolate but was found to be 
antipodal as the optical rotation and circular dichroism were essentially 
opposite, confirming the relative and absolute configuration as shown in (14).  
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Figure 1.8: Structure reassignment of palmerolide A 
 
The structural mis-assignment of the C7, C10 and C11 stereocentres by Baker 
and co-workers occurred due to a simple but common mistake in the Mosher 
ester analysis. In using Mosher acid chlorides in forming the MTPA ester, 
which under Cahn-Ingold priority gives a reversal of assignment in 
stereochemistry, so the (R)-MTPA acid chloride (25) gives the (S)-MTPA 
ester (26, Figure 1.9).19 Unfortunately, Baker and co-workers did not notice 
this not uncommon oversight and the assignments of the C7 and C10 
stereocentres were erroneously reported as (R) instead of (S). This had a 
knock on effect throughout the structure, as the assignment of the C11 
stereocentre was also reported incorrectly as J-based conformational analysis 
between the C10-C11 stereocentres was used to assign the relative 
stereochemistry. Therefore since the C10 stereocentre was mis-assigned as 
(R), the C11 was also mis-assigned as (R) when both should have been (S). 
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Figure 1.9: (R)-MTPA acid chloride (25) to (S)-MTPA ester (26). 
 
1.3.3: Structure of palmerolide C 
 
Palmerolide C (16) contains significant structural variations within the 
macrolide core compared with palmerolide A (14). Until recently the absolute 
and relative configuration of the C8, C9 and C10 stereocentres were unknown 
but after work carried out within our group and in collaboration with 
Professor Baker,22 the macrolide was shown to have the 8R, 9S and 10S 
configuration. This was achieved by comparison of the synthetic degradation 
fragments 27-30 with the natural equivalent (Figure 1.10). 
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Figure 1.10: Degradation fragments 27-30 of palmerolide C (16)  
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1.3.4: Malignant melanoma 
 
Cancer is often thought of as a single disease, with each class having the same 
mechanism of action and behaving in the same manner, which is a common 
misconception. Instead cancer is the name given to a range of specific 
illnesses caused by the body’s cells displaying unregulated growth, which 
invade and destroy healthy tissue including organs. There are over 200 
different types of cancer, which can occur from different causes and have 
differing symptoms, requiring different therapeutic strategies.  
 
One of the most common cancers is skin cancer of which there are two main 
types, malignant melanoma and non-melanoma skin cancer. Malignant 
melanoma is the less common of the two but it is significantly more serious. 
Over the last thirty years malignant melanoma incidence rates have more than 
quadrupled, rising faster than any of the other more common cancers in both 
males and females (Graph 1.1).23 In 2008 approximately 12,000 new cases of 
malignant melanoma were diagnosed in the UK, and more than 98,800 non-
melanoma skin cancers. In the same year around 2,560 people died from skin 
cancer, with 2,070 of these deaths from malignant melanoma and only around 
500 from non-melanoma skin cancer. 24 
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Graph 1.1: Incidence rates of melanoma in the UK 
 
The rates of malignant melanoma have been rising over the past thirty years, 
but due to early detection so are the survival rates which are amongst the 
highest for any cancer. The latest survival rates for malignant melanoma show 
that 81% of men and 90% of women survive the disease.25 However if it is not 
detected early enough the survival rates rapidly decrease. Patients with early 
stage melanoma (stage 0, I and IIA), when the tumours are thin and have no 
nodal spread, can be treated by surgery alone and have survival rates in excess 
of 95%.25 As tumor depth increases it becomes increasingly difficult to 
remove the entire tumor through surgery. Therefore the survival rates 
decrease, as the risk of developing nodal metastasis relates directly to tumor 
thickness. Patients with stage IIB and above melanoma are at risk of 
recurrence as there are currently no effective chemotherapies available. 
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Consequently further research into the understanding of this disease is 
required, as the process of melanoma pathogenesis is not fully understood. 
However a number of key genes and pathways have been implanted with the 
disease. It has been shown that the melanocortin receptor gene, MC1R, 
influences skin pigmentation, and polymorphisms are common within this 
gene.26 These variants have been linked to an increased risk of melanoma and 
also there is some evidence that polymorphisms in the oculocutaneous 
albinism gene, OCA2, may also increase risk.26a,27 
 
1.3.5: Bioactivity of the palmerolides 
 
Of the nine palmerolides isolated, A, C, and E (14, 16, 18) exhibited the most 
interesting biological profiles. Initial screening of palmerolide A (14) in the 
NCI 60 cell line panel revealed inhibition of human melanoma cell lines 
(UACC-62, LC50 = 18 nM and M14 LC50 = 76 nM) as well as activity against 
renal and colon cancer cell lines.18 Further screening of palmerolide A (14) 
revealed that it also inhibited V-ATPase (IC50 = 2 nM), although the specific 
binding site within the V-ATPase protein is currently unknown. 
 
The V-ATPase comprises a class of enzymes that are widely distributed 
throughout eukaryotes. These enzymes occur in many tissues of multicellular 
organisms. V-ATPases perform many diverse functions within eukaryotic 
organisms, such as receptor mediated endocytosis, intracellular targeting of 
lysosomal enzymes, protein processing and degradation and transport of small 
molecules.28 V-ATPases are proton-translocating pumps involved in the 
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regulation of pH for eukaryotic cells and are found in many intracellular 
compartments. The pumps work by transferring protons out of the cytoplasm 
into the organelle, where the hydrolysis of adenosine triphosphate (ATP) 
creates an electrochemical potential across the membrane that drives the 
transport of ions and solutes. It has been shown that V-ATPases are involved 
in the onset of diseases such as osteoporosis, diabetes, pancreatitis and 
melanoma.29 
 
Palmerolide A (14) has additionally demonstrated significant in vivo activity 
in the NCI’s hollow fibre assay. The NCI hollow fiber assay is a standard 
bioassay used by the National Cancer Institute to determine in vivo 
cytotoxicity of anticancer agents.30 The hollow fibre assay has established as a 
very efficient bioassay that can provide quantitative information of drug 
efficacy with minimum expenditures of time and materials. Palmerolide A 
(14) tested negative in COMPARE pattern recognition analyses during the 
NCI hollow fibre assay,18a suggesting a novel mode of action as its mean-
graph profiles did not reveal any significant correlations to the profiles of 
known antitumor compounds contained in the NCI’s standard agent 
database.30a 
 
Palmerolide E (18) was shown to possess similar activity to palmerolide A 
(14).18a  This information coupled with the relative instability of enamides at 
bodily pH suggests that in vivo palmerolide A (14) may be acting as a prodrug 
of the one carbon less palmerolide E (18). The similarity in activity between 
palmerolide A (14) and E (18) is believed to occur due to the C23 aldehyde in 
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palmerolide E’s acting as the unmasked enamide, suggesting the aldehyde 
performs a major role in the activity of these molecules. Palmerolide C (16) 
was also found (in the NCI 60 cell line panel) to inhibit human melanoma cell 
line UACC-62 with an LC50 = 76 nM, which suggests the macrolide core is 
important to the activity.18a 
 
1.4: Salicylihalamide 
 
In 1997, Boyd and co-workers reported the isolation of 
salicylihalamide A (31) and salicylihalamide B (32) from the marine sponge 
Haliclona, collected off the southwest Australian coast (Figure 1.11).31 The 
structure was assigned on the basis of NMR and mass spectroscopy and the 
absolute stereochemistry was assigned by Mosher esters analysis. The 
salicylihalamides represent a novel class of macrocyclic benzolactones 
incorporating salicylic acid, and decorated with a highly unsaturated N-acyl 
enamine side chain.  
 
Once again due to the failure to take into account the change of priority by the 
conversion of the Mosher’s acid chloride to the MTPA ester, the stereocentres 
at C12, C13 and C15 were assigned incorrectly.32 As a result, the 
configuration of C13 is inverted to (R) and the biologically active forms are 
assigned as (-)-salicylihalamide A (33) and (-)-salicylihalamide B (34).  
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Figure 1.11: Structure of (±)-salicylihalamide A (31 and 33) and (±)-
salicylihalamide B (32 and 34) 
 
Screening of (-)-salicylihalamide A (33) showed some promising hits and had 
a unique cytotoxicity profile in the NCI 60-cell line human tumour screen. 
The mean GI50 concentration was 15 nM across the NCI 60 cell line panel, 
with a sensitivity range of ≤ 103.31 The melanoma cell lines were shown to 
have the highest average tumour-type subpanel sensitivity (GI50 = 7 nM, TGI 
= 60 nM) and (-)-salicylihalamide A (33) has also been identified as a target 
for the V-ATPase enzyme (IC50 < 1.0 nM).  
 
Structure-activity relationships (SARs) studies carried out on 
(-)-salicylihalamide A,33 showed the side-chain analogues 35–39 all maintain 
the ability to inhibit V-ATPase, with similar concentrations to those of 33 
(Figure 1.12).33a The analogues 40 and 41 without the enamide suggest that 
the enamide side chain is irreversibly binding to the protein target, as the 
activities of these molecules are both dramatically reduced in in vitro testing. 
Smith and Zheng tested analogues 42, missing the C12 methyl and C13 
hydroxyl, and 43 missing the C9-10 olefin, C12 methyl and C13 hydroxyl, 
which both retained some activity at reduced levels from 33. From these 
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results it was hypothesised that the structure of the macrolide is important for 
activity, but not decisive.33b/c 
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Figure 1.12: Structural analogues 35–43 of (-)-salicylihalamide A 
 
Unlike other V-ATPase inhibitors (-)-salicylihalamide A (33) is able to 
discriminate between mammalian and non-mammalian V-ATPase, suggesting 
that it has a different binding site from classical V-ATPase inhibitors, such as 
bafilomycin A1 (44, Figure 1.13).34  
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Figure 1.13: Structure of bafilomycin A1 (44). 
 
With both (-)-salicylihalamide A (33) and palmerolide A (14) having a 
macrolide core bearing an enamide side chain it is not inconceivable that they 
may share a similar mode of action. This is due to the similar N-acyl enamide 
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side chain, which in the case for the former is necessary for the irreversible 
binding to the protein target. It is hypothesised that salicylihalamide inhibits 
V-ATPase via the enamide side chain forming a covalent bond with a lysine 
residue on the enzyme (Figure 1.14).34a,35 This is proposed to occur via the 
formation of an electrophilic N-acyliminium ion generated form the N-acyl 
enamide under acidic conditions, followed by attack of the active lysine 
residue. The adduct then fragments into a protein-imine complex with release 
of the amide side chain. Subsequent hydrolysis of this protein-imine complex 
could generate the aldehyde as found in palmerolide E (18). 
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Figure 1.14: Interaction of enamide side chain with protein 
 
1.5: Previous synthesis of palmerolide A  
 
To date there have been three total synthesis of palmerolide A, the first being 
completed in 2007 by De Brabander, followed by Nicolaou and Chen shortly 
after, then by Hall in 2009.21,36 There have also been several formal and 
partial syntheses completed.37 
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1.5.1: De Brabander’s synthesis of palmerolide A 
 
In 2007 De Brabander and co-workers synthesized the initially reported 
structure of palmerolide A (23) and the antipode (24) establishing the 
absolute and relative configuration. Their approach to assemble palmerolide 
A relied on a Suzuki cross-coupling reaction of vinyl iodide 45 and borane 46 
to form the C15-16 bond, followed by esterification with enoic acid 47 
(Scheme 1.1).21 Macrocyclization was to be achieved via a Horner-
Wadsworth Emmons olefination, and installation of the enamide side chain 
via a Curtius rearrangement with trapping of the isocyanate with 2-methyl 
propenylmagnesium bromide to give palmerolide A (23). 
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Scheme 1.1: De Brabander’s retrosynthesis of palmerolide A (23) 
 
In the assembly of 23, Suzuki coupling of vinyl iodide 48 and vinyl boronate 
49 using catalytic palladium (0) provided diene 50 (Scheme 1.2).38 The diene 
was esterified with carboxylic acid 47 under Yamaguchi conditions,39 which 
after removal of the TES protecting groups gave diol 51. Selective oxidation 
of the primary alcohol 51 followed by an intramolecular Horner-Wadsworth 
Emmons macrocyclization and subsequent silyl protection gave macrolactone 
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52. CBS reduction of the ketone introduced the C7 stereocentre,40 which after 
TBS protection gave 53. Ester hydrolysis of the C25-ester allowed the 
formation of acyl azide 54. Heating of acyl azide 54 promoted the Curtius 
rearrangement and treatment of the intermediate with 2-methyl 
propenylmagnesium bromide introduced the enamide side chain with high 
levels of efficiency to give 55. This allowed the introduction of the 
carbamate, which was followed by deprotection using TBAF to afford 
palmerolide A (23). The synthesis of the proposed structure of palmerolide A 
(23) was completed in a total of thirty-three steps, with a longest linear 
sequence of twenty-three steps with a 2.9% yield. 
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Scheme 1.2: Assembly of palmerolide A (23) 
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1.5.2: Nicolaou and Chen’s synthesis of palmerolide A 
 
Shortly after De Brabander completed his synthesis, Nicolaou and Chen 
completed their synthesis of the proposed structure of palmerolide A (23), and 
subsequently reported in 2008 the synthesis of the natural palmerolide A (14). 
They envisioned that they could assemble palmerolide A (14) from three 
fragments 56, 57 and 58 via a Stille coupling reaction to form the C15-16, 
esterification and a ring closing metathesis (Scheme 1.3).36a,b 
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Scheme 1.3: Nicolaou and Chen’s retrosynthesis of palmerolide A (14) 
 
The coupling of the C15-16 bond was achieved via Stille coupling between 
vinyl iodide 57 and vinyl stannane 59,41 which provided the tetraene 60 
(Scheme 1.4). The carboxylic acid 61 was esterified with the newly formed 
tetraene 60 under Yamaguchi conditions to give ester 62.39 Introduction of the 
vinyl iodide was achieved by desilylation and oxidation of the primary 
hydroxyl, followed by a Takai olefination,42 which after removal of the two 
MOM protecting groups using boron trifluoride diethyl etherate gave 63. 
Exposure of adduct 63 to Grubbs II catalyst led to formation of the desired 
macrocycle 64 and finally installation of the enamide moiety was achieved via 
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a Buchwald Cu (I)-mediated reaction to give palmerolide A (14). In the 
synthesis of palmerolide A (14) there were a total of 28 steps, with a longest 
linear sequence of fifteen steps with a 1.7 % yield. 
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Scheme 1.4: Assembly of palmerolide A (14) 
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1.5.3: Hall’s synthesis of palmerolide A 
 
In 2009, Hall and co-workers synthesised palmerolide A (14) utilising their 
organoboron chemistry to prepare fragment 65.43 They envisaged the 
synthesis of palmerolide A (14) would be achieved by coupling vinyl iodide 
66 with olefin 67, via hydroboration followed by a Suzuki coupling, then 
macrolactonisation under Yamaguchi conditions (Scheme 1.5).36c Fragment 
67 was to be accessed from pyran 65, which would originate from an Ireland-
Claisen [3,3] rearrangement on alkenyl boronate substrate 68. This strategy 
was to exploit a boronate substituent as a masked alcohol and provide the 
differentiation of the C11 hydroxyl over the C10 and C7 hydroxyls. 
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Scheme 1.5: Hall’s retrosynthesis of palmerolide A (14) 
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The synthesis of fragment 67 began with acylation of alcohol 69, followed by 
formation of the enolsilane to trigger the Ireland-Claisen rearrangement 
(Scheme 1.6),44 which was oxidised with retention of stereochemistry. The 
carboxylic acid was esterified with diazomethane to produce 70 as a single 
stereoisomer. From pyran 70 there was a further eight steps in order to obtain 
fragment 71,36c which was coupled with 66 via a Suzuki coupling to form the 
C13-14 bond giving 72. The Yamaguchi macrolactonization of 72 was 
achieved firstly by selective hydrolysis of the methyl ester, followed by 
treatment of the adduct with 2,4,6-trichlorobenzoyl chloride, DMAP and 
triethylamine to provide the macrolide 73.39 The enoate side chain was 
transformed into the enamide via a Curtius rearrangement, following the 
conditions used by De Brabander in their synthesis of palmerolide A to give 
14.21 The synthesis was completed via nucleophilic cleavage of the PMB 
ether, carbamate formation and deprotection to provide palmerolide A (14), in 
a longest linear sequence of twenty-one steps and 0.8% overall yield. 
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Scheme 1.6: Assembly of palmerolide A (14) 
 
1.6: Structural analogues of palmerolide A 
 
In 2008 Nicolaou synthesised a catalogue of palmerolide A analogues, which 
were subjected to biological evaluation against an array of tumour cells.45 
Initially, diastereoisomers 23, 24, 74 and 75 of palmerolide A were 
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synthesised by inverting the stereocentres at C19 and C20, following the 
route proposed in their efforts to synthesise natural palmerolide A (14, 
Figure 1.15).36a,b 
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Figure 1.15: Diastereoisomers 23, 24, 74 and 75 of palmerolide A synthesised 
by Nicolaou and Chen 
 
These compounds were tested against a panel of cancer cells using Taxol 3 
and natural palmerolide A 14 as standards. Both natural and synthetic 
palmerolide exhibited the same potent activity against all cell lines tested, 
whereas the antipodal palmerolide 24 was at least 100 fold less active. 
Inverting the stereochemistry at the C7, C10 and C11 to give 23; C7, C10, 
C11 and C19 to give 74; and C7, C10, C11 and C20 to give 75, all resulted in 
significant loss of activity (Table 1.1).45 
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3: Taxol
14: natural
14: synthetic
24: ent
23
74
75
UACC-62 MCF-7 SF268 NCI-H460 IA9 PTX22 A8
Cytotoxicity of selected palmerolides against various cancer cell lines (GI50 in µM)
0.022 ± 0.016 0.021 ± 0.0150.079 ± 0.0010.006 ± 0.0010.007 ± 0.0010.026 ± 0.0110.006 ± 0.001
0.057 ± 0.007 0.018 ± 0.0030.066 ± 0.0070.038 ± 0.0030.010 ± 0.0010.030 ± 0.0120.040 ± 0.007
0.062 ± 0.001 0.049 ± 0.0040.073 ± 0.0050.059 ± 0.0010.017 ± 0.0040.048 ± 0.0060.065 ± 0.011
8.077 ± 0.194 8.844 ± 1.301>10>106.589 ± 0.0549.475 ± 0.5936.260 ± 0.174
>10 >10>10>10>10>10>10
5.398 ± 0.362 8.634 ± 1.8607.052 ± 0.474>106.108 ± 0.1346.830 ± 0.0775.415 ± 0.247
8.129 ± 1.187 6.145 ± 0.9225.865 ± 0.5907.131 ± 1.1437.028 ± 0.1927.961 ± 0.5845.567 ± 0.255  
Table 1.1: Activity of palmerolide A diastereoisomers 23, 24, 74 and 75 
 
Analogues 76–79, shown in figure 1.16, were synthesised via a similar 
method to the palmerolide diastereoisomers 23, 24, 74 and 75 but without the 
formation of the C11 carbamate.36a,b Protection of the C10 and C11 hydroxyls 
gave 80. 
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Figure 1.16: Analogues of palmerolide A 76–80 synthesised by Nicolaou and 
Chen 
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Removing the carbamate from the C11 oxygen of palmerolide A resulted in 
an approximately 5-fold decrease of activity across most of the cell lines. The 
carbonate derivative 80 of decarbonated palmerolide 24 was also devoid of 
significant activity (Table 1.2).45 
 
14: natural
76
77
78
79
80
UACC-62 MCF-7 SF268 NCI-H460 IA9 PTX22 A8
Cytotoxicity of selected palmerolides against various cancer cell lines (GI50 in µM)
0.057 ± 0.007 0.018 ± 0.0030.066 ± 0.0070.038 ± 0.0030.010 ± 0.0010.030 ± 0.0120.040 ± 0.007
>10 >10>10>10>10>10>10
>10 >10>10>10>10>108.257 ± 0.047
>10 >10>10>10>10>10>10
0.322 ± 0.088 0.083 ± 0.0060.627 ± 0.0160.288 ± 0.0170.075 ± 0.0030.281 ± 0.1180.200 ± 0.026
8.768 ± 0.698 8.477>10>108.664 ± 0.4949.638 ± 0.3627.299 ± 0.430
 
Table 1.2: Activity of palmerolide A analogues 76–80 
 
The relationship between the polarity of the enamide functionality and the 
potency against the cell lines was then investigated. This was achieved by 
utilising the Buchwald copper catalysed coupling of the vinyl iodide with 
varying primary amides to give a selection of enamide analogues (81–86, 
Figure 1.17).36a,b,45 
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Figure 1.17: Enamide analogues 81–86 synthesised by Nicolaou and Chen 
 
Upon changing the enamide side chain, some interesting trends were shown. 
Exchanging the isoprene moiety in palmerolide A (14), with a methyl group 
81 resulted in more than a 100-fold loss of activity, but when more polar 
groups were substituted such as in 82, 83 and 84 most of the activity was 
retained.  However when the enamide side chain was converted to a nonpolar 
aromatic system as in 85 the compound exhibited almost a 10-fold increase in 
potency against several of the cells tested. When the isoprene substituent on 
the enamide of palmerolide A was altered to its saturated counterpart 86, its 
potency remained at similar levels (Table 1.3).45 
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14: natural
UACC-62 MCF-7 SF268 NCI-H460 IA9 PTX22 A8
Cytotoxicity of selected palmerolides against various cancer cell lines (GI50 in µM)
0.057 ± 0.007 0.018 ± 0.0030.066 ± 0.0070.038 ± 0.0030.010 ± 0.0010.030 ± 0.0120.040 ± 0.007
81
82
83
84
85
86 0.067 ± 0.000 0.057 ± 0.0010.081 ± 0.0060.067 ± 0.0020.061 ± 0.0000.054 ± 0.0000.071 ± 0.008
0.009 ± 0.001 0.006 ± 0.0000.039 ± 0.0020.009 ± 0.0010.007 ± 0.0000.007 ± 0.0010.007 ± 0.000
8.822 ± 0.083 3.514 ± 1.379>107.944 ± 0.4303.796 ± 0.306>107.397 ± 0.262
0.735 ± 0.084 0.072 ± 0.0040.889 ± 0.0290.378 ± 0.1410.078 ± 0.0010.491 ± 0.1320.796 ± 0.166
0.641 ± 0.000 0.460 ± 0.0420.741 ± 0.0030.618 ± 0.0510.430 ± 0.0470.592± 0.0070.755 ± 0.004
>10 6.700 ± 0.411>107.774 ± 1.0947.291 ± 0.137>10>10
 
Table 1.3: Activity of palmerolide A enamide analogues 81–86 
 
In addition to the enamide analogues prepared, a number of macrolide 
analogues were prepared by varying the subunits used in the synthesis of 
palmerolide A. They synthesised the 20-membered macrolide without either 
the C7 hydroxyl 87, or C10 hydroxyl 88, but were unsuccessful in 
synthesising the macrolide missing both the C7 and C10 hydroxyls 89 (Figure 
1.18). 36a,b,45 
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Figure 1.18: De-oxygenated analogues 87–89 synthesised by Nicolaou and 
Chen 
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It was shown that the analogue lacking the C10 hydroxyl 87 lost significant 
activity across the all cell lines tested but for 88 where the C7 hydroxyl was 
removed the potency was shown to be of comparable levels to 
palmerolide A (14, Table 1.4).45 
 
14: natural
UACC-62 MCF-7 SF268 NCI-H460 IA9 PTX22 A8
Cytotoxicity of selected palmerolides against various cancer cell lines (GI50 in µM)
0.057 ± 0.007 0.018 ± 0.0030.066 ± 0.0070.038 ± 0.0030.010 ± 0.0010.030 ± 0.0120.040 ± 0.007
87
88 0.063 ± 0.001 0.061 ± 0.0130.076 ± 0.0000.072 ± 0.0010.055 ± 0.0020.060 ± 0.0040.074 ± 0.000
6.979 ± 0.531 6.691 ± 0.4398.062 ± 0.0377.135 ± 0.6676.396 ± 0.1068.764 ± 0.3157.585 ± 0.252
 
Table 1.4: Activity of de-oxygenated palmerolide A analogues 87 and 88 
 
From this data it can be concluded that the C7 hydroxyl is not essential for 
activity, as the potency of 88 was comparable to palmerolide A (14) in all the 
cell lines tested. It is shown that the C11 carbamate is needed for activity and 
when a non-polar aromatic substituent is appended on the enamide side chain 
such as 85, the potency increases. 
 
1.7: Florence strategy for synthesis of the palmerolides 
 
1.7.1: Strategy for synthesis of palmerolide A 
 
The primary objective of this project was to develop a flexible strategy for the 
synthesis of palmerolide A (14), in which the key subunits can be modified, 
allowing access to a wide range of novel analogues. The structure of 
palmerolide A (14) posed some interesting challenges for a synthetic 
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endeavour as the 20-membered macrocycle contains four stereocentres, four 
(E)-olefins with a C11 carbamate group and a C19 unsaturated enamide side 
chain.  
 
It was envisaged the most efficient way to achieve the synthesis was to devise 
a convergent approach, as it would allow the synthesis of palmerolide A (14), 
while also allowing access to other members of the palmerolide family and 
their analogues, through the alteration of the key subunits. Our strategy differs 
from previous synthesis as it has the functionality present at an early stage 
(Scheme 1.7), which has been shown to be difficult and costly to insert later 
on in the sequence.21,36 This route proposes a late stage enamide coupling via 
a Buchwald coupling of the C24 vinyl iodide.46 The macrolide core 90 is 
dissected into three key subunits, the C1-C8 subunit 91, the C9-C14 subunit 
92 and the C15-C24 subunit 93. The assembly of these subunits was to be 
achieved by coupling the C1-C8 β-ketophosphonate 91 with the C9-C14 
aldehyde 92 via a Horner-Wadsworth Emmons coupling to give the C1-C14 
subunit 94. The C14-C15 bond would be introduced via a Julia-Kocienski 
olefination of the elaborated C1-C14 subunit 94 and the C15-C24 sulfone 93 
followed by formation of the macrocycle 90 via macrolactonisation.39 This 
approach offers both flexibility and high levels of convergence, as the order of 
the key bond couplings could be reversed if necessary, while all the key 
functionalities are present for the core coupling to minimise post-coupling 
operations. Through the application of this strategy it is envisaged that it will 
be possible to access palmerolide A (14) and other members of its family, 
through subtle changes in key subunits. 
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Scheme 1.7: Retrosynthesis of palmerolide A (14) 
 
1.7.2: Strategy for synthesis of palmerolide E 
 
This attractive aspect of our present approach will allow the synthesis of novel 
analogues through the variation of the key subunits or the enamide side chain, 
while also being applicable to other fragments of the palmerolide family. 
Palmerolide E (18) can be obtained via the route developed for palmerolide A 
(14), but by synthesising the alternative C15-C23 subunit 95 with a protected 
hydroxyl, instead of the C15-C24 vinyl iodide 94 (Scheme 1.8). 
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Scheme 1.8: Retrosynthesis of palmerolide E (18) 
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Results and Discussion 
 
2.0: Synthesis of C1-C14 subunit 
 
2.0.1: Retrosynthesis 
 
Following the proposed retrosynthetic plan, the aim was to 
reduce the Weinreb amide 96 to its aldehyde then perform a Horner-
Wadsworth Emmons reaction to couple the C1-C8 subunit (91) with the C9-
C14 subunit (96), forming the desired C8-C9 (E)-olefin of C1-
C14 fragment 97 (Scheme 2.1). The C7 ketone 97 was to be reduced to give 
the (7S)-hydroxyl, this would then be TBS-protected followed by removal of 
the C11 PMB-protecting group. Synthesis of the carbamate, then removal of 
the primary TBS-protecting group would give the C1-C14 subunit (98). 
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Scheme 2.1: Retrosynthesis of C1-C14 subunit 98 
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2.1: Synthesis of C1-C8 subunit 
 
2.1.1: Retrosynthesis 
 
It was envisaged that the preparation of the C1-C8 subunit 91 could be 
achieved using either of the retrosynthetic analysis outlined in Scheme 2.2. 
Starting from lactol 99, Wittig olefination would introduce the C1-C3 enoate. 
Oxidation of the primary alcohol 100 followed by formation of the acid 
chloride and addition of the lithium-anion of dimethyl methylphosphonate 
should furnish the requisite C1-C8 subunit 91. The alternative approach could 
utilize a cross metathesis reaction to introduce the C1-C3 (E)-enoate from 
101. Conversion of 5-hexenoic acid 102 to the β-ketophosphonate via the acid 
chloride, followed by Grubbs cross metathesis with methyl acrylate would 
complete the synthesis of the C1-C8 subunit (91). 
 
101
O
P O
MeO
MeO
91: C1-C8 subunit
O
MeO OHMeO
O OHO
O
P OMe
O
OMe OH
O
99100
102  
Scheme 2.2: Retrosynthesis of C1-C8 subunit 91 
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2.1.2: Synthesis of carboxylic acid 103 
 
The initial route for the synthesis of the C1-C8 subunit 91 started 
with a Wittig olefination of tetrahydro-2H-pyran-2-ol 99 to introduce the C1-
C3 enoate and provide ester 100. Treatment of 99 with methyl 
(triphenylphosphoranylidene) acetate in dichloromethane provided the ester 
100 in good yield with 9 : 1, E : Z selectivity (Scheme 2.3). The resulting 
primary alcohol 100 was oxidised with TEMPO and BAIB in acetonitrile and 
water to give the carboxylic acid 103 in excellent yield.47 
 
O
OHMeO
O
103
OHO
99
OHMeO
O
100
66%
(E : Z = 9 : 1)
PPh3
MeO2C
TEMPO, BAIB
98%
 
Scheme 2.3: Synthesis of carboxylic acid 103 
 
A common problem with traditional methods for oxidising alcohols to 
carboxylic acids is that the reagents and conditions tend to be harsh. A milder 
method is the TEMPO oxidation, which can oxidise the alcohol to the 
aldehyde or the carboxylic acid depending on the solvent system used.48 In the 
reaction, TEMPO mediates the oxidation of the alcohol to the aldehyde, 
followed by regeneration using stoichiometric quantities of BAIB, so further 
oxidation can occur to give the carboxylic acid (Scheme 2.4).49 
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Scheme 2.4: TEMPO oxidation mechanism 
 
2.1.3: Attempted synthesis of C1-C8 subunit (91) 
 
With the carboxylic acid 103 in hand, the acid chloride was synthesised via 
the reaction of 103 in dichloromethane with Ghosez reagent (104), a mild 
reagent for converting carboxylic acids into their corresponding acid 
chlorides.50 The crude acid chloride was reacted directly, without any 
purification, with the lithium anion of dimethyl methylphosphonate in 
tetrahydrofuran but unfortunately this did not form the desired β-
ketophosphonate 91 and no starting acid 103 was recovered (Scheme 2.5). 
 
42 
 
O
OHMeO
O
103
O
MeO
O
91
P OMe
O
OMe
N
Cl1. 104 =
2.                     ,
 LiHMDS
P OMe
O
OMe
 
Scheme 2.5: Attempted synthesis of C1-C8 subunit 91 
 
2.1.4: Attempted synthesis of β-ketophosphonate 101 
 
A similar route was also attempted with the introduction of the phosphonate to 
an acid chloride. TEMPO oxidation of 5-hexen-1-ol 105, in acetonitrile and 
water (1 : 1) gave carboxylic acid 102 in 80% yield.47 Carboxylic acid 102 
was reacted with Ghosez reagent (104),50 to give the acid chloride, which was 
used directly in the reaction with dimethyl methylphosphonate and LiHMDS 
in tetrahydrofuran but again the β-ketophosphonate (101) was not formed and 
the starting acid 102 could not be recovered (Scheme 2.6).  
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Scheme 2.6: Attempted synthesis of β-ketophosphonate 101 
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2.1.5: Synthesis of β-ketophosphonate 101 
 
Following the unsuccessful attempts to introduce the phosphonate by 
displacement, the C1-C8 subunit (91) synthesis was modified to have the 
phosphonate in place from the start of the sequence. Treatment of β-
ketophosphonate 106 with sodium hydride and n-butyl lithium formed the 
dianion, which underwent alkylation with 4-bromobutene to afford the desired 
phosphonate 101 in excellent yield (Scheme 2.7).51  
 
P OMe
O
OMe
O
P OMe
O
OMe
OBr
NaH, BuLi
95%
106 101  
Scheme 2.7: Synthesis of β-ketophosphonate 101 
 
2.1.6: Cross metathesis reaction 
 
Cross metathesis reactions are a powerful method for forming carbon-carbon 
double bonds, they can tolerate many functional groups and are reactive 
towards a large range of olefins.52 Many metal catalysts have been 
developed for this purpose such as Schrock’s alkoxy imidomolybdenum 
complex (108),53 Grubbs I generation (109) and Grubbs II generation 
catalysts (107, Figure 2.1).54,55 Molybdenum catalysts are very active but they 
are unstable to air and are required to be prepared and used under an inert 
atmosphere. To combat this Grubbs and co-workers developed ruthenium 
alkylidenes, these catalysts are more stable and have proved to be compatible 
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with numerous functional groups, becoming benchmark catalysts for these 
transformations. 
 
107
MoCH3C(CF3)2O
N
CH3C(CF3)2O
Ph
i-Pr i-Pr
Ru
PCy3
PCy3
PhCl
Cl Ru
PCy3
PhCl
Cl
NMesMesN
108 109  
Figure 2.1: Commonly used cross metathesis catalysts 
 
Grubbs ruthenium-based catalysts exhibit good reactivity in a variety of cross 
metathesis reactions. The electron rich phosphine ligands of the ruthenium 
metal centre in 107 and 109 increases metathesis reactivity, and the N-
heterocyclic carbene ligand in 107 is believed to help to stabilise the 
ruthenium intermediate in the catalytic cycle.54,55  
 
With the appearance of well-defined catalysts, the mechanism of the olefin 
metathesis reaction was investigated thoroughly. After numerous kinetics 
experiments, Grubbs and co-workers were able to determine that the olefin 
metathesis reaction proceeds through a dissociative mechanism. The first step 
consists in the release of a phosphine from the catalyst (110) to provide the 14 
electron species 111 (Scheme 2.8).56,57 Ruthenium then coordinates with the 
olefin to give intermediate 112 which then forms metallocyclobutane 113. 
Retro [2+2] cycloaddition provides metal carbenoid 114 and following 
coordination with the second olefin gives intermediate 115, which then forms 
the second metallocyclobutane 116. A retro [2+2] cycloaddition provides the 
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cross-metathesis product 117 as well as the propagating species 118 that can 
re-coordinate with the olefin and re-enter the catalytic cycle. 
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Scheme 2.8: Dissociative mechanism for olefin cross metathesis 
 
In its first applications, cross metathesis suffered from the fact that mixtures 
of products were obtained with low levels of selectivity. Indeed, a cross 
metathesis reaction can give six possible products not including the unreacted 
starting material (Scheme 2.9). This lack of selectivity had limited the utility 
of cross metathesis reactions in synthesis however, significant progress has 
been made in the recent years. Grubbs and co-workers have investigated 
cross-metathesis using different classes of olefins and described a general 
empirical model useful to predict product selectivity.58 By reacting an olefin 
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of high reactivity (electron rich) with an olefin of lower reactivity (electron 
poor), it is possible to achieve a selective cross-metathesis and to obtain 
products with excellent E : Z ratios. 
 
R1R
R R1
-C2H4
R1R
1
RR
6 possible products  
Scheme 2.9: Mixture of products in cross metathesis 
 
2.1.7: Synthesis of C1-C8 subunit (91) utilising cross metathesis  
 
Introduction of the C2-C3 (E)-enoate was then achieved via a cross metathesis 
reaction of phosphonate 101 with methyl acrylate and 1 mol% of Grubbs II 
catalyst (107), which gave the C1-C8 subunit 91 in excellent yield with high 
levels of E : Z selectivity (15 : 1, Scheme 2.10), as determined via 1H NMR 
spectroscopy. 
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Scheme 2.10: Cross metathesis to synthesize C1-C8 subunit (91) 
2.1.8: Synthesis of C1-C8 subunit using catalyst 119 
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The cross metathesis reaction shown in scheme 2.10 was also attempted using 
a similar ruthenium based catalyst developed by Prof. Steve Nolan (119, 
Figure 2.2) with the intention of either improving the yield or the E : Z 
selectivity by the use of milder reaction conditions.59  
 
119
Ru
P
Cl
Cl
NMesMesN
F3C
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Figure 2.2: Nolan-modified ruthenium catalyst 119 
 
This reaction using catalyst 119 was completed using the same equivalents of 
reagents and 1 mol% of the catalyst. Initially when the reaction was left 
overnight at room temperature, there was 55% conversion with recovery of 
starting material, but when 119 was used in the same conditions as those used 
earlier in the Grubbs II cross metathesis, with heating under reflux for forty 
hours, the C1-C8 subunit 91 was produced with a yield of 79% and 10 : 1 
E : Z  selectivity (Scheme 2.11). 
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Scheme 2.11: Modified cross metathesis reaction 
 
In summary the synthesis of the C1-C8 subunit 91, was completed via an 
alkylation of the β-ketophosphonate 106 with 4-bromobutene, then a cross 
metathesis reaction of 101 using Grubbs II catalyst and methyl acrylate to 
give the C1-C8 subunit 91 in excellent yield and selectivity over the 
two steps (Scheme 2.12). 
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Scheme 2.12: Synthesis of C1-C8 subunit 91 
 
With the C1-C8 subunit 91 in hand, the attention turned towards the synthesis 
of the C9-C14 subunit 96, so the Horner-Wadsworth Emmons reaction to 
form the C8-C9 olefin could be performed.  
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2.2: Synthesis of C9-C14 subunit 
 
2.2.1: Retrosynthesis 
 
It was proposed that the fully protected C9-C14 subunit 96 could be 
synthesised by the reaction sequence outlined in Scheme 2.13, where a 
Horner-Wadsworth Emmons reaction involving triethyl phosphonoacetate and 
the oxidized protected diol 120, would give enoate 121. Sharpless asymmetric 
dihydroxylation of enoate 121 would provide diol 122, which was expected to 
be monoprotected as its TBS-ether 123. It was anticipated that hydrogen 
bonding between the β-hydroxyl and ester group of diol 122 would ensure that 
protection would occur primarily on the α-hydroxyl group. Subsequent 
protection of the β-hydroxyl as its PMB-ether should provide the fully 
protected C9-C14 fragment 96. Formation of the Weinreb amide 96 then 
reduction would give the corresponding aldehyde to be used in the Horner-
Wadsworth Emmons reaction with the C1-C8 subunit (91). 
 
TBSO
PMBO
N
O
96
TBSO
TBSO
PMBO
OEt
O
124
OTBS
TBSO
OH
OEt
O
123
OTBS
TBSO
OH
OEt
O
122
OH
TBSO OEt
O
121
TBSO
120
H
O
OMe
 
Scheme 2.13: Retrosynthesis of C9-C14 subunit 96 
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2.2.2: Synthesis of enoate 121 
 
The synthesis of the C9-C14 subunit began from 1,4-butanediol 125, which 
was mono-protected as its TBS-ether 126, via careful control of the reaction 
equivalents, in excellent yield (Scheme 2.14). Swern oxidation gave the 
aldehyde, which was immediately followed by a Horner-Wadsworth Emmons 
reaction using the Masamune-Roush conditions,60 with triethyl 
phosphonoacetate 127, to provide enoate 121 in excellent yield over the two-
step sequence with excellent E : Z selectivity (30 : 1). The isomers could be 
separated with ease via column chromatography. 
 
TBSO OEt
O
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E  : Z = 30 : 1
127 = EtO P OEt
OO
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Scheme 2.14: Synthesis of enoate 121 
 
2.2.3: Sharpless asymmetric dihydroxylation 
 
The next stage involved a Sharpless asymmetric dihydroxylation to introduce 
the required syn-hydroxylation at C10-C11.61 Reacting AD-mix-α with enoate 
121 and methanesulfonamide, gave the 1,2-diol 122 in excellent 
yield (Scheme 2.15). 
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Scheme 2.15: Sharpless asymmetric dihydroxylation of 122 
 
The diastereoselectivity of this reaction is controlled by the choice of 
cinchona alkaloid ligand, either (DHQ)2-PHAL (128) in AD-mix-α or 
(DHQD)2-PHAL (129) in AD-mix-β (Figure 2.3).61a,b 
 
N N
OOH
N
H
N
N N
OMeMeO
Et Et
N N
OO
N N
OMeMeO
N
Et
H
N
Et
128: α = (DHQ)2-PHAL 129: β = (DHQD)2-PHAL
H
 
Figure 2.3: Cinchona alkaloid ligands 128 and 129 
 
To determine which of the cinchona alkaloid ligands will give the desired 
stereochemical outcome the Sharpless mnemonic must be used (Scheme 
2.16).62,63 Employing AD-mix-α leads to high levels of α-facial selectivity and 
gives addition from below the plane, using the mnemonic, while AD-mix-β 
will give the opposite.  
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Scheme 2.16: Sharpless mnemonic for prediction of stereochemistry 
 
When the Sharpless mnemonic is applied to the enoate 121 (Scheme 2.17), it 
can be seen that the ester functionality is acting as the large substituent and 
the side chain as the medium substituent. With the use of AD-mix-α the 
stereochemistry predicted is C10-(R) and C11-(S). 
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Scheme 2.17: Sharpless mnemonic applied for enoate 121 
 
2.2.4: Selective protection of diol 122 
 
With diol 122 in hand, the focus was turned to the selective protection of the 
α-hydroxyl. After considerable effort Murray found that reacting methyl-diol 
130 with benzoyl chloride under basic conditions, using DMAP as a 
nucleophilic catalyst, for three hours at -78 °C, consumed all the starting 
L
S M
H
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material and upon purification, 36% of the β-protected hydroxyl 131 and 49% 
of the α-protected hydroxyl 132 were found (Scheme 2.18).64  
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Scheme 2.18: Attempted selective protection of diol 130 
 
Further investigation of the reaction conditions found that the isolated 
yield could be improved to 79% by starting the reaction at -78 °C and 
allowing the reaction to progress at -50 °C for sixteen hours (Scheme 2.19). It 
is believed that the α-protected benzoate (132) forms first, as indicated by the 
higher yield of this product at shorter reaction times (3 h, 36%), and elevating 
the temperature and extending the reaction time, allows equilibration to the 
more thermodynamically stable β-protected benzoate (131).  
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Scheme 2.19: Selective benzoyl protection of diol 130 
 
Application of this protocol to diol 122, was shown to give comparable yields 
under the same condition as the reaction with 130. This reaction was also 
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shown to work in a multigram scale where using 4.8 g of diol 122 gave the β-
protected benzoate 133 in 77% yield (Scheme 2.20).   
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Scheme 2.20: Selective benzoyl protection of diol 122 
 
2.2.5: Synthesis of the C9-C14 subunit (96) 
 
The β-protected benzoate 133 was then protected as its TBS-ether via 
treatment of the unprotected α-hydroxyl with TBSCl and imidazole to give the 
orthogonally protected diol ester 134 in excellent yield. Conversion of 134 to 
deprotected Weinreb amide 135 occurred in excellent yield (Scheme 2.21).  
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Scheme 2.21: Synthesis of Weinreb amide 135 
 
In the formation of Weinreb amide 135, the conditions are shown to also 
remove the benzoyl protecting group. These two transformations occur 
stepwise as the alkoxy group is the preferred leaving group from both 
tetrahedral intermediates (Scheme 2.22).  
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Scheme 2.22: Formation of the Weinreb amide 
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This left only the secondary C11-hydroxyl to be protected as its PMB-ether. 
Thus, treatment of alcohol 135 with PMBTCA and scandium triflate, provided 
the fully protected C9-C14 subunit (96) in good yield (Scheme 2.23).65  
 
TBSO N
OOH
TBSO
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Scheme 2.23: PMB-protection to give the C9-C14 subunit (96) 
 
In summary the C9-C14 subunit (96) was synthesised via a Horner-
Wadsworth Emmons reaction to give the enoate 121, then dihydroxylation to 
give diol 122. This was selectively β-protected as benzoyl ether 133 and 
after three further steps, gave the C9-C14 subunit (96) in 25% yield 
over 8 steps (Scheme 2.24).  
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Scheme 2.24: Synthesis of C9-C14 subunit 96 
 
2.3: Synthesis of C1-C14 subunit 
 
2.3.1: Horner-Wadsworth Emmons coupling 
 
With both the C1-C8 subunit (91) and the C9-C14 subunit (96) in hand, the 
next step was to form the C8-C9 (E)-olefin of 97. The reaction was carried out 
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by treating the C9-C14 Weinreb amide (96) with DIBAL to give aldehyde 136 
that was used directly in the Horner-Wadsworth Emmons reaction with the 
C1-C8 subunit (91) using K2CO3 and 18-crown-6 to give the C1-C14 subunit 
(97) in a 71% yield over the two steps with good E : Z selectivity (Scheme 
2.25). 
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Scheme 2.25: Formation of C8-C9 (E)-olefin in C1-C14 subunit (97) 
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2.3.2: CSA deprotection of 97 
 
The proposed strategy for the coupling of the C1-C14 subunit (98) with either 
the C15-C24 (93, palmerolide A) or the C15-C23 subunit (95, palmerolide E) 
requires that the primary TBS-ether group of 98 be cleaved in the presence of 
a secondary TBS. The resultant primary alcohol can then be oxidised to an 
aldehyde prior to performing the proposed Julia-Kocienski olefination with 
either 93 or 95, which would give the pre-cyclised skeleton of either 
palmerolide A or E, respectively.  
 
The selective cleavage of the primary TBS-ether in the presence of the 
secondary TBS-ether of 97 proceeded using CSA in a 1 : 6 mixture 
of methanol : dichloromethane for one and a half hours giving 137 in 
excellent yield (Scheme 2.26).66 The time and ratios of methanol to 
dichloromethane had to be carefully monitored as if the reaction was left for 
too long, deprotection of the allylic C10-TBS ether was observed.  
 
MeO
O
O
TBSO
OPMB
TBSO
97
CSA,
MeOH : CH2Cl2 (1 : 6)
0 °C
1.5 h
81%
MeO
O
O
TBSO
OPMB
HO
137  
Scheme 2.26: Deprotection of C14-hydroxyl 
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2.3.3: Removal of PMB ether 
 
With the removal of the primary TBS-protecting group shown to be 
successful, the deprotection of the C11 PMB-protecting group was 
investigated. This procedure has been shown to be problematic at later stages 
in previous palmerolide A syntheses, such as Hall’s synthesis of palmerolide 
A, where the deprotection of the C11-PMB and C7- and C10-TIPS had a 
combined yield of 16% for the two steps.36c This was attributed to the benzyl 
ring of the PMB folding across the macrolide ring, which can interact with the 
diene contained within the macrolide core. Anticipating this, the deprotection 
was attempted before the Julia-Kocienski olefination with the C15-C24 
subunit (93), as the C14-C15 and C16-C17 olefins were not yet in place. 97 
was smoothly reacted with recrystallized DDQ to give the C11 deprotected 
subunit 138 in excellent yield (Scheme 2.27).  
 
MeO
O
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O
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Scheme 2.27: DDQ deprotection of 97 
 
DDQ (2,3-dichloro-5,6-dicyano-1,4-benzoquinone) is a powerful and 
selective reagent for deprotections,67 though it can also be used as a reagent 
for oxidative couplings68 and the dehydrogenation of hydroaromatic 
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compounds.69 Deprotection of the p-methoxybenzyl ether proceeds via two 
single electron transfers with the methoxy group stablising the intermediates, 
which is followed by a formal hydride transfer to give alcohol and p-
methoxybenzaldehyde (Scheme 2.28). 
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Scheme 2.28: Mechanism of DDQ deprotection 
 
2.3.4: Reduction of C7 ketone 
 
The next challenge to overcome was the selective reduction of the C7 ketone. 
Our strategy required it to be reduced giving the (7S)-hydroxyl, which was 
expected to result from using (R)-CBS as De Brabander has utilised this 
method on macrolide 52 in his synthesis of palmerolide A (23, Scheme 1.2).21  
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Initially the reduction was attempted with NaBH4, to test that the ketone could 
be reduced to the alcohol (Scheme 2.29). This was completed by treating 
ketone 97, with NaBH4 to give alcohol 139 in 83% yield as a 1 : 1 ratio of 
diastereoisomers.  
 
MeO
O
O
TBSO
OPMB
TBSO
97
NaBH4
83%
MeO
O
TBSO
OPMB
TBSO
139
OH
 
Scheme 2.29: NaBH4 reduction of C7 ketone 97 
 
2.3.5: CBS reduction of C7 ketone 
 
In 1987, E. J. Corey and co-workers developed the enantioselective reduction 
of an achiral ketone in the presence of a chiral borane.70 One of these borane 
reagents is (R)-methyl oxazaborolidine (140, (R)-CBS, Figure 2.4), which can 
be used to reduce prochiral ketones to give the corresponding alcohols in high 
enantiomeric excess. Catalytic amounts of the CBS reagent are needed, and 
when treated with BH3·THF in situ the diborane complex is formed, where it 
acts as both a Lewis acid and a chiral auxiliary. 
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N
B
O
Me
Ph
PhH
140: (R)-MeCBS  
Figure 2.4: Structure of (R)-CBS (140) 
 
After showing the reduction could be completed using NaBH4, it was then 
attempted using (R)-CBS (140) to introduce the desired C7-hydroxyl 
selectivity (Scheme 2.30). Initially the reaction was attempted using the same 
conditions used by De Brabander in his synthesis of palmerolide A (23), but 
this did not provide any alcohol (141) and the starting ketone (97) was not 
recovered. The reaction was also attempted under various conditions with 
different temperatures, time and equivalents of the reagents used (Table 2.1) 
but all the attempts were unsuccessful. 
 
MeO
O
O
TBSO
OPMB
TBSO
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Scheme 2.30: Attempted (R)-CBS reduction of C7 ketone 97 
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Solvent Temperature(°C)
(R)-CBS
(eq)
BH3·THF
(eq)Time
THF
THF
THF
THF
40 min
1 hr
4 hr
4 hr
3
3
3
3
2
3
3
3
-40
-78
-78
-78 - -40
 
Table 2.1: Conditions used in (R)-CBS reduction of C7 ketone 97 
 
2.3.6: Noyori hydrogenation 
 
With the unsuccessful reduction using the (R)-CBS reagent (140), the 
attention was turned to a different method, which was to use a Noyori 
hydrogenation,71 with catalyst 142 (Figure 2.5) developed by Clark et al.72 
The Noyori asymmetric hydrogenation is used for enantioselective 
hydrogenation of ketones, aldehydes and imines, using a chiral ruthenium 
catalyst. 
 
N
H2
Ru
N
Cl
Cl
PPh2
DMSO
142  
Figure 2.5: Catalyst 142 used in Noyori hydrogenation 
 
The hydrogenation of ketone 97 was attempted using 0.5% of catalyst 142, at 
70 °C with KOtBu under 30 bars of hydrogen in isopropyl alcohol, but 
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unfortunately this did not provide any of alcohol 141 (Scheme 2.31), and the 
hydrogenation was found to saturate both the C2-C3 and C8-C9 double bonds.  
 
MeO
O
O
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OPMB
TBSO
97
0.5% cat (142)
70 °C, IPA
KOtBu, H2 (30 bar)
15 hours
MeO
O
TBSO
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141
OH
 
Scheme 2.31: Conditions used in attempted Noyori hydrogenation of 
ketone 97 
 
2.3.7: DIP-Cl reduction of C7 ketone  
 
The next attempt to reduce the C7 ketone was to use B-
chlorodiisopinocampheylborane (Ipc2BCl, known commercially as DIP-Cl) 
pioneered by Brown et al.73 DIP-Cl has been shown to be very effective for 
the asymmetric reduction of simple ketones, such as alkyl ketones, α-hindered 
ketones and perfluoroalkyl ketones.74 Initially the reaction was attempted 
using (+)-DIP-Cl, as using the mnemonic shown it was quite difficult to 
distinguish which group would be the large substituent and which would be 
the small in subunit 97 (Figure 2.6). 
 
 
Figure 2.6: Mnemonic used to determine selectivity using DIP-Cl 
Me
H
B
Cl
O
RL Rs
Me H
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DIP-Cl efficiently reduces aromatic ketones to chiral secondary alcohols by 
de-hydroboration and loss of pinene (Scheme 2.32).75 The reduction proceeds 
via a six-membered cyclic, transition state where the β-hydrogen of the iso-
pinocampheyl group is transferred to the carbonyl carbon and α-pinene is 
released.  
 
Me
H
B
Cl
O
RL Rs
Me H
B
Cl
O
RL Rs
Me H
H
(-)-α-pinene  
Scheme 2.32: Mechanism for DIP-Cl reduction. 
 
Treating the ketone 97 with (+)-DIP-Cl in THF at -78 °C, then warming up 
the reaction mixture to room temperature and stirring for sixteen hours 
afforded a separable mixture of (7S : 7R) alcohols 141 and 143 in good yield 
(Scheme 2.33).  
 
MeO
O
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OPMB
TBSO
97
MeO
O
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OPMB
TBSO
(7S)-141
OH
(+)-DIP-Cl
66%
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Scheme 2.33: (+)-DIP-Cl reduction of C7 ketone 97 
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2.3.8: Mosher ester analysis 
 
To determine the selectivity of the (+)-DIP-Cl reduction, alcohol 143 was 
separately reacted with both (R)- and (S)- MTPA acids. This 
treatment of alcohol 143 in dichloromethane with the MTPA acid, N,N'-
dicyclohexylcarbodiimide and DMAP at room temperature gave the MTPA 
esters 144 and 145 (Scheme 2.34).   
 
MeO
O
TBSO
OPMB
TBSO
143
(R)- or (S)-MTPA,
DCC, DMAP
MeO
O
TBSO
OPMB
TBSO
O
O
CF3
Ph
144, 57%
OH
MeO
O
TBSO
OPMB
TBSO
O
O
F3C
Ph
145, 51%
MeO
OMe
 
Scheme 2.34: Synthesis of Mosher esters 144 and 145 
 
The Mosher method uses α-methoxy-α-(trifluoromethyl)-phenylacetic acid  
(MTPA) esters for assigning the absolute configuration. It is based upon the 
assumption that the MTPA derivatives will adopt a preferred conformation in 
solution where the carbinol proton, ester carbonyl and trifluoromethyl group 
all sit in the same plane (Figure 2.7).76 Due to the diamagnetic effect of the 
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phenyl group when the MTPA group adopts this confirmation, the 1H NMR 
signals of Ha, Hb, and Hc in the (R)-MTPA ester appear upfield relative to the 
corresponding signals of the (S)-MTPA ester, while the Hx, Hy and Hz in the 
(R)-MTPA ester appear downfield. Therefore the absolute configuration can 
be assigned by calculating Δδ = -0.02 for as many 1H NMR signals as possible 
for each of the (R)- and (S)-MTPA esters. Using this data it is possible to 
construct a molecular model showing that protons with δ>0 and protons with 
δ<0 lie on opposite sides of the MTPA plane, confirming the absolute 
configuration. 
 
 
Figure 2.7: Configurational models for Mosher ester analysis 
 
Comparison of the 1H NMR of 144 and 145 showed an upfield shift of the C8-
C12 protons of 144 as the phenyl group shields them; conversely, the (R)-
MTPA derivative 145 experienced an upfield shift on C2-C6 region (Table 
2.2). Therefore, subtraction of the 1H NMR δ values for the (R)-MTPA ester 
from the (S)-MTPA ester gives a positive value for the C2-C6 region and a 
negative value in the C8-C12 region, allowing the assignment of the C7 
stereocentre in the (+)-DIP-Cl reduction giving the 7R configuration as the 
major diastereoisomer. 
δ βγ
δ' γ'
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O
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Ph OMe
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Proton δS (ppm) δR (ppm) δS - δR (ppm)
2
3
4
5
6
7
8
9
10
11
12
5.80
6.87
2.20
1.47
1.75
4.31
5.60
5.86
4.27
3.28
1.63
5.75
6.88
2.13
1.35
1.73
4.29
5.68
5.96
4.29
3.30
1.68
+0.05
+0.01
+0.07
+0.12
+0.02
+0.02
-0.08
-0.10
-0.02
-0.02
-0.05
 
Table 2.2: Mosher ester analysis of (+)-DIP-Cl reduction of 97 
 
With the reaction using (+)-DIP-Cl proving successful but giving the opposite 
selectivity needed, the reaction was attempted with (-)-DIP-Cl (Scheme 
2.35).75 Under the same conditions treatment of 97 gave a 5 : 1 ratio in favour 
of what was assumed to be the desired 7S diastereoisomer 141. 
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Scheme 2.35: (-)-DIP-Cl reduction of C7 ketone 97 
 
 
69 
Mosher ester analysis was performed to confirm the selectivity of the (-)-DIP-
Cl reduction, by treating alcohol 141 with both (R)- and (S)-MTPA acids, 
giving 146 and 147 (Scheme 2.36). 
 
MeO
O
TBSO
OPMB
TBSO
141
(R)- or (S)-MTPA,
DCC, DMAP
MeO
O
TBSO
OPMB
TBSO
O
O
CF3
Ph
146, 67%
OH
MeO
O
TBSO
OPMB
TBSO
O
O
F3C
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Scheme 2.36: Mosher ester analysis of 141 
 
The two (R)- and (S)-Mosher ester derivatives 146 and 147 were subjected to 
the same 1H NMR analysis as 144 and 145 confirming the selectivity of the 
(-)-DIP-Cl reduction as 5 : 1 for 7S : 7R (Table 2.3, Figure 2.8), as subtraction 
of the 1H NMR δ values for the (R)-MTPA ester from the (S)-MTPA ester 
gives a negative value for the C2-C6 region and a positive value in the C8-C12 
region. 
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Proton δS (ppm) δR (ppm) δS - δR (ppm)
2
3
4
5
6
7
8
9
10
11
12
5.75
6.87
2.12
1.60
1.75
4.29
5.68
6.00
4.35
3.35
1.65
5.80
6.87
2.20
1.64
1.81
4.30
5.62
5.93
4.31
3.29
1.61
-0.05
0.00
-0.08
-0.04
-0.06
-0.01
+0.06
+0.07
+0.04
+0.06
+0.04
 
Table 2.3: Mosher ester analysis of (-)-DIP-Cl reduction of 97 
 
 
Figure 2.8: 1H NMR comparison of (R)- and (S)-Mosher ester derivatives 146 
and 147.  
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2.3.9: Synthesis of C1-C14 subunit 98 
 
Using the conditions developed above it was attempted to synthesize the fully 
elaborated C1-C14 subunit (98). This was achieved by TBS protection of 141, 
giving 148 followed by deprotecting with recrystallised DDQ to remove the 
PMB-protecting group to give alcohol 149 in good yield. The free hydroxyl 
was then reacted with trichloroacetyl isocyanate, followed by treatment with 
potassium carbonate in methanol to give carbamate 150.77 This was followed 
by the selective deprotection of the primary TBS-protecting group using CSA 
in methanol and dichloromethane, in a 1 : 6 ratio, to give the fully elaborated 
C1-C14 subunit (98) in good yield (Scheme 2.38). 
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OTBS
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O
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69%
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Scheme 2.38: Synthesis of the fully elaborated C1-C14 subunit 98 
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2.4: Conclusion 
 
The C1-C14 subunit 98 was synthesised by reacting the C1-C8 subunit 91 
with the reduced C9-C14 subunit 136 via a Horner-Wadsworth-Emmons to 
give the C8-C9 olefin 97. The selective reduction of the C7 ketone was shown 
to be successful using (-)-DIP-Cl, which was then protected as its TBS-ether 
148. The PMB-ether was pre-emptively deprotected followed by formation of 
the carbamate 150 and deprotection of the primary TBS-ether to give the fully 
elaborated C1-C14 subunit 98 (Scheme 2.39) in seven steps and 19% overall 
yield. 
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Scheme 2.39: Synthesis of C1-C14 subunit 98 
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Results and Discussion 
 
3.0: Synthesis of C15-C23 subunit for palmerolide E (18) 
 
3.1: Retrosynthesis 
 
The synthesis of the unsaturated C15-C23 subunit 95 (Scheme 3.1) was 
envisioned to begin with a Horner-Wadsworth Emmons olefination of the (S)-
Roche ester derived aldehyde 152, to provide the trisubstituted enoate 153, 
which could be reduced to give the alcohol then protected as its TBS-ether 
154. Elaboration of 154 to aldehyde 155 would then set the stage for the 
vinylogous Mukaiyama aldol reaction with silyl ketene acetal 156 under 
suitable Lewis acidic conditions, to generate the desired 1,2-syn adduct 157. 
Finally, TES-protection of the C19 alcohol followed by reduction and sulfone 
formation at the C15 terminus to give the C15-C23 subunit 95. 
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Scheme 3.1: Retrosynthesis of C15-C23 subunit 95 
 
3.1.1: Horner-Wadsworth Emmons olefination 
 
The synthesis of the C15-C23 subunit (95) began with PMB-protection of the 
free hydroxyl of (S)-Roche ester 158, using PMBTCA and PPTS to give 159 
in good yield (Scheme 3.2).78 The Weinreb amide 160 was then formed by 
treating the protected Roche ester (159) with N,O-dimethyl hydroxylamine 
hydrochloride and iso-propylmagnesium chloride, ensuring the temperature of 
the reaction did not rise above -15 °C, giving 160 in excellent yield. 
Synthesizing Weinreb amide 160 to gain access to aldehyde 152 was chosen 
over reducing the ester 159 to the corresponding alcohol followed by 
oxidation to the aldehyde in order to prevent epimerization of the C20 
stereocentre. 
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Scheme 3.2: Synthesis of PMB-protected Weinreb amide 160 
 
Olefin synthesis, employing phosphonium ylides was introduced by Wittig 
and Geissle in 1953.79 Shortly after in 1958, Horner disclosed a modified 
Wittig reaction employing phosphonate-stabilized carbanions.80 Wadsworth 
and Emmons investigated this further, showing that phosphonate-stabilized 
carbanions are more nucleophilic than their corresponding phosphonium 
ylides.81 The Horner-Wadsworth-Emmons reaction is the chemical reaction of 
stabilized phosphonate carbanions with aldehydes or ketones to produce 
predominantly E-olefins (Scheme 3.3).82 The reaction mechanism proceeds 
via the nucleophillic addition of the enolate to the aldehyde, which gives the 
two intermediates; the stereochemistry is set by steric control, where the 
antiperiplanar approach of the carbanion to the carbonyl group is favored 
when the smaller aldehydic hydrogen eclipses the bulky phosphoranyl moiety. 
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This places the ester group syn to the aldehyde R’ group. The resultant olefin 
can assume the more stable E-orientation, as interconversion between the 
intermediates is possible. 
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Scheme 3.3: Mechanism for Horner-Wadsworth Emmons reaction 
 
The PMB-protected Weinreb amide 160 was treated with DIBAL to give 
aldehyde 152, which was used immediately and without purification, due 
to facile epimerization of the α-chiral aldehyde. The crude aldehyde 
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152 was reacted in a Horner-Wadsworth Emmons reaction using triethyl 2-
phosphonopropionate to give the α, β-unsaturated ester 153 (Scheme 3.4). 
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Scheme 3.4: Horner-Wadsworth Emmons reaction to synthesise α, β-
unsaturated ester 153 
 
The Horner-Wadsworth Emmons reaction of 152 was attempted using various 
bases and conditions. Initially it was attempted by treating of the 
aldehyde 152 with LiHMDS and triethyl 2-phosphonopropionate which gave 
the α, β-unsaturated ester 153  (E : Z = 1 : 4) in a moderate yield for the two 
steps (Table 3.1).83 The selectivity of the reaction was determined by 1H NMR 
spectroscopy,82 which in this instance appears to be favoured as the reaction is 
under kinetic control. 
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Base Yield (%)from 160 E  : Z
LiHMDS
LiCl,
Hünig's base
Ba(OH)2·H2O
wet THF
58
65
70
1 : 4
4 : 1
9 : 1
 
Table 3.1: Conditions used in Horner-Wadsworth Emmons reaction of 152  
 
Due to the excess formation of the undesired (Z)-isomer this reaction was 
attempted using the Masamune-Roush conditions.60 Treatment of aldehyde 
152 with lithium chloride, Hünig’s base and triethyl 2-phosphonopropionate, 
gave a mixture of isomers of ester 153 (E : Z = 4 : 1) in a 65% yield for the 
two steps (Table 3.1). There is an increase in the E : Z ratio as the 
thermodynamic product is now favoured. 
 
Although a change in the selectivity of the reaction was observed, it was 
believed that the 4 : 1 ratio could be increased. Activated barium hydroxide 
has been shown to increase the (E)-selectivity in the Horner-Wadsworth-
Emmons reaction.84 It has been hypothesised that the microcrystalline 
structure of the barium hydroxide is crucial to its catalytic activity with the 
reaction proceeding via an interfacial solid-liquid mechanism.85 The reaction 
was carried out by treating a mixture of activated barium hydroxide and 
triethyl 2-phosphonopropionate in tetrahydrofuran, with with aldehyde 152 in 
wet tetrahydrofuran, giving the desired (E)-regioisomer 153 in a good yield 
for the two steps and good selectivity (E : Z = 9 : 1, Table 3.1). 
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3.1.2: Synthesis of C19-C23 aldehyde 155 
 
The synthesis of aldehyde 155 started with the reduction of ester 153, using 
DIBAL, to give alcohol 161 in excellent yield. This was followed by TBS 
protection of alcohol 161 to afford the di-protected fragment 154 
(Scheme 3.5). Deprotection of the PMB ether, using DDQ in dichloromethane 
followed by oxidation using Dess-Martin periodinane gave aldehyde 155. The 
stage was now set to explore the introduction of silyl ketene acetal 156 in a 
vinylogous aldol reaction.  
 
OPMBHO
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Scheme 3.5: Synthesis of aldehyde 155 
 
Dess-Martin periodinane is a hypervalent iodine compound, which offers 
selective and mild oxidation of alcohols to their corresponding aldehydes and 
the product is easily separated from the iodo by-product. Dess-Martin 
periodinane works by displacement of an acetyl group by the alcohol 
(Scheme 3.6). A second acetate group then acts as a base, deprotonating the 
alcohol to form the aldehyde. 
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Scheme 3.6: Mechanism for Dess-Martin periodinane oxidation  
 
3.2: Aldol reaction 
 
The next step of the sequence was to react the aldehyde (155) with silyl 
ketene acetal 156 to give the aldol adduct (157, Scheme 3.7). This was to be 
initially attempted using a vinylogous Mukaiyama aldol reaction.86  
 
OMe
OTMS
156
TBSO H
O
155
Lewis Acid
CH2Cl2
TBSO OMe
OOH
157
 
Scheme 3.7: Vinylogous Mukaiyama aldol reaction to synthesis aldol 
adduct 157 
 
3.2.1: Vinylogous Mukaiyama aldol 
 
Formation of the desired 1,2-syn adduct 157 was to be attempted utilising the 
substrate controlled vinylogous Mukaiyama aldol reaction with aldehyde 155 
and silyl ketene acetal 156, prepared from methyl-3,3-dimethyl 
acrylate 161 (Scheme 3.8).  
 
81 
 
OMe
O TMSCl, LDA
63%
161
OMe
OTMS
156  
Scheme 3.8: Synthesis of silyl ketene acetal 156 
 
Unfortunately treatment of aldehyde 155 with silyl ketene acetal 156 and 
BF3·OEt2 in dichloromethane at low temperature did not form any of the 
desired isomer (Scheme 3.9) giving only degradation of the starting 
material.85b The reaction was attempted under various conditions with varying 
equivalents of reagents and Lewis acid, but each attempt provided none of the 
aldol adduct (157) and no starting material was recovered, as the use of 
BF3·OEt2 led to degradation of the starting material in all cases (Table 3.2).  
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Scheme 3.9: Attempted vinylogous Mukaiyama aldol using BF3·OEt2 
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Reagent
(eq)
Lewis aicd
(eq)
Time
(Min)
Temperature
(°C)
Yield
(%)
OTMS
OMe
(2)
OTMS
OMe
(2)
OTMS
OMe
(2)
OTMS
OMe
(4)
OTMS
OMe
(2)
OTMS
OMe
(2)
OTMS
OMe
(2)
BF3·OEt
(4)
BF3·OEt
(6)
BF3·OEt
(2)
BF3·OEt
(2)
BF3·OEt
(2)
BF3·OEt
(1)
BF3·OEt
(4)
10
15
30
10
30
30
30
-95
-95 to -78
-78
-78
-95
-78
-78
 
Table 3.2: Conditions attempted in vinylogous Mukaiyama aldol using 
BF3·OEt2 
 
With the unsuccessful attempts of the vinylogous Mukaiyama aldol using 
BF3·OEt2, due to the degradation of the aldehyde 155, the reaction was 
attempted using TiCl2(OiPr)2 (Scheme 3.10).87 This reaction was investigated 
using various conditions but again the starting material 155 was unrecoverable 
and the product 157 was not formed (Table 3.3). 
 
 
83 
OMe
OTMS
156
TBSO H
O
155
TBSO OMe
OOH
157
TiCl2(OiPr)2
CH2Cl2
 
Scheme 3.10: Attempted vinylogous Mukaiyama aldol of 156  and 155 using 
TiCl2(OiPr)2 
 
Reagent
(eq)
Lewis aicd
(eq)
Time
(Min)
Temperature
(°C)
Yield
(%)
OTMS
OMe
(2)
OTMS
OMe
(2)
OTMS
OMe
(4)
OTMS
OMe
(4)
OTMS
OMe
(2)
TiCl2(OiPr)2
(6)
TiCl2(OiPr)2
(2)
TiCl2(OiPr)2
(6)
TiCl2(OiPr)2
(2)
TiCl2(OiPr)2
(6)
180
90
180
180
180
-78
-78
-78
-78
-78
 
Table 3.3: Conditions attempted in vinylogous Mukaiyama aldol using 
TiCl2(OiPr)2 
 
3.2.2: Lithium aldol 
 
After the unsuccessful vinylogous Mukaiyama aldol with both BF3·OEt2 and 
TiCl2(OiPr)2, a lithium aldol reaction with aldehyde 155 and acrylate 161 was 
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attempted to confirm that the aldol bond could be formed. Treatment of 
acrylate 161 with LDA and aldehyde 155 in tetrahydofuran at -78 °C gave a 
separable mixture of isomers (α : γ = 4 : 1) in moderate yield (Scheme 3.11).  
 
OMe
O
161
TBSO H
O
155
LDA, THF,
-78 °C
53%
α : γ = 4 : 1
TBSO OMe
OOH
157
TBSO
OMeO
162  
Scheme 3.11: Lithium aldol reaction of 155 and 161 
 
The α-regioisomer was favoured in this reaction as it proceeds via a 
Zimmerman-Traxler transition-state (Figure 3.1).88 
 
 
Figure 3.1: Zimmerman-Traxler transition-state 
 
3.2.3: Yamamoto’s aluminium tris-(2,6-diphenylphenoxide) aldol 
 
An alternative method to synthesise γ-aldol adducts is Yamamoto’s 
aldol reaction, which utilises aluminium tris-(2,6-diphenylphenoxide) 
(ATPH, 163, Figure 3.2) as a bulky Lewis acid.89  
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Figure 3.2: Aluminium tris-(2,6-diphenylphenoxide) (163) 
 
This proceeds by complexing the ATPH 163 Lewis acid to enolate 164, which 
reacts with aldehyde 165 to give the γ-aldol adduct 166 (or when no 
complexation with 163 occurs the α-aldol adduct 167 is formed, 
Scheme 3.12). Direct aldol reactions of conjugated esters with aldehydes, 
initiated with LDA using ATPH (163) as the key reagent, have been shown to 
proceed with high γ-regioselectivities.88a,d This can be explained by the large 
steric effects of the ATPH (163), which block attack via the α-carbon by 
encapsulating the aldehyde substrate (164), therefore the γ-carbon is the 
preferred position of attack. 
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Scheme 3.12: Representation of Yamamoto’s aldol reaction 
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Using ATPH (163), a mixed aldol reaction between 3-methylbut-2-enal (168) 
and aldehyde 155 in toluene with LDA as a base, was attempted (Scheme 
3.13).88 However this reaction did not produce the desired product (169) with 
the starting aldehyde 155 recovered. 
 
168
TBSO H
O
H
O
ATPH (163), 
LDA
TBSO H
OOH
155 169  
Scheme 3.13: Attempted Yamamoto’s aldol reaction using ATPH (163), 
aldehyde 155 and 3-methylbut-2-enal (168) 
 
Due to the unsuccessful reaction using 168, a similar reaction was tested again 
using ATPH reagent (163) but with methyl-3,3-dimethyl acrylate 161 
(Scheme 3.14).88a This was carried out by treating acrylate 161 with a solution 
of ATPH 163 in toluene followed by the addition of aldehyde 155, this was 
left stirring for twenty minutes to allow complexation of the substrates to the 
ATPH after which LDA was added and the reaction was left at -78 °C for 
thirty minutes. This gave the product 157 in 55% yield with good γ-
regioselectivity (α : γ = 1 : 7; γ-isomer d.r. = 4 : 1). The diastereomeric ratio 
was obtained via Mosher ester analysis explained below, while the α : γ 
regioselectivity of the reaction was established by 1H NMR spectroscopy. 
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Scheme 3.14: Yamamoto’s aldol reaction using ATPH 163, aldehyde 155 and 
methyl-3, 3-dimethyl acrylate 161 
 
3.2.4: Felkin-Anh control 
 
The selective introduction of the C19-hydroxyl stereocentre in 157 is 
proposed to arise from a stereoselective Felkin-Anh addition of the acrylate 
161 to aldehyde 155.90 Using a Newman projection, the largest substituent is 
placed furthest from both the oxygen and hydrogen, with no eclipsing 
interactions; this gives the lowest energy conformation possible (Figure 3.3). 
The nucleophile attacks at 107° from the C=O bond with two possible 
trajectories of attack. The nucleophile selectively attacks past the small (S) 
substituent of the aldehyde (A) which is the least hindered path, giving the 
less stable product as the nucleophile reacts with the most reactive conformer. 
This is an example of the Curtin-Hammett principle, which states that it is the 
relative energies of the competing transition states that control selectivity, not 
the relative energies of the starting materials.  
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Figure 3.3: Principles of Felkin-Anh control. 
 
The absolute stereochemistry and selectivity of the aldol reaction was 
confirmed via Mosher ester analysis. The alcohol 157 was reacted with, N,N'-
dicyclohexylcarbodiimide,  DMAP and both the (R)- and (S)-MTPA acids 
separately at room temperature to give the MTPA esters 170 and 171 
respectively (Scheme 3.15).75 After analysis by 1H NMR spectroscopy, the 
aldol reaction was shown to have a diastereomeric ratio of 4 : 1 in favour of 
the (R)-diastereomer (Table 3.4).  
 
TBSO OMe
OOH
157
TBSO OMe
OO
171, 41%
TBSO OMe
OO
170, 43%
O
OMePh
O
CF3Ph
CF3
OMe
(R)- or (S)-MTPA,
DCC, DMAP
  
Scheme 3.15: Mosher ester analysis of aldol adduct 157 
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TBSO
OH
OMe
O
1519
23
Proton δS (ppm) δR (ppm) δS - δR (ppm)
16
18a
18b
19
20
21
23
+0.05
+0.08
+0.06
+0.02
-0.06
-0.09
-0.02
5.80 5.75
2.29 2.21
2.13 2.07
5.08 5.06
2.72 2.78
5.25 5.34
4.01 4.03  
Table 3.4: Mosher ester analysis of aldol adduct 157 
 
3.3: Alternate C15-C23 synthesis (172) 
 
Due to the observed breakdown of aldehyde 155 during, in particular, the 
Mukaiyama aldol reaction, an alternative substrate (173) was synthesised with 
the TBS-protecting group replaced with a PMB-protecting group, which we 
believed would be less susceptible to deconstruct under the acidic Mukaiyama 
conditions. This was achieved via a similar route starting with TBS-protection 
of the (S)-Roche ester 158, and formation of the Weinreb amide 174 (Scheme 
3.16). This was then reduced to the aldehyde using DIBAL and reacted under 
the same conditions used previously for the Horner-Wadsworth Emmons 
reaction giving 175, which after reduction of the ester and PMB-protection 
gave 176. Removal of the TBS-protecting group was facilitated with TBAF 
under standard conditions and oxidation using Dess-Martin periodinane gave 
173, to be tested in both the Mukaiyama and Yamamoto aldol reaction.  
 
 
90 
OTBS
O
EtO
OTBSPMBO
176
HPMBO
173
1. TBAF
2. DMP
82% over
two steps
O
MeO OH
O
N OTBS
O
MeO
1. TBSCl, ImH
2. Me(MeO)NH·HCl
iPrMgCl
90% over 
two steps
1. DIBAL
2. Ba(OH)2·H2O
X, wet THF
72% over
two steps
(E  :  Z = 9 : 1)
P OEtEtO
O O
EtO
1. DIBAL
2. PMBCl, NaH
50% over
two steps
X =
158 174
175
 
Scheme 3.16: Synthesis of alternative C19-C23 aldehyde 173 
 
3.3.1: Aldol reaction on PMB-protected aldehyde 173 
 
Aldehyde 173 was subjected to both the vinylogous Mukaiyama aldol 
conditions previously tried on aldehyde 155. Treating aldehyde 173 with 
ketene acetal 156 and BF3·OEt2 at -78 °C again gave only degradation of the 
starting material (Scheme 3.17).85 The aldehyde (173) was also reacted using 
TiCl2(OiPr)2 as the Lewis acid, but again this only broke down the starting 
material.86  
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Scheme 3.17: Mukaiyama aldol reaction of aldehyde 173 
 
Again due to the failure of the Mukaiyama aldol reaction, aldehyde 176 was 
reacted under Yamamoto’s protocol to see if the yield of the key aldol 
reaction could be improved. Aldehyde 176 was reacted with 161 under the 
conditions developed for TBS-protected aldehyde 155, to give the PMB-
protected aldol adduct 172, albeit in a lower yield though with similar 
regioselectivity (α : γ = 1 : 6, γ-isomer d.r. = 4 : 1, Scheme 3.18).88 
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ATPH (163), 
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Scheme 3.18: Yamamoto’s aldol reaction using ATPH 163, aldehyde 173 and 
acrylate 161 
 
Due to the lower yield observed with PMB-protected aldehyde 173 it was 
decided to continue with TBS-protected aldol adduct 157 to complete the 
synthesis of the C15-C23 subunit 95. 
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3.4: Completion of C15-C23 subunit 95 
 
Taking forward 157, the final steps to provide the C15-C23 subunit 95 started 
with the protection of secondary alcohol 157 under standard conditions using 
TES-chloride and imidazole in dichloromethane to give 177 (Scheme 3.19). 
The resulting ester was reduced using DIBAL to give alcohol 178, and 
subsequent formation of the sulfone 95 via a Mitsunobu reaction to give the 
sulfide followed by oxidation completed the synthesis of the C15-C23 subunit 
(95).91,92  
 
TBSO OMe
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89%
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178
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Scheme 3.19: Final steps to synthesise the C15-C23 subunit (95) 
 
3.5: Conclusion 
 
The C15-C23 subunit 95 was synthesised starting from the (S)-Roche 
ester 158, which after PMB-protection and formation of the Weinreb 
amide gave 160. This was reduced using DIBAL and used in a Horner-
Wadsworth Emmons reaction with activated barium hydroxide to give 
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ester 153. A further four steps generated aldehyde 155, which was used 
in a Yamamoto’s aldol reaction to give the γ-aldol adduct (157) with 
moderate diastereoselectivity. 157 was protected and reduced to give the 
free primary alcohol 178 and after formation of the sulfone finished the 
synthesis of the C15-C23 subunit (95) in a 9% overall yield over 13 
steps (Scheme 3.20). 
 
13 steps
9% yieldOH
O
MeO
158
TBSO SO2Ar
TESO
95  
Scheme 3.20: Synthesis of C15-C23 subunit (95) 
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Results and Discussion 
 
4.0: Synthesis of C15-C24 subunit for palmerolide A (14) 
 
4.1: Retrosynthesis 
 
The synthesis of the unsaturated C15-C24 subunit 93 was envisioned to arise 
via a similar method to the synthesis of the C15-C23 subunit 95, starting from 
the same (S)-Roche ester 158 through to previously synthesised alcohol 160, 
obtained from reduction of ester 153; alcohol 160 was to then be reacted in a 
Corey-Fuchs reaction followed by hydrostannation to form vinyl iodide 
179 (Scheme 4.1). The vinyl iodide 179 was then to be reacted under the 
Yamamoto’s aldol conditions, developed for the synthesis of the C15-C23 
subunit (95), to give 180 followed by TES-protection and sulfone formation to 
give the C15-C24 subunit 93. 
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Scheme 4.1: Retrosynthesis of C15-C24 subunit 93 
 
4.2: Synthesis of vinyl iodide 192 
 
With access to alcohol 160 established in the synthesis of the C15-C23 
subunit (95) for palmerolide E, introduction of the terminal C23 vinyl iodide 
was required to give the C15-C24 subunit (93). This sequence started with 
oxidation of alcohol 160 with Dess-Martin periodinane to afford aldehyde 181 
in 80% yield (Scheme 4.2).  
 
HO OPMB
H OPMB
O
160 181
Dess-Martin
80%
 
Scheme 4.2: Synthesis of aldehyde 181 
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4.2.1: Synthesis of alkyne 182 
 
The initial attempt to synthesise alkyne 182 used a Corey-Fuchs reaction 
(Scheme 4.3).93 Treatment of aldehyde 181 with carbon tetrabromide, 
triphenylphosphine and zinc, was expected to give in situ the dibromo 
intermediate 183, followed by formation of the alkyne with n-BuLi, but 
unfortunately this protocol did not provide the any of the desired product 182, 
the dibromo intermediate 183 or return the starting aldehyde 181.  
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Scheme 4.3: Attempted Corey-Fuchs reaction 
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4.2.2: Seyferth-Gilbert reaction 
 
With the failure of the Corey-Fuchs reaction our attention turned to an 
alternative alkynylation method: the Seyferth-Gilbert alkynylation.94 This 
homologation is a base promoted alkynylation, reacting the reagent (184) with 
an aldehyde to give the corresponding alkyne. It proceeds by deprotonation of 
the Seyferth-Gilbert reagent, which then adds to the carbonyl compound 
forming an alkoxide, this closes to give an oxaphosphetane. A cyclo-
elimination yields a diazoalkene, which upon warming decomposes with loss 
of nitrogen to give the vinylidene carbene. This then undergoes a 1,2-
migration to form the requisite alkyne (Scheme 4.4). 
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Scheme 4.4: Seyferth-Gilbert mechanism 
 
The Seyferth-Gilbert reagent can be prepared by two different methods, the 
first from reacting 185 with trimethyl phosphite to give 186, this is then 
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treated with hydrazine to give phosphonate 187; followed by formation of the 
Seyferth-Gilbert reagent 184 by reacting the amine 187 with sodium nitrite to 
generate the diazo phosphonate 184 (Scheme 4.5).95  
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Scheme 4.5: First method to synthesise the Seyferth-Gilbert reagent (184)  
 
Due to the poor yields and tricky synthesis associated with this route, 
an alternative route was investigated. This involved treating dimethyl 
methylphosphonate (188) with n-BuLi and 2,2,2-trifluoroethyl trifluoroacetate 
to give the intermediate 189, which after treatment with p-ABSA gave 
Seyferth-Gilbert reagent (184) in two steps and an improved overall yield of 
46% (Scheme 4.6).96 
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Scheme 4.6: Second method to synthesise the Seyferth-Gilbert reagent (184) 
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The Seyferth-Gilbert alkynylation was carried out by adding aldehyde 181 to 
a solution of dried potassium tert-butoxide and Seyferth-Gilbert reagent (184) 
in tetrahydrofuran, then stirred for 16 hours to successfully give the alkyne 
182 in a 32% yield (Scheme 4.7).  
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Scheme 4.7: Formation of alkyne 182 using Seyferth-Gilbert reagent 
 
4.2.3: Bestmann-Ohira reaction  
 
Due to both the difficult synthesis of the Seyferth-Gilbert reagent (184) and 
the poor yielding alkynylation reaction, the Bestmann-Ohira reagent (190) 
was utilized which can be synthesised readily in one step by treating 
dimethyl (2-oxopropyl)phosphonate (106) with tosyl azide and sodium 
hydride giving the Bestmann-Ohira reagent (190) in a 69% yield 
(Scheme 4.8).97  
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Scheme 4.8: Synthesis of Bestmann-Ohira reagent 
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The mechanism of the Bestmann-Ohira reaction proceeds via a similar 
method to the Seyferth-Gilbert reaction, initially there is attack of the 
methanol into the β-ketophosphonate, followed by loss of methyl acetate to 
generate the deprotonated Seyferth-Gilbert reagent (Scheme 4.9), from there 
the reaction follows the same route as the Seyferth-Gilbert mechanism 
described above.  
 
 
Scheme 4.9: Bestmann-Ohira mechanism 
 
The reaction of aldehyde 181 with the Bestmann-Ohira reagent (190) was 
carried out by treating the reagent 190 with caesium carbonate in methanol, 
followed by addition of aldehyde 181 at 0 °C. The solution was warmed to 
room temperature upon which it was left stirring overnight giving alkyne 182 
in a 58% yield. This route was preferred due to the ease of reagent synthesis 
(Scheme 4.10). 
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Scheme 4.10: Bestmann-Ohira synthesis of PMB-protected alkyne 182 
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4.2.4: Synthesis of vinyl iodide 192 
 
With alkyne 182 in hand the next challenge in the C15-C24 subunit synthesis 
was the formation of the vinyl iodide; this was expected to be achieved via a 
hydrostannylation reaction of 182. Hydrostannylation reactions are palladium 
(II) catalysed syn-addition of the alkyl tin to an alkyne, which leads to a vinyl-
stannane.98 They are carried out under mild conditions and can tolerate the 
presence of a wide variety of functional groups and have been shown to give 
good regio- and stereo-control.  
 
The hydrostannation was realised by treating alkyne 182 with tributyltin 
hydride and catalytic palladium(II) to give the vinyl stannane intermediate, 
after the solvent was removed the intermediate was reacted with iodine in 
dichloromethane to give the vinyl iodide 191 in moderate yield (Scheme 
4.11).  
 
OPMB
182
H Bu3SnH, PdCl2·(PPh3)2;then I2
51%
OPMB
191
I
 
Scheme 4.11: Synthesis of PMB-protected vinyl iodide 191 
 
The PMB-protecting group of vinyl iodide 191 then had to be removed to 
facilitate the subsequent aldol reaction; the deprotection was achieved by 
treating vinyl iodide 191 with DDQ to give alcohol 192 in good 
yield (Scheme 4.12). 
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Scheme 4.12: DDQ deprotection of PMB-protected vinyl iodide 191 
 
4.3: Alternate C19-C24 subunit (192) synthesis 
 
In an attempt to increase the yield of vinyl iodide 192, the alternative TBS-
protected vinyl iodide (193) was synthesised alongside the PMB-protected 
vinyl iodide (191). This was accomplished starting from the analogous 
alcohol 195, which could be readily oxidised using Dess-Martin periodinane 
to give the corresponding aldehyde, which was treated with the Bestmann-
Ohira reagent (190),96 giving alkyne (195, Scheme 4.13). Hydrostannylation 
of alkyne 195 followed by iodination gave the TBS-protected vinyl iodide 
(193) in a disappointing 33% yield over the 3 steps.97 
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Scheme 4.13: Synthesis of TBS-protected vinyl iodide 193 
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4.3.1: Takai olefination 
 
Due to the poor yields observed for the formation of both PMB- and TBS-
protected alkynes 182 and 194 and the subsequent vinyl iodides 192 and 193, 
the Takai olefination was investigated as an alternative. This involves the 
treatment of an aldehyde with chromium (II) chloride and iodoform to 
synthesise the vinyl iodide.99  
 
In the reaction mechanism proposed by Takai, chromium(II) is oxidized to 
chromium(III) upon replacing iodine from iodoform to give A, this is repeated 
to give di-chromium intermediate B. This geminal carbodianion complex 
reacts with the aldehyde in a 1,2-addition across one of the carbon-chromium 
bonds to give C and in the next step both chromium bearing groups engage in 
an elimination reaction to generate the desired vinyl iodide D 
(Scheme 4.14).98  
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Scheme 4.14: Takai olefination mechanism 
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The Takai olefination was carried out on the TBS-protected aldehyde, by 
addition of a solution of the aldehyde and iodoform in dioxane to a solution of 
chromium(II) chloride in THF (Scheme 4.15). This solution was left to stir 
overnight giving vinyl iodide 193 in a pleasing 70% yield over the two steps 
with good E : Z selectivity, which was established via 1H NMR spectroscopy.  
 
OTBS
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IHO OTBS
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1. Dess-Martin
2. CrCl2, CHI3
70% over
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E  :  Z = 14 : 1  
Scheme 4.15: Synthesis of TBS-protected vinyl iodide 193 via a Takai 
olefination 
 
With the improved formation of the vinyl iodide via a Takai olefination, the 
TBS-protected vinyl iodide 193 was deprotected using TBAF to give the 
previously synthesised alcohol 192, in good yield (Scheme 4.16). 
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Scheme 4.16: TBAF deprotection of TBS-protected vinyl iodide 193 
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4.4: Completion of C15-C24 subunit (93)  
 
4.4.1: Yamamoto’s aldol reaction 
 
With the deprotected vinyl iodide 192 in hand, the attention was turned to the 
aldol reaction between the oxidised alcohol 192 and 3,3-dimethyl acrylate 
(161), to introduce the diene and the C19 stereocentre. This was achieved 
using the same conditions developed in the synthesis of the C15-C23 subunit 
(95), with Dess-Martin periodinane oxidation to give the aldehyde 179 in 
good yield, followed by Yamamoto’s aldol reaction using 3,3-dimethyl 
acrylate (161), ATPH (163), and LDA giving vinyl iodide γ-aldol adduct 
(180), in moderate yield with 7 : 1 γ : α selectivity and a 3 : 1 syn : anti 
ratio (Scheme 4.17).88 
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Scheme 4.17: Synthesis of vinyl iodide aldol adduct 180 
 
4.4.2: Final steps towards the C15-C24 subunit (93)  
 
After the aldol reaction, the free hydroxyl of aldol adduct 180 was protected 
as its TES-ether, by reacting the alcohol 180 with TES-chloride and 
imidazole, to give 196 (Scheme 4.18). Ester 196 was reduced to alcohol 197 
using DIBAL at -78 °C. This was then transformed to the sulfone 93, via a 
Mitsunobu reaction to give the sulfide intermediate followed by oxidation to 
give the sulfone in good yield over the two steps, completing the synthesis of 
the C15-C24 subunit (93).90,91 
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Scheme 4.18: Final steps completing the synthesis of the C15-C24 subunit 
(93) 
 
4.5: Conclusion 
 
The C15-C24 subunit (93) was synthesised via a similar method to the 
synthesis of the C15-C23 subunit (95), but included formation of vinyl 
iodide 195. This was achieved via a Takai olefination, which after 
Yamamoto’s aldol reaction and formation of the sulfone gave the C15-C24 
subunit (93) in a 6% overall yield over the 14 steps (Scheme 4.19).  
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I
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SO2Ar
93  
Scheme 4.19: Synthesis of the C15-C24 subunit (93) 
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Results and Discussion 
 
5.0: Attempted synthesis of C1-C23 subunit for palmerolide E (198) 
 
5.1: Retrosynthesis 
 
To form the macrolide core of palmerolide E (198) the C1-C14 subunit (98) 
had to be coupled with the C15-C23 subunit (95). This was envisaged to be 
achieved via a Julia-Kocienski olefination between the oxidised C1-C14 
subunit (199) with the C15-C23 subunit (95) to form the C14-C15 olefin of 
198 (Scheme 5.1). 
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Scheme 5.1: Retrosynthesis of C1-C23 subunit (198) 
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5.2: C1-C14 subunit (98) coupling with C15-C23 subunit (95) 
 
5.2.1: Classical Julia olefination 
 
In 1973, Julia and Paris reported an alkene bond construction protocol via a 
reductive elimination of β-acyloxysulfones (Scheme 5.2).100 This olefination 
relied on the formation of a sulfonyl anion by deprotonation of the phenyl 
sulfone, followed by the addition of an aldehyde to give the β-acyloxysulfone, 
which after acylation then reductive elimination gives the olefin. This method 
gave access to the alkene functionality in a stereoselective manner with (E)-
selective products. 
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Scheme 5.2: Classical Julia olefination mechanism 
 
5.2.2: Modified Julia olefination 
 
In the 1990’s, Julia and co-workers reported a modified Julia olefination 
reaction substituting the phenylsulfone for a heteroaryl sulfone derivative 
(Figure 5.1).101 Benzothiazol-2-ylsulfones (BT sulfone) and a further three 
major modifications of the sulfone heterocycle have been reported, which all 
display various degrees of reactivity and stereoselectivity.102,103,104 
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Figure 5.1: Heterocyclic variants of the modified Julia olefination 
 
In comparison with the phenyl sulfone, the BT-sulfone protocol gives rise to 
the alkene product via an alternative pathway (Scheme 5.3).105,106 The reaction 
commences with the deprotonation of BT-sulfone, and the resulting anion acts 
as the nucleophilic partner in the reaction manifold. This species subsequently 
adds to the electrophilic carbonyl component, forming a transient β-
alkoxysulfone intermediate. The alkoxide, attacks the electrophilic C=N bond 
of the benzothiazole portion of the molecule in an intramolecular fashion. 
This series of consecutive reactions results in a putative spirocyclic 
intermediate that selectively breaks down via an overall Smiles rearrangement 
to afford the alkene together with loss of sulfur dioxide and elimination of 
metallated benzothiazolone. 
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Scheme 5.3: Mechanistic rationale for modified Julia olefination 
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The stereoselectivity of the modified Julia olefination is dependent upon the 
R’ and R” substituents of both the sulfone and carbonyl components. When 
the R’ and R” groups are non-conjugated alkyl substituents, the resultant 
alkene product displays little or no stereocontrol. This is attributable to the 
poor diastereoselective addition of the aldehyde to the sulfone component. 
Alternatively, when the R’ group is a vinyl or aryl substituent and the R” 
substituent is an alkyl group, the (Z)-alkene product dominates. This outcome 
can be explained by the stabilization of the metallated sulfone by the 
conjugated R’ group, which allows the β-alkoxysulfone to undergo reversible 
retroaddition/addition reactions, which leads to the equilibration of the 
diastereomeric alkoxides (Scheme 5.3).  
 
5.2.3: Modified Julia-Kocienski olefination 
 
In 1998, Kocienski and co-workers reported a 1-phenyl-1H-tetrazol-5-yl (PT) 
sulfone as an alternative to the BT-sulfone for the modified Juila 
olefination.101 Using the PT-sulfone there is reduced tendency to self-
condense providing a greater selectivity for the E-alkene. Kocienski tested the 
effect of both solvent polarity and base counterion on the outcome of the 
olefination reaction. An analogous trend to the BT-sulfone was observed; 
increased solvent polarity enhanced the tendency towards the formation of E-
alkenes (DME > THF > Et2O > PhMe), as did increasing the size of the 
counterion (Li+ < Na+ < K+). 
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The mechanism of the modified Julia-Kocienski follows that of the BT-
sulfone (Scheme 5.4),104 initial deprotonation with base forms the lithium 
anion E and subsequent addition of a carbonyl gives the two β-alkoxysulfones 
F and G. However, unlike the BT-sulfone, the addition of the aldehyde to the 
PT-sulfone predominantly forms the anti-adduct G, due to the bulky nature of 
the phenyl substituent. The Smiles rearrangement orients the R groups in a 
syn-arrangement H to reduce the steric clash with the phenyl group and 
subsequent elimination of the sulfur dioxide and the PT group gives an E-
alkene. 
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Scheme 5.4: Mechanism of modified Julia-Kocienski olefination 
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5.2.4: Attempted synthesis of C14-C15 olefin 
 
To set the stage for the Julia-Kocienski olefination alcohol 98 had to be 
oxidised to the aldehyde 199. This was achieved by treating alcohol 98 with 
Dess-Martin periodinane to give the aldehyde 199 (Scheme 5.5).  
 
MeO
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O
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Dess-Martin
 
Scheme 5.5: Dess-Martin periodinane oxidation of alcohol 98 
 
The Julia-Kocienski olefination was attempted by treating the C15-C23 
sulfone (95) with LiHMDS at -78 °C for ten minutes then addition of the 
freshly prepared aldehyde 199, the reaction mixture was left stirring at -78 °C 
for four hours, but unfortunately this did not give any of the C1-C23 product 
(198) and no starting aldehyde was recovered (Scheme 5.6). This reaction was 
attempted using various conditions and different bases but none tested 
provided the C1-C23 subunit 198 (Table 5.1). 
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Scheme 5.6: Attempted Julia-Kocienski olefination between the C1-C14 
aldehyde (199) and the C15-C23 sulfone (95) 
 
 
Table 5.1: Conditions attempted in the Julia-Kocienski olefination between 
the C1-C14 aldehyde (199) and the C15-C23 sulfone (95) 
 
5.3: Conclusion 
 
We believe the unsuccessful attempts at the Julia-Kocienski olefination, were 
due to the small scale of the reaction and moisture being present in the 
reaction mixture. Hence it is hoped that this can be rectified by increasing the 
scale of the reaction, or if needed by swapping the substituents and placing the 
sulfone on the C1-C14 subunit and the aldehyde on the C15-C23 subunit. 
Sulfone
(eq)
Aldehyde
(eq) Time
Temperature
(°C)
Yield
(%)
-78
-78
-78
4 hours
6 hours
4 hours
1
1.2
1.2
1
1
1
Base
(eq)
LiHMDS
1.5
LiHMDS
1.5
NaHMDS
1.7
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Unfortunately due the lack of material this reaction between the C1-C14 
aldehyde (199) and the C15-C23 sulfone (95) could not be repeated and tested 
on a larger scale. 
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Summary and Future Work 
 
6.1 Final steps towards palmerolide E (18) 
 
Once the problems with the Julia-Kocienski olefination, between aldehyde 
199 and the C15-C23 subunit (95) have been overcome, there would be a 
further four steps to complete the synthesis of palmerolide E (18); involving 
TES-deprotection, macrolactonization, deprotection of the three TBS-
protected alcohols and oxidation of the primary alcohol to the aldehyde, 
which would give palmerolide E (18) in a longest linear sequence of twenty 
steps (Scheme 6.1) 
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Scheme 6.1: Final steps towards the synthesis of palmerolide E (18) 
 
6.2 Final steps towards palmerolide A (14) 
 
The synthesis of palmerolide A (14) is expected to be completed following a 
similar route devised for the synthesis of palmerolide E (18, Scheme 6.2). A 
Julia-Kocienski olefination between aldehyde 199 and the C15-C24 subunit 
(93), followed by TES-deprotection and macrolactonization should furnish 
macrolide 201, which after a global deprotection and introduction of the 
enamide would give palmerolide A (14), in a longest linear sequence of 
twenty steps.  
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Scheme 6.2: Final steps towards the synthesis of palmerolide A (14) 
 
6.3 Summary 
 
In the synthesis of palmerolide A (14), the coupling between the C1-C8 
fragment (91) and the C9-C14 fragment (96) was achieved. Further 
elaboration gave the C1-C14 subunit (98), which can also be used in the 
synthesis of palmerolide E (18). The synthesis of both the C15-24 subunit 
(93) for palmerolide A and the C15-C23 subunit (95) for palmerolide E, have 
been completed with the investigation into the Julia-Kocienski coupling of 
these fragments with the oxidised C1-C14 subunit (199) under investigation. 
Although neither synthesis of palmerolide A or E were completed, significant 
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progress was made and useful information into the key fragments was 
obtained during these studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
121 
Experimental 
 
7.1: General experimental details 
 
All reactions were performed in flame dried glassware under a positive 
pressure of argon, with magnetic stirring unless otherwise stated.  
 
7.2: General procedures 
 
1H NMR spectra were recorded on the following instruments: Bruker Avance 
300 (300.1 MHz) instrument, Bruker Avance II 400 (400.1 MHz) instrument 
or Bruker Avance 500 (499.9 MHz) instrument. An internal reference of δH 
7.27  and 7.16 was used for the residual protons in CDCl3 and C6D6 
respectively. The chemical shift data for each signal are given as δ in units of 
parts per million (ppm) relative to tetramethylsilane (TMS) where δTMS = 0.00 
ppm. The multiplicity of each signal is indicated by: s (singlet); br s (broad 
singlet); d (doublet); t (triplet); dd (doublet of doublets); ddd (doublet of 
doublet of doublets); dddd (doublet of doublet of doublet of doublets); ddt 
(doublet of doublet of triplets); q (quartet); qd (quartet of doublets); or m 
(multiplet). The number of protons (n) for a given resonance is indicated by 
nH. Coupling constants (J) are quoted in Hz, they are recorded to the nearest 
0.1 Hz and are uncorrected. Assignments were determined either on the basis 
of unambiguous chemical shift, coupling pattern or by analogy to fully 
interpreted spectra. 
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13C NMR spectra were recorded on a Bruker Avance 300 (75.5 MHz) 
instrument, Bruker Avance II 400 (100.6 MHz) instrument or Bruker Avance 
500 (125.7 MHz) at probe temperature using an internal deuterium lock. The 
chemical shift data for each signal are reported in ppm on the δ scale (δTMS = 
0). The solvent peak was used as a reference value for 13C NMR: CDCl3 = 
77.00 or C6D6 = 128.06. 
 
IR spectra were recorded on a Perkin-Elmer Paragon Series 1000 FTIR 
spectrometer as thin films. Absorption maxima (vmax) are reported in 
wavenumbers (cm-1).  
 
Optical rotations were recorded on a Perkin-Elmer Model 341 automatic 
polarimeter instrument at the sodium D line (589 nm), in cells with a path 
length of 1 cm and are reported as: , concentration (c in g/100 mL) and 
solvent, where T is temperature in °C. 
 
HRMS and LRMS (High and Low resolution mass spectrometry) were 
recorded using a Thermofisher LTQ Orbitrap XL mass spectrometer, Finnigan 
MAT 900 XLT mass spectrometer, Micromass Quattro II mass spectrometer, 
Water ZQ4000 mass spectrometer or a Thermofisher DSQ-II mass 
spectrometer by EPSRC national mass spectrometry service (Swansea, UK) 
using Electron Impact (EI), Electron Ionisation (ES), Chemical 
Ionisation (CI), Fast Atom Bombardment (FAB) or Atmospheric Pressure 
Chemical Ionisation (APCI) techniques. Other spectra were recorded on a 
Thermo Fisher Q Exactive mass spectrometeror a Waters micromass LCT 
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mass spectrometer by the University of St Andrews mass spectrometry service 
(School of Chemistry and Biomolecular Sciences).  
 
Analytical thin layer chromatography (TLC) was carried out on E. Merck 
precoated (25 µm) silica gel 60 F254 plates. Reagent grade ethyl acetate, 
hexanes (commercial mixture), dichloromethane and methanol were 
purchased and used as is for chromatography. Visualisation was by absorption 
of UV light, or thermal development after dipping in either an aqueous 
solution of potassium permanganate, an ethanolic solution of 
phosphomolybdic acid (PMA) or an anisaldehyde dip.  
 
Flash column chromatography was carried out on silica gel 60 (E. Merck, 40-
63 µm) under a positive pressure of compressed air.  
 
Kugelrohr bulb-to-bulb distillations were carried out using a Büchi B-585 
machine. Boiling points are the actual oven temperatures. 
 
Reagents and Solvents were purified by standard means. Dimethyl sulfoxide 
(DMSO) was dried over CaH2, distilled under high vacuum and stored over 
4Å molecular sieves. Methanol was distilled from magnesium methoxide in a 
recycling still under nitrogen. Ethyl acetate was purified by washing with 5% 
Na2CO3, and saturated aqueous CaCl2 and dried with MgSO4. 
Dichloromethane, tetrahydrofuran (THF), diethyl ether and toluene were dried 
by passage through two columns of alumina using an M-BRAUN SPS-800 
solvent purification system. Anhydrous N,N-dimethylformamide was 
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purchased from Aldrich UK and dried by distillation from 4 Å molecular 
sieves onto 4 Å molecular sieves under an atmosphere of argon. 
Triethylamine (Et3N) and BF3·Et2O were distilled from CaH2 under Ar. 
Oxalyl chloride was distilled from CaH2 into potassium carbonate under 
argon. All other reagents were purchased from Acros UK, Aldrich UK, Fisher 
UK or Molekula. All other chemical were used as received, except otherwise 
stated in the experimental procedure. Aqueous solutions of sodium 
bicoarbonate (NaHCO3), sodium chloride (brine), potassium sodium tartrate 
and ammonium chloride (NH4Cl) were saturated. All experiments were 
performed under anhydrous conditions and an inert atmosphere of argon, 
using a vacuum manifold with argon passed through calcium chloride and 
self-indicating silica gel. Hexane refers to n-hexane and petroleum ether to the 
fraction boiling between 40 and 60 °C. Room temperature refers to the 
temperature of approximately 22 °C. 
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7.3: Preparation of reagents 
 
Methyl 2-(triphenylphosphoranylidene) acetate (200)107 
 
O
O
PPh3  
 
To a stirred solution of triphenylphosphine (18.0 g, 68.6 mmol) in ethyl 
acetate (120 mL), was added a solution of methyl bromoacetate (6.50 mL, 
68.6 mmol) in ethyl acetate (30 mL). The solution was left to stir for 14 h at 
room temperature upon which a white precipitate formed. The precipitate was 
filtered off, washed with diethyl ether (30 mL) and the filtrate was dried over 
MgSO4. The mixture was dissolved in dichloromethane (150 mL), separated 
with 1 M NaOH (100 mL) and vigorously shaken. The layers were separated 
and the aqueous layer was extracted with dichloromethane (3 x 40 mL). The 
combined organic layers were washed with brine, dried over MgSO4 then 
concentrated in vacuo to give the product 200 (21.7 g, 95%) as a white 
powder.  
 
1H NMR (300 MHz, CDCl3) δ 7.70–7.43 (15H, m, Ar-H), 3.53 (3H, s, O-
CH3) and 2.91 (1H, s, C-CH). 
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1-Hydroxy-1,2-benziodoxol-3 (1H)-one 1-oxide (201)108 
 
O
I OH
O
O  
 
2-Iodobenzoic acid (50.0 g, 200 mmol) was added to a solution of 
Oxone (181.0 g, 290 mmol) in water (650 mL). The reaction mixture was 
warmed to 75 °C then stirred at this temperature for 3 h, after which the 
suspension was cooled to 5 °C and left stirring at this temperature for 2 h. The 
mixture was filtered, then rinsed with water (6 x 100 mL) and acetone (2 x 
100 mL), the precipitate was dried at room temperature for 16 h to give the 
product 201 (48.5 g, 87%) as a white crystalline solid. 
 
1,1,1-Triacetoxy-1,1-dihydro-1,2-benziodoxol-3 (1H)-one (202)109 
 
O
I
OAc
OAcAcO
O  
 
1-Hydroxy-1,2-benziodoxol-3 (1H)-one 1-oxide 201 (48.5 g, 170 mmol) was 
added to a solution of Ac2O (200 mL) and TsOH·H2O (500 mg). The mixture 
was heated to 80 °C and stirred at this temperature for 3 h, then cooled to 
0 °C. The cold mixture was filtered, and then rinsed with diethyl ether (5 x 
50 mL). The resulting white crystalline solid 202 (59.5 g, 81%) was 
transferred to an argon flushed dark flask, and stored in a freezer. 
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1H NMR (300 MHz, CDCl3) δ 8.29 (1H, d, J = 8.1 Hz, Ar-H), 8.09 (1H, t, J = 
8.1 Hz, Ar-H), 7.93-7.90 (2H, m, Ar-H), 2.32 (3H, s, CH3) and 1.99 (6H, s, 2 
x CH3). 
 
Diazomethyl dimethylphosphonate (184)94,95 
 
P
N2
OMe
O
OMe
 
 
Method A: 
A solution of N-(bromomethyl)phthalimide 185 (10.0 g, 41.7 mmol), 
trimethyl phosphite (5.40 mL, 45.8 mmol) in xylene (20 mL) was heated 
under reflux for 5 h. The solvent was partially reduced in vacuo and the 
resulting solid was filtered and dried under vacuum to give 186 (10.9 g, 93%) 
as a white powder.  
To a solution of 186 (8.40 g, 31.0 mmol) in ethanol (130 mL), was added 
hydrazine (2.65 mL, 54.6 mmol). The reaction mixture was refluxed for 1.5 h. 
The un-reacted phosphonate 186 was filtered off; the mixture was 
concentrated under reduced pressure and distilled (120 °C, 0.5 mbar) to give 
187 (530 mg, 12%) as a colourless oil. 
To a solution of 187 (500 g, 3.60 mmol) in dichloromethane (10 mL) at -5 °C, 
was added a solution of aqueous NaNO2 (300 mg, 4.30 mmol) in water (3 
mL), followed by acetic acid (430 mg, 7.20 mmol). The reaction mixture was 
stirred for 4 h at 0 °C. The reaction was quenched with aqueous potassium 
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carbonate (4 mL), extracted with dichloromethane (3 x 10 mL), dried over 
potassium carbonate, filtered and reduced under pressure. The product was 
purified by distillation (87 °C, 0.5 mbar) to give the diazomethyl 
dimethylphosphonate 184 (380 mg, 70%) as a colourless oil. 
 
Method B:  
A mixture of dimethyl methylphosphonate 188 (2.00 g, 16.1 mmol) in 
THF (40 mL) was cooled to -78 °C, and n-butyl lithium (1.6 M in hexane, 
10.1 mL, 16.1 mmol) was slowly added to the mixture and stirred for 30 min. 
2,2,2-Trifluoroethyl trifluoroacetate (3.20 mL, 24.2 mmol) was added and the 
mixture was warmed to room temperature over 15 min. The mixture was 
partitioned between diethyl ether (250 mL) and 3M HCl (10 mL), and the 
organic layer was washed with aqueous NaHCO3, brine, dried over MgSO4 
and concentrated under reduced pressure. The residue 189 was dissolved in 
acetonitrile (40 mL), followed by the addition of 4-acetamidobenzenesulfonyl 
azide (4.10 g, 16.1 mmol). The solution was cooled to 0 °C and triethylamine 
(2.20 mL, 16.1 mmol) was slowly added. The solution was stirred for 16 h at 
room temperature and the solvent was then removed under reduced pressure. 
The crude residue was suspended in chloroform (20 mL) filtered and washed 
with chloroform (10 mL). Column chromatography (1 : 9, hexane : ethyl 
acetate) of the concentrated filtrate gave the product 184 (1.12 g, 46%) as a 
colourless oil. 
 
1H NMR (300 MHz, CDCl3) δ 3.97 (1H, d, J = 10.6 Hz, CH) and 3.82 (6H, d, 
J = 10.5 Hz, O-CH3). 
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Dimethyl 1-diazo-2-oxopropyl phosphonate (190)96 
 
P
N2
OMe
O
OMe
O
 
 
A solution of TsCl (8.00 g, 42.0 mmol) and sodium azide (2.73 g, 42.0 mmol) 
in acetone (120 mL) and water (120 mL) was stirred at 0 ºC for 2 h. The 
acetone was evaporated, and the reaction mixture was extracted from diethyl 
ether (3 x 80 mL), and the organic phase was dried in Na2SO4. Evaporation of 
the solvent gave tosyl azide (8.10 g, 98%) as a colourless oil.  
A solution of NaH (990 mg, 41.5 mmol) in THF (150 mL) was cooled to 0 ºC. 
Dimethyl (2-oxopropyl)phosphonate 106 (6.26 ml, 37.7 mmol) in THF 
(50 mL) was added and the resulting mixture was stirred at 0 ºC for 1 h after 
which tosyl azide (8.10 g, 37.7 mmol) was added and left to stir for 30 min. 
The reaction mixture was purified by column chromatography (1 : 9, hexane : 
ethyl acetate) to afford Bestmann-Ohiro reagent 190 (5.10 g, 69%) as a 
colourless oil. 
 
1H NMR (300 MHz, CDCl3) δ 3.86 (6H, d, J = 11.9 Hz, 2 x O-CH3) and 2.28 
(3H, s, CH3). 
 
 (Z)-Trimethyl (1-methoxy-3-methyl-1, 3-butadienyloxy)silane (156)110 
 
OTMS
OMe  
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A solution of n-butyl lithium (1.6 M in hexane, 32.9 mL, 52.5 mmol) was 
added to a solution of diisopropylamine (6.90 mL, 52.6 mmol) in 
THF (60 mL) at -78 °C. The mixture was stirred for 30 min and methyl-3,3-
dimethyl acrylate 161 (5.00 g, 43.8 mmol) and TMSCl 
(7.60 mL, 56.94 mmol) were added sequentially over 15 min intervals. After 
30 min the mixture was warmed to room temperature, stirred for a further 2 h, 
and quenched with NaHCO3 (40 mL). The organic portions were extracted 
with dichloromethane (3 x 40 mL) and the combined organic extracts were 
dried over MgSO4. The solvent was removed under reduced pressure and the 
residue was purified by Kugelrohr distillation (40 °C, 0.5 mbar) to afford the 
silyl enol ether 156 (5.11 g, 63%) as a colourless oil. 
 
1H NMR (300 MHz, CDCl3) δ 4.78 (1H, dt, J =  2.7, 0.8 Hz, H4a), 4.53 (1H, 
dq, J = 2.7, 1.4 Hz, H4b), 4.26 (1H, s, CH2), 3.54 (3H, s, OCH3), 1.93 (3H, dd, 
J = 1.4, 0.7 Hz, CH3) and 0.22 (9H, s, SiCH3). 
 
 4-Methoxybenzyl-2,2,2-trichloroacetimidate (203)111 
 
O
O
NH
CCl3
 
 
To a solution of 4-methoxybenzyl alcohol (34.0 g, 250 mmol) in a KOH (300 
mL, 100g in 100 mL of H2O) and dichloromethane (300 mL) solution was 
added TBA·H2SO4 (870 mg, 2.56 mmol). This was cooled to -10 °C upon 
which TCCN (29.6 mL, 294.4 mol) was added, the resulting mixture was 
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warmed to room temperature then left to stir for 1 h. The product was 
extracted with dichloromethane (3 x 100 mL), dried over Na2SO4, the solvent 
removed under reduced pressure and the residue was purified by Kugelrohr 
distillation (150 °C, 0.5 mbar) to give the product 203 (53.2 g, 77%) as a pale 
orange oil.  
 
1H NMR δ (300 MHz, CDCl3) δ 7.38 (2H, d, J = 8.8 Hz, ArH), 6.92 (2H, d, J 
= 8.8 Hz, ArH), 5.30 (2H, s, CH2) and 3.83 (3H, s, OCH3). 
 
7.4: Experimental for Chapter 2 
 
Tetrahydro-2H-pyran-2-ol (99)112 
 
OHO
 
 
Concentrated HCl (15.0 mL, 95.1 mmol) was added to a stirring solution of 
3,4-dihydro-2H-pyran (40.0 g, 476 mmol) in water (440 mL) at 0 °C over 10 
min. The solution was allowed to warm to room temperature and stirred for 
3 h. The reaction was quenched with aqueous NaHCO3, the product extracted 
with dichloromethane (3 x 100 mL), dried over MgSO4 and concentrated 
under reduced pressure. The product was subsequently purified using 
Kugelrohr distillation (80 °C, 2 mbar) to give the product 99 (27.1 g, 56%) as 
a colourless oil.  
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Rf 0.71 (20% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
4.84-4.80 (1H, m, H1), 4.46 (1H, d, J = 4.6 Hz, O-H), 3.98–3.89 (1H, m, H5a), 
3.51–3.43 (1H, m, H5b), 1.83–1.69 (2H, m, H2) and 1.51–1.42 (4H, m, H3 and 
H4). 
 
(E)-Methyl-7-hydroxyhept-2-enoate (100)113 
 
O
O
OH  
 
To a stirred solution of carbomethoxymethyl triphenylphosphonium 200 
(9.20 g, 27.4 mmol) in THF (100 mL) was added, 2-tetrahydro-2H-pyran-2-ol 
99 (2.00 g, 19.6 mmol) and the mixture was heated under reflux for 3 h. The 
solvent was removed under reduced pressure, and the concentrate was stirred 
for 45 min in a 7 : 3 mixture of diethyl ether and petroleum ether (40 mL). 
The resulting suspension was filtered and washed with the same mixture 
(10 mL). The crude mixture was concentrated under reduced pressure and the 
residue was purified by column chromatographed (4 : 1, hexane : ethyl 
acetate) to give the product 100 (2.03 g, 66%, E : Z = 9 : 1) as a colourless oil. 
 
Rf 0.55 (50% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
6.96 (1H, dt, J = 15.8, 6.8 Hz, H3), 5.82 (1H, dt, J = 15.7, 1.6 Hz, H2), 3.71 
(3H, s, O-CH3), 3.68-3.61 (2H, m, H7), 2.27–2.20 (2H, m, H4) and 1.68–1.48 
(4H, m, H5 and H6). 
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(E)-7-Methoxy-7-oxo-hept-5-enoic acid (103)114 
 
O
O
OH
O
 
 
To a solution of TEMPO (100 mg, 640 µmol) and BIAB (2.06 g, 6.41 mmol) 
in a mixture of acetonitrile and water (14 mL, 1 : 1), (E)-methyl-7-
hydroxyhept-2-enoate 100 (500 mg, 3.20 mmol) was added at 0 °C. The 
solution was allowed to warm to room temperature where it was stirred for 
12 h. The reaction was quenched with aqueous NH4Cl (10 mL), extracted with 
dichloromethane (3 x 15 mL) and dried over sodium sulfate. The residue was 
purified by column chromatography (1 : 9, hexane : ethyl acetate) to provide 
the carboxylic acid 103 (0.54 g, 98%) as a colourless oil. 
 
Rf 0.51 (50% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
11.07 (1H, br s, C(O)-OH), 6.94 (1H, dt, J = 15.6, 6.9 Hz, H5), 5.84 (1H, dt, J 
= 15.7, 1.5 Hz, H6), 3.70 (3H, s, O-CH3), 2.36 (2H, t, J = 7.3 Hz, H2) 2.26 
(2H, ddt, J = 7.4, 7.0, 1.6 Hz, CH4) and 1.79 (2H, tt, J = 7.4, 7.3 Hz, H3)  
 
5-Hexenoic acid (103)115 
 
OH
O
 
 
To a solution of TEMPO (625 mg, 4.0 mmol) and BIAB (12.9 g, 40.0 mmol) 
in a mixture of acetonitrile and water (100 mL, 1 : 1), 5-hexen-1-ol 105 (2.00 
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g, 20.0 mmol) was added at 0 °C. The solution was allowed to warm to room 
temperature where it was stirred for 14 h. The reaction was quenched with 
aqueous NH4Cl (100 mL), extracted with dichloromethane (3 x 100 mL) and 
dried over sodium sulfate. The residue was purified by column 
chromatography (1 : 9, hexane : ethyl acetate) to provide the carboxylic acid 
103 (1.21 g, 80%) as a colourless oil. 
 
Rf 0.39 (20% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
11.82 (1H, br s, OH), 5.83-5.73 (1H, m, H5), 5.07-4.99 (2H, m, H6), 2.37 (2H, 
t, 7.6 Hz, H2), 2.15-2.09, (2H, m, H4) and 1.74 (2H, tt, 7.6, 7.6 Hz, H3). 
 
Dimethyl-2-oxohept-6-enylphosphonate (101) 
 
O
P
O
O
O
 
 
To a suspension of NaH (520 mg, 21.6 mmol, 60% dispersion in mineral oil) 
in THF (30 mL), dimethyl-2-oxypropylphosphonate 106 (1.70 mL, 12.0 
mmol) was added drop wise, at room temperature. The resulting mixture was 
stirred for 1.5 h prior to the addition of a solution of n-butyl lithium in hexane 
(8.25 mL of a 1.6 M in hexane, 13.2 mmol) at 0 °C. The solution was stirred 
for 20 min and 4-bromobutene (1.40 mL, 14.4 mmol) was added. The 
resulting mixture was warmed to room temperature and stirred for a further 
3 h. The reaction was quenched with 2M HCl (8 mL), extracted with 
dichloromethane (3 x 15 mL), the combined organic extracts were washed 
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with brine (20 mL) and dried over MgSO4. The solvent was removed under 
reduced pressure and column chromatography (1 : 9, hexane : ethyl acetate) 
afforded the product 101 (2.45 g, 95%) as a colourless oil. 
 
Rf 0.47 (5% MeOH : CH2Cl2); IR (thin film) 2957, 1713, 1360, 1252, 1184, 
1018, 825 and 808 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.70 (1H, ddt, J = 
10.3, 8.6, 6.9 Hz, H6), 4.99–4.89 (2H, m, H7), 3.72 (6H, d, J = 11.2 Hz, PO-
CH3 x 2), 3.03 (2H, d, J = 22.8 Hz, H1), 2.57 (2H, t, J = 7.3 Hz, H3), 2.00 (2H, 
dt, J = 7.2, 7.2 Hz, H5) and 1.63 (2H, tt, J = 7.3, 7.3 Hz, H4); 13C NMR (75 
MHz, CDCl3) δ 201.6, 137.8, 115.1, 52.9, 52.9, 43.2, 41.9, 32.7 and 22.3; 
HRMS (ES+) calc. For C9H18O4P [M + H]+ 221.0937, found 221.0937. 
 
Methyl-8-(dimethoxyphosphoryl)-7-oxooct-(2E)-enoate (91) 
 
O
P
O
O
O
O
O
 
 
Method A: 
To a solution of dimethyl-2-oxohept-6-enylphosphonate 101 (2.20 g, 9.99 
mmol) in dichloromethane (30 mL) was added methyl acrylate (30 mL) and 
Grubbs II catalyst 107 (100 mg, 118 µmol). The solution was heated under 
reflux for 16 h upon which a further portion of Grubb’s second-generation 
catalyst 107 (100 mg, 118 µmol) was added and this was left stirring at this 
temperature for a further 24 h. The solution was concentrated under reduced 
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pressure and purified by column chromatography (1 : 9, hexane : ethyl 
acetate) to yield the olefin 91 (2.78 g, 94 %, E : Z = 15 : 1) as a brown oil. 
 
Method B: 
To a solution of dimethyl-2-oxohept-6-enylphosphonate 101 (180 mg, 820 
µmol) in dichloromethane (3 mL) was added a solution of methyl acrylate (3 
mL) and a solution of the Nolan-modified ruthenium catalyst 119 (10.0 mg, 
8.81 µmol) in dichloromethane (5 mL). The solution was heated under reflux 
for 16 h upon which a further portion of the Nolan-modified ruthenium 
catalyst 119 (10.0 mg, 8.81 µmol) was added and this was left stirring at this 
temperature for a further 24 h. The solution was concentrated under reduced 
pressure and purified by column chromatography (1 : 9, hexane : ethyl 
acetate) to yield the olefin 91 (170 mg, 79 %, E : Z = 10 : 1) as a brown oil. 
 
Rf 0.59 (5% MeOH : CH2Cl2); IR (thin film) 2957, 1713, 1653, 1437, 1254, 
1182, 1018, 829 and 814 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.90 (1H, dt, J 
= 15.6, 7.0 Hz, H3), 5.81 (1H, dt, J = 15.7, 1.5 Hz, H2), 3.76 (6H, d, J = 11.3 
Hz, PO-CH3 x 2), 3.76 (3H, s, C(O)O-CH3), 3.06 (2H, d, J = 22.9 Hz, H8), 
2.63 (2H, t, J = 7.2 Hz, H6), 2.20 (2H, ddt, J = 1.6, 7.1, 7.1 Hz, H4) and 1.74 
(2H, tt, J = 7.3, 7.2 Hz, H5); 13C NMR (75 MHz, CDCl3) δ 202.2, 147.2, 
134.2, 124.0, 52.1, 50.5, 42.0, 39.6, 25.4 and 20.5; HRMS (ES+) calc. For 
C11H20O6P [M + H]+ 279.0992, found 279.0996. 
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4-(tert-Butyldimethylsilyl)oxy-butan-1-ol (126)116 
 
TBSO OH  
 
To a solution of 1,4-butanediol 125 (19.7 mL, 222 mmol), triethylamine 
(13.4 mL, 96.2 mmol) and DMAP (900 mg, 7.36 mmol) in dichloromethane 
(80 mL) at room temperature was slowly added a solution of TBSCl (11.2 g, 
74.3 mmol) in dichloromethane (20 mL). After 16 h, the reaction solution was 
quenched with brine (100 mL) and the organics were extracted with 
dichloromethane (3 × 50 mL). The combined organic extracts were washed 
with water (200 mL), brine (100 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure. Purification by column chromatography 
(7 : 3, hexane : ethyl acetate) provided alcohol 126 (25.8 g, 86%) as a 
colourless oil. 
 
Rf 0.43 (50% EtOA : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 3.70-
3.62 (4H, m, H1 + H4), 2.54 (1H, t, J = 5.4 Hz, OH), 1.71-1.60 (4H, m, H2 + 
H3), 0.91 (9H, s, Si-C(CH3)3), 0.08 (6H, m, Si-CH3).  
 
4-(tert-Butyldimethylsilyl)oxy-butanal (204)115 
 
TBSO H
O
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To a solution of oxalyl chloride (6.78 mL, 78.4 mmol) in dichloromethane 
(100 mL) at -78 ºC was slowly added DMSO (6.66 mL, 94.2 mmol). After 
30 min, a solution of alcohol 126 (8.00 g, 39.2 mmol) in dichloromethane 
(50 mL) was added dropwise. After 2 h, triethylamine (19.1 mL, 274 mmol) 
was added and the slurry was allowed to attain room temperature. After 1 h, 
an aqueous solution of NH4Cl (100 mL) was added and the organics were 
extracted with dichloromethane (3 × 100 mL). The combined organic extracts 
were washed with water (100 mL), brine (100 mL), dried (MgSO4), filtered 
and concentrated under reduced pressure to give the crude aldehyde 204, 
which was used without further purification. 
 
Rf 0.71 (25% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
9.80 (1H, t, J = 1.7 Hz, CHO), 3.66 (2H, t, J = 5.9 Hz, H4), 2.51 (2H, dt, J = 
1.7, 7.2 Hz, H2), 1.87 (2H, m, H3), 0.89 (9H, s, Si-C(CH3)3) and 0.05 (6H, m, 
Si-CH3).  
 
(E)-Ethyl 6-(tert-butyldimethylsilyl)oxy-hex-2-enoate (121)115 
 
TBSO
O
OEt  
 
To a solution of triethyl phosphonoacetate 127 (9.36 mL, 51.0 mmol), lithium 
chloride (11.1 g, 262 mmol) and Hünig’s base (4.30 mL, 35.2 mmol) in 
acetonitrile (100 mL) at room temperature was added a solution of freshly 
prepared aldehyde 204 (39.2 mmol) in acetonitrile (50 mL). After 18 h, water 
(100 mL) was added and the organics were extracted with ethyl acetate (3 × 
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100 mL). The combined extracts were dried (MgSO4) and concentrated under 
reduced pressure. Purification by column chromatography (9 : 1, hexane : 
ethyl acetate) provided (E)-enoate 121 (7.10 g, 70% over two steps, E : Z = 30 
: 1) as a colourless oil. 
 
Rf 0.52 (25% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.00 (1H, dt, J = 15.7, 7.0 Hz, H3), 5.84 (1H, dt, J = 15.7, 1.6 Hz, H2), 4.19 
(2H, q, J = 7.9 Hz, OCH2), 3.47 (2H, t, J = 6.1 Hz, H6), 2.28 (2H, ddt, J = 1.6, 
8.4, 7.0 Hz, H4), 1.72-1.63 (2H, m, H5), 1.29 (3H, t, J = 7.2 Hz, OCH2CH3), 
0.90 (9H, s, Si-C(CH3)3) and 0.05 (6H, m, Si-CH3). 
 
(2R, 3S)-Ethyl-6-(tert-butyldimethylsilyl)oxy-2, 3-dihydrohexanoate (122) 
 
TBSO
O
OEt
OH
OH
 
 
To a solution of enoate 121 (6.81 g, 26.4 mmol) in t-BuOH : H2O (1 : 1, 
120 mL) at 0 ºC was added methanesulfonamide (5.01 g, 52.7 mmol) and AD-
mix-α (39.6 g, 1.5 g/mmol of 128). The solution was allowed to attain room 
temperature, and after 16 h, sodium thiosulfate (78.6 g, 316 mmol) was added. 
After 1 h, water (100 mL) and dichloromethane (100 mL) were added and the 
organics were extracted with dichloromethane (3 × 100 mL). The combined 
organic extracts were dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by column chromatography (3 : 2, hexane : ethyl 
acetate) provided diol 122 (7.52 g, 93%) as a colourless oil. 
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Rf 0.43 (50% ethyl acetate : petroleum ether);  -15.1 (c 1.1, CHCl3); IR 
(thin film) 3412, 2955, 2854, 1747, 1472, 1256, 1100, 837 and 777 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.29 (2H, q, J = 7.1 Hz, OCH2) 4.07 (1H, d, J = 
2.2 Hz, H2), 3.97-3.92 (1H, m, H3), 3.74-3.65 (2H, m, H6), 1.75-1.69 (4H, m, 
H4 + H5), 1.32 (3H, t, J = 7.1 Hz, OCH2CH3), 0.90 (9H, s, Si-C(CH3)3) and 
0.08 (6H, m, Si-CH3); 13C NMR (100 MHz, CDCl3) δ 173.4, 73.6, 72.3, 63.3, 
61.2, 31.0, 29.0, 25.9, 18.3, 14.2 and -5.4; HRMS (ES+) calc. for C14H31O5Si 
([M+H]+) 307.1935, found 307.1938. 
 
(2R, 3S)-6-(tert-Butyldimethylsilyl)oxy-2-hydroxy-1-ethoxy-1-oxohexan-3-
yl benzoate (133) 
 
TBSO
O
OEt
OBz
OH
 
 
To a solution of diol 122 (4.81 g, 16.5 mmol), triethylamine (5.76 mL, 41.4 
mmol) and DMAP (60.0 mg, 570 µmol) in dichloromethane (70 mL) at -78 ºC 
was added benzoyl chloride (1.95 mL, 16.9 mmol) dropwise. After 1 h, the 
reaction solution was allowed to attain -50 ºC. After a further 16 h, an 
aqueous solution of NaHCO3 (100 mL) was added, and the organics were 
extracted with dichloromethane (3 × 80 mL). The combined organic extracts 
were dried (Na2SO4), filtered and concentrated under reduced pressure. 
Purification by column chromatography (19 : 1, hexane : ethyl acetate) 
provided benzoate 133 (5.06 g, 77%) as a colourless oil. 
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Rf 0.51 (25% ethyl acetate : petroleum ether);  -209 (c 1.0, CHCl3); IR 
(thin film) 3493, 2954, 2858, 1748, 1723, 1452, 1271, 1110, 835, 777 and 712 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.02-7.99 (2H, m, Ar-H), 7.60-7.54 (1H, 
m, Ar-H), 7.47-7.41 (2H, m, Ar-H), 5.46 (1H, dt, J = 7.0, 2.2 Hz, H3), 4.35 
(1H, dd, J = 7.5, 2.2 Hz, H2), 4.18 (2H, q, J = 7.2 Hz, OCH2CH3), 3.70-3.65 
(2H, m, H6), 3.11 (1H, d, J = 7.4, OH), 2.00-1.92 (2H, m, H4), 1.70-1.62 (2H, 
m, H5), 1.21 (3H, t, J = 7.2 Hz, OCH2CH3), 0.90 (9H, s, Si-C(CH3)3), 0.05 
(3H, m, Si-CH3) and 0.04 (3H, m, Si-CH3); 13C NMR (100 MHz, CDCl3) δ 
172.9, 165.8, 133.3, 129.9, 129.8, 128.5, 74.8, 71.9, 62.8, 62.3, 28.7, 27.3, 
26.1, 18.4, 14.2 and -5.2; HRMS (ES+) calc. for C21H35O6Si ([M+H]+) 
411.2197, found 411.2184. 
 
(2R, 3S)-2, 6-Bis(tert-butyldimethylsilyl)oxy-1-ethoxy-1-oxohexan-3-yl 
benzoate (134) 
 
TBSO
O
OEt
OBz
OTBS
 
 
To a solution of TBSCl (2.44 g, 16.2 mmol) and imidazole (2.20 g, 32.3 
mmol) in DMF (5 mL) at 0 ºC was added a solution of alcohol 133 (4.27 g, 
10.8 mmol) in DMF (4 mL). After 14 h, a saturated solution of NH4Cl 
(10 mL) was added and the organics were extracted with dichloromethane 
(3 × 10 mL). The combined organic extracts were washed with water (40 mL) 
and brine (20 mL), then dried (Na2SO4), filtered and concentrated under 
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reduced pressure. Purification by column chromatography (99 : 1 to 19 : 1, 
hexane : ethyl acetate) provided bis-TBS-ether 134 (4.80 g, 87%) as a 
colourless oil. 
 
Rf 0.47 (10% ethyl acetate : petroleum ether);  -3.0 (c 1.0, CHCl3); IR 
(thin film) 2955, 2858, 1762, 1724, 1473, 1271, 1109, 837, 778 and 711 cm-1; 
1H NMR (400 MHz, CDCl3) δ 8.06-8.03 (2H, m, Ar-H), 7.58-7.52 (1H, m, 
Ar-H), 7.46-7.40 (2H, m, Ar-H), 5.40-5.34 (1H, dt, J = 7.1, 3.9 Hz, H3), 4.41 
(1H, d, J = 4.0 Hz, H2), 4.13 (2H, q, J = 7.2 Hz, OCH2CH3), 3.68-3.60 (2H, 
m, H6), 1.94-1.83 (2H, m, H4), 1.66-1.59 (2H, m, H5), 1.18 (3H, t, J = 7.3 Hz, 
OCH2CH3), 0.93 (9H, s, Si-C(CH3)3), 0.89 (9H, s, Si-C(CH3)3), 0.11 (3H, m, 
Si-CH3), 0.06 (3H, m, Si-CH3) and 0.04 (6H, m, 2 x Si-CH3); 13C NMR (100 
MHz, CDCl3) δ 171.3, 166.1, 133.0, 130.3, 129.8, 128.4, 75.2, 73.4, 62.8, 
61.1, 29.0, 26.7, 26.0, 25.8, 22.8, 18.3, 14.2, -4.8 and -5.2; HRMS (ES+) calc. 
for C27H49O6Si2 ([M+H]+) 525.3068, found 525.3049. 
 
(2R,3S)-2,6-Bis(tert-butyldimethylsilyl)oxy-3-hydroxy-N-methoxy-N-
methyl hexanamide (135) 
 
TBSO N
OOH
TBSO
OMe
 
 
To a solution of ethyl-ester 134 (3.18 g, 6.21 mmol) and N,O-dimethyl 
hydroxylamine hydrochloride (900 mg, 9.11 mmol) in THF (75 mL) at -30 ºC 
was slowly added iso-propylmagnesium chloride (13.9 mL, 27.9 mmol, 2M in 
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THF). The reaction solution was allowed to attain room temperature and after 
6 h a saturated solution of NH4Cl (70 mL) was added. The organics were 
extracted with dichloromethane (3 × 80 mL) and the combined organic 
extracts were dried (Na2SO4), filtered and concentrated under reduced 
pressure. Purification by column chromatography (4 : 1, hexane : ethyl 
acetate) provided Weinreb amide 135 (2.31 g, 85%) as a colourless oil. 
 
Rf 0.40 (40% ethyl acetate : petroleum ether);  -12.5 (c 1.1, CHCl3); IR 
(thin film) 2930, 2857, 1726, 1646, 1473, 1387, 1255, 1098, 837, 778 and 706 
cm-1; 1H NMR (400 MHz, CDCl3) δ 4.48 (1H, d, J = 3.6 Hz, H2), 3.83-3.77 
(1H, m, H3), 3.71 (3H, s, NOCH3), 3.68-3.63 (2H, m, H6), 3.57 (3H, s, NCH3), 
1.78-1.53 (4H, m, H4 + H5), 0.94 (9H, s, Si-C(CH3)3), 0.90 (9H, s, Si-
C(CH3)3), 0.13 (3H, s, Si-CH3), 0.09 (3H, s, Si-CH3) and 0.05 (6H, s, 2 × Si-
CH3); 13C NMR (100 MHz, CDCl3) δ 170.0, 72.5, 63.0, 61.2, 61.0, 33.8, 
30.4, 29.1, 26.0, 25.8, 18.4, 18.3, -4.6, -5.3 and -5.3; HRMS (ES+) calc. for 
C20H46NO5Si2 ([M+H]+) 436.2905, found 436.2909. 
 
(2R,3S)-2,6-Bis(tert-butyldimethylsilyl)oxy-3-(p-methoxybenzyl)oxy-N-
methoxy-N-methyl hexanamide (96) 
 
TBSO N
OPMBO
TBSO
OMe
 
 
To a solution of alcohol 135 (2.00 g, 4.60 mmol) and PMBTCA (1.62 g, 
5.74 mmol) in toluene (40 mL) at 0 ºC was added scandium (III) triflate 
 
144 
(134 mg, 240 µmol). After 6 h, the reaction mixture was filtered, and the 
filtrand was washed with hexane (3 x 30 mL). The filtrate was concentrated 
under reduced pressure. Purification by column chromatography (19 : 1, 
hexane : ethyl acetate) provided PMB ether 96 (1.96 g, 77%) as a colourless 
oil. 
 
Rf 0.57 (25% ethyl acetate : petroleum ether);  -0.9 (c 1.0, CHCl3); IR 
(thin film) 2930, 2857, 1726, 1646, 1473, 1387, 1255, 1098, 837, 778 and 706 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27 (2H, d J = 8.6 Hz, Ar-H), 6.86 (2H, 
d J = 8.6 Hz, Ar-H), 4.74-4.55 (2H, m, OCHaHbPhOMe + H2), 4.52 (1H, d, J 
= 11.0 Hz, OCHaHbPhOMe), 3.80 (3H, s, NOCH3), 3.75-3.65 (4H, m, NCH3), 
3.60-3.53 (2H, m, H6), 3.20 (3H, br s, ArOCH3), 1.78-1.41 (4H, m, H5 + H4), 
0.93 (9H, s, Si-C(CH3)3), 0.88 (9H, s, Si-C(CH3)3), 0.10 (3H, s, Si-CH3), 0.1 
(3H, s, Si-CH3) and 0.03 (6H, s, 2 × Si-CH3); 13C NMR (100 MHz, CDCl3) δ 
159.1, 131.0, 129.7, 113.7, 80.5, 72.9, 63.1, 55.3, 29.2, 27.3, 26.0, 25.9, 18.3, 
-4.7, -5.0 and -5.3; HRMS (ES+) calc. for C28H54NO6Si2 ([M+H]+) 556.3479, 
found 556.3484. 
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(2E, 8E, 10S, 11S)-Methyl-10, 14-bis((tert-butyldimethylsilyl)oxy)-11-(4-
methoxy benzyl)oxy-7-oxotetradeca-2, 8-dienoate (97) 
 
MeO
O
O
TBSO
OPMB
TBSO
 
 
To a solution of Weinreb amide 96 (1.02 g, 1.88 mmol) in THF (20 mL) at -
78 ºC was added DIBAL (3.6 mL, 3.60 mmol, 1 M in dichloromethane). After 
1 h, the reaction solution was transferred to a stirring aqueous solution of 
Rochelle salt (30 mL) via cannula. After 3 h, the organics were extracted with 
dichloromethane (3 × 30 mL) and the combined organic extracts were dried 
over Na2SO4, filtered and concentrated under reduced pressure, to give 
aldehyde 136 which was used without further purification.  
A mixture of 18-crown-6 (700 mg, 2.66 mmol), ground K2CO3 (3.66 g, 
26.6 mmol) in toluene (50 mL) was stirred for 1 h at room temperature prior 
to the introduction of a solution of the freshly prepared aldehyde 136 in 
toluene (10 mL), followed by a solution of C1-C8 phosphonate 91 (2.10 
g, 15.2 mmol) in toluene (10 mL). After 20 h, an aqueous solution of NH4Cl 
(50 mL) was added and the organics were extracted with dichloromethane 
(3 × 50 mL) and the combined organic extracts were washed with water 
(50 mL), dried over Na2SO4, filtered and concentrated under reduced 
pressure. Purification by column chromatography (9 : 1, hexane : ethyl 
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acetate) provided dienoate  97 (861 mg, 71% over two steps, E : Z = 6 : 1) as a 
colourless oil. 
 
Rf 0.33 (25% ethyl acetate : petroleum ether);  -11.8 (c 1.0, CHCl3); IR 
(thin film) 2929, 2856, 1722, 1674, 1612, 1514, 1247, 1093, 1035, 837 and 
775 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29-7.26 (2H, m, Ar-H), 7.01-6.81 
(4H, m, Ar-H, H3 + H9), 6.29 (1H, dd, J = 15.7, 1.7 Hz, H8), 5.85 (1H, dt, J = 
15.5, 1.4 Hz, H2), 4.58-4.41 (3H, m, OCH2Ph + H10), 3.82 (3H, s, OCH3), 
3.74 (3H, s, OCH3), 3.62-3.52 (2H, m, H11 + H14a), 3.45-3.36 (1H, m, H14b), 
2.59 (2H, t, J = 7.5 Hz, H6), 2.29-2.18 (2H, m, H4), 1.85-1.59 (6H, m, H12 + 
H13 + H5), 0.90 (9H, s, Si-C(CH3)3), 0.88 (9H, s, Si-C(CH3)3) and 0.04-0.01 
(12H, m, 4 × Si-CH3); 13C NMR (100 MHz, CDCl3) δ 199.4, 166.9, 158.9, 
148.6, 146.0, 130.4, 129.6, 129.5, 129.4, 121.5, 113.8, 81.8, 80.4, 72.4, 63.1, 
55.3, 51.4, 39.0, 31.4, 29.5, 29.1, 27.2, 26.0, 25.8, 22.3, 18.1, -4.8, -5.0 and -
5.3; HRMS (ES+) calc. for C35H64NO7Si2 ([M+NH4]+) 666.4221, found 
666.4216. 
 
(2E, 8E, 10S, 11S)-Methyl-10-((tert-butyldimethylsilyl)oxy)-14-hydorxy-
11-(4-methoxy benzyl)oxy-7-oxotetradeca-2, 8-dienoate (137) 
 
MeO
O
O
TBSO
OPMB
HO
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To a solution of silyl ether 97 (20.0 mg, 31.0 µmol) in dichloromethane : 
methanol (1.4 mL, 6 : 1) at room temperature was added CSA (1.00 mg, 3.10 
µmol). The reaction mixture was left to stir for 1.5 h, then quenched with a 
saturated solution of NaHCO3 (1 mL), extracted with diethyl ether and dried 
over Na2SO4. The mixture was filtered and the resulting solution was 
concentrated under reduced pressure, and then purified by column 
chromatography (7 : 3, hexane : ethyl acetate) to give the primary alcohol 137 
(13.6 mg, 81%) as a colourless oil. 
 
Rf 0.31 (50% ethyl acetate : petroleum ether);  -10.3 (c 1.0, CHCl3); IR 
(thin film) 2953, 2928, 2856, 1717, 1653, 1514, 1456, 1254, 1035, 839 and 
779 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29-7.27 (2H, m, Ar-H), 6.93-6.86 
(4H, m, Ar-H, H3 + H9), 6.30 (1H, dd, J = 1.8, 16.0 Hz, H8), 5.85 (1H, dt, J = 
1.5, 15.7 Hz, H2), 4.61-4.49 (3H, m, OCH2Ph + H10), 3.81 (3H, s, OMe), 3.70 
(3H, s, OMe), 3.60-3.57 (2H, m, H11 + H14a), 3.44-3.40 (1H, m, H14b), 3.20 
(1H, br s, OH), 2.60 (2H, t, J = 7.5 Hz, H6), 2.29-2.18 (2H, m, H4), 1.82-1.56 
(6H, m, H12 + H13 + H5), 0.92 (9H, s, Si-C(CH3)3), 0.05 (3H, s, Si-CH3) and 
0.03 (3H, s, Si-CH3); 13C NMR (126 MHz, CDCl3) δ 199.4, 167.0, 159.4, 
148.6, 145.6, 132.1, 129.8, 121.5, 113.9, 113.7, 81.8, 80.3, 72.5, 62.8, 55.3, 
51.5, 39.1, 31.4, 29.7, 29.4, 25.9, 22.2, 18.2, -4.8 and -5.0; HRMS (ES+) calc. 
for C29H50NO7Si ([M+NH4]+) 552.3351, found 552.3343. 
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(2E, 8E, 10S, 11S)-Methyl-10, 14-bis((tert-butyldimethylsilyl)oxy)-11-
hydorxy-7-oxotetradeca-2, 8-dienoate (138) 
 
MeO
O
O
TBSO
OH
TBSO
 
 
To a solution of PMB ether 97 (19 mg, 28 µmol) in dichloromethane 
(1.0 mL) and pH 7 buffer (100 µL) at 0 °C, was added recrystallised 
DDQ (13 mg, 82 µmol). The solution was stirred at room temperature for 
2 h and quenched with NaHCO3 (2 mL), extracted with dichloromethane 
(3 x 2 mL). The solution was concentrated under reduced pressure and 
purified by column chromatography (4 : 1 to 7 : 3, hexane : ethyl acetate) to 
yield the alcohol 138 (12 mg, 81%) as a colourless oil. 
 
Rf 0.22 (50% ethyl acetate : petroleum ether);  +0.90 (c 1.0, CHCl3); IR 
(thin film) 3393, 2953, 2928, 2856, 1720, 1661, 1472, 1462, 1254, 1096, 834 
and 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.94 (1H, dt, J = 15.7, 7,0 Hz, 
H3), 6.85 (1H, dd, J = 5.2, 15.9 Hz, H9), 6.25 (1H, dd, J = 1.6, 16.0 Hz, H8), 
5.83 (1H, dt, J = 15.7, 1.6 Hz, H2), 4.25 (1H, ddd, J = 4.3, 5.0, 1.5 Hz, H10), 
3.72 (3H, s, OMe), 3.69-3.60 (2H, m, H11 + H14a), 3.55-3.51 (1H, m, H14b), 
3.20 (1H, br s, OH), 2.59 (2H, t, J = 7.2 Hz, H6), 2.26-2.20 (2H, m, H4), 1.83-
1.55 (6H, m, H12 + H13 + H5), 0.91 (9H, s, Si-C(CH3)3), 0.88 (9H, s, Si-
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C(CH3)3) and 0.07-0.04 (12H, m, 4 × Si-CH3); 13C NMR (100 MHz, CDCl3) 
δ 199.4, 166.9, 145.8, 129.7, 121.6, 75.1, 74.5, 63.2, 51.4, 39.2, 31.6, 29.7, 
29.6, 29.3, 25.9, 25.9, 22.2, 18.3, 18.2, -5.0 and -5.4; HRMS (ES+) calc. for 
C27H53O6Si2 ([M+H]+) 529.3375, found 529.3369. 
 
(2E, 7R, 8E, 10S, 11S)-Methyl-10, 14-bis((tert-butyldimethylsilyl)oxy)-7-
hydroxy-11-((4-methoxy benzyl)oxy)tetradeca-2, 8-dienoate (143) 
 
MeO
O
OH
TBSO
OPMB
TBSO
 
 
To a solution of (+)-DIP-Cl (161 mg, 500 µmol) in THF (5.0 mL) at -78 °C, 
was added a solution of ketone 97 (32.0 mg, 50.0 µmol) in THF (5.0 mL).  
The reaction was warmed to room temperature and left to stir for 16 h, when it 
was quenched with NH4Cl (6 mL), extracted with diethyl ether (3 x 5 mL) and 
dried over MgSO4 to give a mixture of diastereoisomers (7S : 7R = 1 : 3). The 
product was purified by column chromatography (17 : 3, hexane : ethyl 
acetate) to give (7R)-alcohol 143 (20.6 mg, 66%) as a colourless oil. 
 
Rf 0.32 (30% ethyl acetate : petroleum ether);  -1.5 (c 1.1, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.28-7.25 (2H, m, Ar-H), 6.96 (1H, dt, J = 15.6, 
7.0 Hz, H3), 6.88 (2H, d, J = 8.8 Hz, Ar-H), 5.83 (1H, dt, J = 1.6, 15.6 Hz, 
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H2), 5.75-5.71 (2H, m, H8 + H9), 4.61-4.48 (2H, m, OCH2Ph), 4.30-4.28 (1H, 
m, H10), 4.17-4.10 (1H, m, H7), 3.81 (3H, s, OMe), 3.73 (3H, s, OMe), 3.67-
3.55 (2H, m, H11 + H14a), 3.34-3.30 (1H, m, H14b), 2.25-2.20 (2H, m, H4), 
1.90-1.47 (8H, m, H12 + H13 + H6  + H5), 0.90 (18H, s, 2 × Si-C(CH3)3) and 
0.05-0.03 (12H, m, 4 × Si-CH3). 
 
(R)-MTPA ester of 143 (144) 
 
MeO
O
TBSO
OPMB
TBSO
O
O
CF3
Ph
MeO
 
 
To a solution of alcohol 143 (3 mg, 4.70 µmol), DCC (2.0 mg, 9.4 µmol) and 
DMAP (2 mg) in dichloromethane (2.0 mL) at room temperature was added 
(+)-(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (2.2 mg, 9.4 µmol). 
After 6 h, the crude reaction mixture was purified directly by column 
chromatography (19 : 1, hexane : ethyl acetate) to give (R)-MTPA ester 144 
(2.3 mg, 57%). 
 
Rf  0.42 (20%, ethyl acetate : hexane); 1H NMR (400 MHz, CDCl3) δ 7.50-
7.47 (2H, m, Ar-H), 7.42-7.38 (3H, m, Ar-H), 7.28-7.25 (2H, m, Ar-H), 6.90-
6.87 (3H, m, Ar-H + H3), 5.97-5.95 (1H, m, H9), 5.75 (1H, dt, J = 1.6, 15.5 
Hz, H2), 5.69-5.68 (1H, m, H8), 4.61-4.48 (2H, m, OCH2Ph), 4.30-4.27 (2H, 
m, H7 + H10), 3.81 (3H, s, OMe), 3.73 (3H, s, OMe), 3.58-3.55 (1H, m, H14a), 
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3.47 (3H, d, J = 1.1 Hz, MTPA-OCH3), 3.34-3.28 (1H, m, H11 + H14b), 2.15-
2.10 (2H, m, H4), 1.85-1.34 (8H, m, H12 + H13 + H6  + H5), 0.90 (18H, s, 2 × 
Si-C(CH3)3) and 0.05-0.03 (12H, m, 4 × Si-CH3). 
 
(S)-MTPA ester of 143 (145) 
 
MeO
O
TBSO
OPMB
TBSO
O
O
F3C
Ph
OMe
 
 
To a solution of alcohol 143 (3 mg, 4.70 µmol), DCC (2.0 mg, 9.4 µmol) and 
DMAP (2 mg) in dichloromethane (2.0 mL) at room temperature was added 
(+)-(S)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (2.2 mg, 9.4 µmol). 
After 6 h, the crude reaction mixture was purified directly by column 
chromatography (19 : 1, hexane : ethyl acetate) to give (S)-MTPA ester 145 
(2.1 mg, 51%). 
 
Rf  0.43 (20%, ethyl acetate : hexane); 1H NMR (400 MHz, CDCl3) δ 7.49-
7.47 (2H, m, Ar-H), 7.41-7.37 (3H, m, Ar-H), 7.28-7.25 (2H, m, Ar-H), 6.90-
6.86 (3H, m, Ar-H + H3), 5.87-5.86 (1H, m, H9), 5.80 (1H, dt, J = 1.4, 15.0 
Hz, H2), 5.69-.5.67 (1H, m, H8), 4.56-4.45 (2H, m, OCH2Ph), 4.32-4.30 (1H, 
m, H7), 4.28-4.27 (1H, m, H10), 3.80 (3H, s, OMe), 3.75 (3H, s, OMe), 3.56-
3.54 (1H, m, H14a), 3.50 (3H, d, J = 1.3 Hz, MTPA-OCH3), 3.30-3.26 (1H, m, 
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H11 + H14b), 2.21-2.19 (2H, m, H4), 1.90-1.40 (8H, m, H12 + H13 + H6  + H5), 
0.90 (18H, s, 2 × Si-C(CH3)3) and 0.05-0.03 (12H, m, 4 × Si-CH3). 
 
(2E, 7S, 8E, 10S, 11S)-Methyl-10, 14-bis((tert-butyldimethylsilyl)oxy)-7-
hydroxy-11-((4-methoxy benzyl)oxy)tetradeca-2, 8-dienoate (141) 
 
MeO
O
OH
TBSO
OPMB
TBSO
 
 
To a solution of (-)-DIP-Cl (2.50 g, 7.71 mmol) in THF (40 mL) at -78 °C, 
was added a solution of ketone 97 (500 mg, 771 µmol) in THF (20 mL).  The 
reaction was warmed to room temperature and left to stir for 16 h, when it was 
quenched with NH4Cl (30 mL), extracted with diethyl ether (3 x 30 mL) and 
dried over MgSO4 to give a mixture of diastereoisomers (7S : 7R = 5 : 1). The 
product was purified by column chromatography (17 : 3, hexane : ethyl 
acetate) to give (7S)-alcohol 141 (350 mg, 69%) as a colourless oil. 
 
Rf 0.35 (30% ethyl acetate : hexanes);  -8.2 (c 1.0, CHCl3); IR (thin film) 
3402, 2951, 2928, 2857, 1742, 1514, 1247, 1093, 833 and 775 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.28-7.25 (2H, m, Ar-H), 6.96 (1H, dt, J = 15.6, 6.8 Hz, 
H3), 6.88 (2H, d, J = 8.3 Hz, Ar-H), 5.83 (1H, dt, J = 1.5, 1.55 Hz, H2), 5.74-
5.69 (2H, m, H8 + H9), 4.63-4.49 (2H, m, OCH2Ph), 4.32-4.29 (1H, m, H10), 
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4.15-4.10 (1H, m, H7), 3.82 (3H, s, OMe), 3.74 (3H, s, OMe), 3.66-3.56 (2H, 
m, H11 + H14a), 3.37-3.31 (1H, m, H14b), 2.27-2.20 (2H, m, H4), 1.92-1.50 (8H, 
m, H12 + H13 + H6  + H5), 0.91 (18H, s, 2 × Si-C(CH3)3) and 0.06-0.04 (12H, 
m, 4 × Si-CH3); 13C NMR (75 MHz, CDCl3) δ 167.4, 159.6, 149.7, 134.5, 
131.1, 130.8, 130.0, 121.5, 114.1, 82.7, 73.2, 72.7, 72.5, 63.7, 55.6, 51.7, 
45.3, 36.8, 32.4, 30.0, 29.9, 26.2, 26.2, 24.3, 18.4, -4.4 and -4.9; HRMS (ES+) 
calc. for C35H66NO7Si2 ([M+NH4]+) 668.4367, found 669.4391. 
 
(R)-MTPA ester of 141 (146) !
MeO
O
TBSO
OPMB
TBSO
O
O
CF3
Ph
MeO
 
 
To a solution of alcohol 141 (3 mg, 4.70 µmol), DCC (2.0 mg, 9.4 µmol) and 
DMAP (2 mg) in dichloromethane (2.0 mL) at room temperature was added 
(+)-(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (2.2 mg, 9.4 µmol). 
After 6 h, the crude reaction mixture was purified directly by column 
chromatography (19 : 1, hexane : ethyl acetate) to give (R)-MTPA ester 146 
(2.7 mg, 67%). 
 
Rf  0.40 (20%, ethyl acetate : hexane); 1H NMR (400 MHz, CDCl3) δ 7.51-
7.48 (2H, m, Ar-H), 7.37-7.32 (3H, m, Ar-H), 7.28-7.25 (2H, m, Ar-H), 6.88-
6.87 (3H, m, Ar-H + H3), 5.93-5.92 (1H, m, H9), 5.80 (1H, dt, J = 1.5, 15.4 
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Hz, H2), 5.63-5.61 (1H, m, H8), 4.54-4.41 (2H, m, OCH2Ph), 4.31-4.29 (2H, 
m, H7 + H10), 3.82 (3H, s, OMe), 3.73 (3H, s, OMe), 3.58-3.55 (1H, m, H14a), 
3.49 (3H, d, J = 1.2 Hz, MTPA-OCH3), 3.30-3.26 (1H, m, H11 + H14b), 2.21-
2.19 (2H, m, H4), 1.98-1.52 (8H, m, H12 + H13 + H6  + H5), 0.90 (18H, s, 2 × 
Si-C(CH3)3) and 0.05-0.03 (12H, m, 4 × Si-CH3). 
 
(S)-MTPA ester of 141 (147) 
 
MeO
O
TBSO
OPMB
TBSO
O
O
F3C
Ph
OMe
 
 
To a solution of alcohol 141 (3 mg, 4.70 µmol), DCC (2.0 mg, 9.4 µmol) and 
DMAP (2 mg) in dichloromethane (2.0 mL) at room temperature was added 
(+)-(S)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (2.2 mg, 9.4 µmol). 
After 6 h, the crude reaction mixture was purified directly by column 
chromatography (19 : 1, hexane : ethyl acetate) to give (S)-MTPA ester 147 
(2.3 mg, 56%). 
 
Rf  0.42 (20%, ethyl acetate : hexane); 1H NMR (400 MHz, CDCl3) δ 7.52-
7.48 (2H, m, Ar-H), 7.39-7.35 (3H, m, Ar-H), 7.28-7.25 (2H, m, Ar-H), 6.88-
6.86 (3H, m, Ar-H + H3), 6.01-5.99 (1H, m, H9), 5.75 (1H, dt, J = 1.6, 15.5 
Hz, H2), 5.69-5.67 (1H, m, H8), 4.65-4.54 (2H, m, OCH2Ph), 4.36-4.33 (1H, 
m, H10), 4.30-4.28 (1H, m, H7), 3.79 (3H, s, OMe), 3.74 (3H, s, OMe), 3.55-
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3.52 (1H, m, H14a), 3.45 (3H, d, J = 1.1 Hz, MTPA-OCH3), 3.36-3.30 (1H, m, 
H11 + H14b), 2.14-2.10 (2H, m, H4), 1.90-1.52 (8H, m, H12 + H13 + H6  + H5), 
0.90 (18H, s, 2 × Si-C(CH3)3) and 0.05-0.03 (12H, m, 4 × Si-CH3). 
 
(2E, 7S, 8E, 10S, 11S)-Methyl-7, 10, 14-tris((tert-butyldimethylsilyl)oxy-
11-((4-methoxy benzyl)oxy)tetradeca-2, 8-dienoate (148) 
 
MeO
O
OTBS
TBSO
OPMB
TBSO
 
 
To a solution of alcohol 141 (285 mg, 440 µmol) in dichloromethane (5 mL) 
at room temperature, was added imidazole (57 mg, 670 µmol), 
TBSCl (100 mg, 585 µmol) and DMAP (5.0 mg) The mixture was stirred at 
room temperature for 16 h, and quenched with ammonium chloride (5 mL), 
the product extracted with dichloromethane (3 x 5 mL) and the combined 
organic extracts were dried over MgSO4. The crude residue was purified using 
column chromatography (19 : 1, hexane : ethyl acetate) to afford the silyl enol 
ether 148 (301 mg, 89%) as a colourless oil. 
 
Rf 0.57 (20% ethyl acetate : petroleum ether);  -13.0 (c 2.1, CHCl3); IR 
(thin film) 3309, 2950, 2929, 2850, 1732, 1517, 1247, 1093, 1030, 835 and 
775 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27-7.25 (2H, m, Ar-H), 6.99-6.92 
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(1H, m, H3), 6.87 (2H, d, J = 8.3 Hz, Ar-H), 5.81 (1H, dt, J = 1.5, 15.5 Hz, 
H2), 5.69-5.59 (2H, m, H8 + H9), 4.62-4.47 (2H, m, OCH2Ph), 4.29-4.27 (1H, 
m, H10), 4.15-4.11 (1H, m, H7), 3.81 (3H, s, Ar-OMe), 3.73 (3H, s, OMe), 
3.61-3.49 (2H, m, H11 + H14a), 3.31-3.27 (1H, m, H14b), 2.23-2.16 (2H, m, H4), 
1.75-1.44 (8H, m, H12 + H13 + H6  + H5), 0.92 (9H, s, Si-C(CH3)3), 0.89 (9H, s, 
Si-C(CH3)3), 0.88 (9H, s, Si-C(CH3)3) and 0.04-0.01 (18H, m, 6 × Si-CH3); 
13C NMR (100 MHz, CDCl3) δ 167.5, 159.0, 149.4, 134.1, 131.1, 129.3, 
128.8, 120.9, 113.6, 82.4, 72.9, 72.8, 72.2, 63.4, 55.3, 51.3, 37.8, 32.2, 29.7, 
29.5, 29.5, 26.1, 26.0, 25.9, 23.7, 18.4, 18.2, -4.6, -4.8 and -5.3; HRMS (ES+) 
calc. for C41H80NO7Si3 ([M+NH4]+) 782.5232, found 782.5224. 
 
(2E, 7S, 8E, 10S, 11S)-Methyl-7, 10, 14-tris((tert-butyldimethylsilyl)oxy-
11-hydroxytetradeca-2, 8-dienoate (149) 
 
MeO
O
OTBS
TBSO
OH
TBSO
 
 
To a solution of PMB ether 148 (150 mg, 196 µmol) in dichloromethane 
(2 mL) and pH 7 buffer (200 µL) at 0 °C, was added recrystallised 
DDQ (133 mg, 588 µmol). The solution was stirred at room temperature for 
3 h and quenched with NaHCO3 (40 mL), extracted with dichloromethane 
(3 x 30 mL), and dried over Na2SO4. The solution was concentrated under 
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reduced pressure and purified by column chromatography (4 : 1 to 7 : 3, 
hexane : ethyl acetate) to yield the alcohol 149 (96 mg, 76%) as a colourless 
oil. 
 
Rf 0.18 (50% ethyl acetate : petroleum ether);  +4.0 (c 1.0, CHCl3); IR 
(thin film) 3418, 2921, 2847, 1719, 1277, 1126, 835 and 766 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.95 (1H, dt, J = 6.9, 15.7 Hz, H3), 5.82 (1H, dt, J = 1.5, 
15.7 Hz, H2), 5.69-5.50 (2H, m, H8 + H9), 4.16-4.11 (1H, m, H10), 3.91-3.86 
(1H, m, H7), 3.73-3.63 (5H, m, OMe, H11 + H14a), 3.43-3.37 (1H, m, H14b), 
2.23-2.18 (2H, m, H4), 1.74-1.48 (8H, m, H12 + H13 + H6  + H5), 0.90 (9H, s, 
Si-C(CH3)3), 0.89 (18H, s, 2 x Si-C(CH3)3), 0.09 (6H, s, 2 × Si-CH3) and 
0.05-0.02 (12H, m, 4 × Si-CH3); 13C NMR (100 MHz, CDCl3) δ 167.3, 149.4, 
136.6, 129.4, 121.2, 75.1, 72.4, 63.0, 53.6, 51.6, 37.6, 32.3, 29.9, 29.7, 29.7, 
26.0, 26.0, 25.9, 23.6, 18.3, 18.2, -4.3, -4.6 and -4.7; HRMS (ES+) calc. for 
C33H72NO6Si3 ([M+NH4]+) 662.4667, found 662.4651. 
 
(2E, 7S, 8E, 10S, 11S)-Methyl-7, 10, 14-tris((tert-butyldimethylsilyl)oxy-
11-(carbamoyloxy)tetradeca-2, 8-dienoate (150) 
 
MeO
O
OTBS
TBSO
O
TBSO
NH2
O
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To a solution of alcohol 149 (80 mg, 154 µmol) in dichloromethane (2 mL), 
trichloroacetyl isocyanate (185 µL, 1.55 mmol) was added. The reaction 
mixture was stirred for 1 h at room temperature, upon which the solvent was 
removed under vacuo, then redissolved in methanol (5.0 mL). To this dried 
potassium carbonate (145 mg, 1.05 mmol) was added, and this was left to stir 
for 16 h at room temperature, upon which it was quenched with water (5 mL), 
extracted with dichloromethane (3 x 5 mL) and dried over Na2SO4. The 
mixture was purified using column chromatography (7 : 3, hexane : ethyl 
acetate) to give carbamate 150 (74 mg, 69%) as a colourless oil.  
 
Rf 0.29 (40% ethyl acetate : petroleum ether);  -14.0 (c 0.2, CHCl3); IR 
(thin film) 2953, 2928, 2855, 1717, 1707, 1506, 1065, 1051, 835 and 775 cm-
1; 1H NMR (400 MHz, CDCl3) δ 6.95 (1H, dt, J = 6.9, 15.8 Hz, H3), 5.83 (1H, 
dt, J = 1.5, 15.7 Hz, H2), 5.71-5.53 (2H, m, H8 + H9), 4.75-4.58 (3H, m, NH2 + 
H11), 4.24 (1H, t, J = 5.2 Hz, H10), 4.14-4.04 (3H, m, H7 + H14), 3.73 (3H, s, 
OMe), 2.24-2.19 (2H, m, H4), 1.71-1.48 (8H, m, H12 + H13 + H6  + H5), 0.90 
(18H, s, 2 x Si-C(CH3)3), 0.89 (9H, s, Si-C(CH3)3), 0.08 (6H, s, 2 × Si-CH3) 
and 0.05-0.03 (12H, m, 4 × Si-CH3); 13C NMR (100 MHz, CDCl3) δ 167.4, 
156.6, 150.0, 135.6, 128.0, 121.1, 76.9, 73.1, 72.6, 65.2, 51.6, 37.7, 32.3, 
30.0, 29.9, 29.9, 26.0, 26.0, 25.9, 23.7, 18.4, 18.3, -4.4, -4.7 and -4.8; HRMS 
(ES+) calc. for C34H70NO7Si3 ([M+H]+) 688.4460, found 688.4463. 
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(2E, 7S, 8E, 10S, 11S)-Methyl 7, 10-bis((tert-butyldimethylsilyl)oxy-11-
(carbamoyloxy)-14-hydroxytetradeca-2, 8-dienoate (98) 
 
MeO
O
OTBS
TBSO
O
HO
NH2
O
 
 
To a solution of silyl ether 150 (50 mg, 72 µmol) in dichloromethane : 
methanol (2.5 mL, 6 : 1) at room temperature was added CSA (2.0 mg, 11.1 
µmol). The reaction mixture was left to stir for 2 h, then quenched with 
sodium bicarbonate (3 mL), extracted with dichloromethane (3 x 5 mL) and 
dried over Na2SO4. The mixture was filtered and the resulting solution was 
concentrated under reduced pressure, then purified by column 
chromatography (3 : 2, hexane : ethyl acetate) to give the primary alcohol 98 
(41.4 mg, 80%) as a colourless oil. 
 
Rf 0.28 (50% ethyl acetate : petroleum ether);  -8.4 (c 0.1, CHCl3); IR 
(thin film) 3466, 3364, 2979, 2929, 2854, 1714, 1366, 1312, 1278, 1188, 
1128, 835 and 775 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.96 (1H, dt, J = 6.9, 
15.7 Hz, H3), 5.83 (1H, dt, J = 1.5, 15.7 Hz, H2), 5.70-5.53 (2H, m, H8 + H9), 
4.75-4.58 (3H, m, NH2 + H11), 4.26-4.22 (1H, m, H10), 4.17-4.11 (1H, m, H7), 
4.06-4.04 (2H, m, H14), 3.73 (3H, s, OMe), 2.23-2.20 (2H, m, H4), 1.73-1.45 
(8H, m, H12 + H13 + H6  + H5), 0.90 (18H, s, 2 x Si-C(CH3)3), and 0.05-0.03 
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(12H, m, 4 × Si-CH3); 13C NMR (100 MHz, CDCl3) δ 166.8, 156.5, 148.5, 
130.9, 129.4, 121.9, 77.4, 75.8, 74.8, 63.0, 52.8, 32.8, 32.0, 30.8, 29.5, 26.1, 
26.0, 21.9, 18.4, 18.3, -4.4 and -4.5; HRMS (ES+) calc. for C28H56NO7Si2 
([M+H]+) 574.3595, found 574.3591. 
 
7.5: Experimental for Chapter 3 
 
(2S)-Methyl-3-(para-methoxybenzyl)-2-methylpropanoate (159)117 
 
OPMBMeO
O
 
 
To a solution of (S)-Roche ester 158 (10.0 g, 84.6 mmol) in dichloromethane 
(200 mL) at 0 ºC, PMBTCA (28.7 g, 101.6 mmol) was added followed by 
careful addition of PPTS (1.00 g, 4.23 mmol). After 3 h at 0 ºC the reaction 
was warmed to room temperature, then left stirring for 16 h, upon which it 
was quenched with NH4Cl (200 mL), washed with dichloromethane (3 x 
150 mL) and dried over MgSO4. Purification by column chromatography (9 : 
1, hexane : ethyl acetate) provided PMB ether 159 (17.1 g, 85%) as a 
colourless oil. 
 
Rf 0.60 (30% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.31 (2H, d, J = 8.7 Hz, Ar-H), 6.91 (2H, d, J = 8.6 Hz, Ar-H), 4.49 (2H, s, 
OCH2PhOMe), 3.82 (3H, s, PhOCH3), 3.79 (1H, dd, J = 9.1, 7.3 Hz, H3a), 
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3.71-3.66 (4H, m, H3b + OCH3), 2.80 (1H, ddq, J = 14.4, 7.1, 5.9 Hz H2) and 
1.20 (3H, d, J = 7.1 Hz, CHCH3). 
 
(2S)-Methyl-3-(tert-butyldimethysilyloxy)-2-methylpropanoate (205)118 
 
OTBSMeO
O
 
 
To a solution of (S)-Roche ester 158 (10.0 g, 84.6 mmol) in dichloromethane 
(200 mL) at room temperature, was added imidazole (8.64 g, 127 mmol) and 
TBSCl (15.3 g, 101.6 mmol). The mixture was stirred at room temperature for 
16 h, and quenched with NH4Cl (300 mL) and the product was extracted with 
dichloromethane (3 x 150 mL), washed with brine (150 mL) and water 
(150 mL). The combined organic extracts were dried over MgSO4. The crude 
residue was purified using column chromatography (9 : 1, hexane : ethyl 
acetate) to afford the silyl ether 205 (15.9 g, 98%) as a colourless oil. 
 
Rf 0.50 (20% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
3.78 (1H, dd, J = 9.7, 6.9 Hz, H3a) 3.69-3.63 (4H, m, H3b + OCH3), 2.66 (2H, 
ddq, J = 13.1, 7.0, 6.1 Hz, H2), 1.15 (3H, d, J = 7.0 Hz, CHCH3), 0.88 (9H, s, 
Si-C(CH3)3), and 0.05 (6H, m, 2 × Si-CH3). 
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(2S)-3-(para-Methoxybenzyl)-N-methoxy-2, N-dimethyl propanamide 
(160)116 
 
OPMBN
O
MeO
 
 
To a solution of PMB-protected Roche ester 159 (16.0 g, 67.1 mmol) and 
N,O-dimethyl hydroxylamine hydrochloride (10.5 g, 107 mmol) in 
THF (300 mL) at -30 ºC was slowly added iso-propylmagnesium chloride 
(89.2 mL, 178.4 mmol, 2M in THF). The reaction solution was stirred at this 
temperature for 3 h upon which a saturated solution of NH4Cl (300 mL) was 
added. The organics were extracted with dichloromethane (3 x 200 mL) and 
the combined organic extracts were dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification by column chromatography 
(4 : 1, hexane : ethyl acetate) provided Weinreb amide 160 (16.9 g, 94%) as a 
colourless oil. 
 
Rf 0.53 (30% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.24 (2H, d, J = 8.6 Hz, Ar-H), 6.87 (2H, d, J = 8.6 Hz, Ar-H), 4.45 (2H, s, 
OCH2PhOMe), 3.81 (3H, s, PhOCH3), 3.71-3.67 (4H, m, H3a + NOCH3), 3.40 
(1H, dd, J = 8.9, 5.8 Hz, H3b), 3.31-3.19 (4H, m, H2 + NCH3) and 1.11 (3H, d, 
J = 6.9 Hz, CCH3). 
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(2S)-3-(tert-Butyldimethysilyloxy)-N-methoxy-2, N-dimethyl 
propanamide (174)117 
 
OTBSN
O
MeO
 
 
To a solution of TBS-protected Roche ester 205 (15.0 g, 64.6 mmol) and N,O-
dimethyl hydroxylamine hydrochloride (9.50 g, 96.9 mmol) in THF (300 mL) 
at -30 ºC was slowly added iso-propylmagnesium chloride (146 mL, 291 
mmol, 2M in THF). The reaction solution was stirred at this temperature for 
3 h upon which a saturated solution of NH4Cl (300 mL) was added. The 
organics were extracted with dichloromethane (3 x 200 mL) and the combined 
organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure. Purification by column chromatography (9 : 1, hexane : 
ethyl acetate) provided Weinreb amide 174 (15.5 g, 92% yield) as a colourless 
oil. 
 
Rf 0.48 (20% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
3.84 (1H, dd, J = 9.5, 8.1 Hz, H3a), 3.72 (3H, s, NOCH3), 3.54 (1H, dd, J = 
9.5, 6.1 Hz, H3b), 3.25-3.10 (4H, m, H2 + NCH3), 1.08 (3H, d, J = 7.0 Hz, 
CCH3), 0.88 (9H, s, Si-C(CH3)3), and 0.05 (6H, m, 2 × Si-CH3). 
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(2S)-3-(para-methoxybenzyl)-2-methylpropanal (152)116 
 
OPMBH
O
 
 
To a solution of Weinreb amide 160 (10.0 g, 37.4 mmol) in dichloromethane 
(100 mL) at -78 °C, was added DIBAL (75.0 mL, 75.0 mmol, 1 M in 
dichloromethane). The mixture was stirred for 3 h and quenched with aqueous 
potassium sodium tartrate (200 mL), and the mixture was stirred for a further 
2 h. The crude product was extracted with diethyl ether (3 x 100 mL), which 
was washed with brine, dried over MgSO4 and the solvent was removed under 
reduced pressure to give the crude aldehyde 152, which was used without 
further purification in the next step.  · 
 
Rf 0.48 (20% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
9.64 (1H, d, J = 1.6 Hz, H1), 7.16 (2H, d, J = 8.7 Hz, ArH), 6.81 (2H, d, J = 
8.7 Hz, ArH), 3.73 (3H, s, PhOCH3) 3.58 (1H, dd, J = 9.4, 6.7 Hz, H3a), 3.53 
(1H, dd, J = 9.4, 5.3 Hz, H3a), 2.61-2.53 (1H, m, H2) and 1.05 (3H, d, J = 7.1 
Hz, CCH3). 
 
(2E, 4S)-Ethyl-5-(para-methoxybenzyl)-2,4-dimethylpent-2-enoate 
(153)116 
 
OPMBEtO
O
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Method A: 
Triethyl-2-phosphonopropionate (2.44 mL, 11.4 mmol) was added to a 
stirring solution of LiHMDS (1.0 M in hexane, 12.4 mL, 12.4 mmol) in THF 
(50 mL) at -78 °C. The solution was left to stir for 20 min before the 
crude aldehyde 152 (9.20 mmol) was slowly added. The solution was warmed 
to -40 °C and stirred for 17 h. The reaction was quenched with NH4Cl (25 
mL), extracted with dichloromethane (3 x 20 mL) and the combined organic 
extracts were dried over MgSO4 and concentrated under reduced pressure. The 
residue was purified by column chromatography (4 : 1, hexane : ethyl acetate) 
to give ester 153 (1.56 g, 58% over two steps, E : Z  = 4 : 1) as a colourless 
oil. 
 
Method B: 
LiCl (900 mg, 19.2 mmol) was flame dried prior to use. A mixture of 
acetonitrile (70 mL) and LiCl, was cooled at 0 °C, and triethyl-2-
phosphonopropionate (2.3 mL, 10.6 mmol) and Hünig’s base (3.4 mL, 19.2 
mmol) were added. The mixture was maintained at 0 °C for 20 min, and the 
crude aldehyde 152 (9.50 mmol) was added. The mixture was warmed to 
room temperature and stirred for 13 h, prior to the addition of water (40 mL). 
The organic portions were extracted with ethyl acetate (3 x 20 mL). The 
combined organic layers was washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by column 
chromatography (4 : 1, hexane : ethyl acetate) to give ester 153 (1.81 g, 65% 
over two steps, E : Z = 4 : 1) as a colourless oil. 
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Method C: 
To a stirring solution of activated barium hydroxide (11.6 g, 35.7 mmol) in 
THF (150 mL), triethyl-2-phosphonopropionate (11.7 mL, 67.2 mmol) was 
added. The mixture was stirred for 30 min at room temperature, and the crude 
aldehyde 152 (37.4 mmol), in wet THF (40 : 1, THF : water, 100 mL) was 
added. The mixture was stirred at room temperature for 16 h, the mixture was 
filtered, and the crude product extracted with dichloromethane (3 x 100 mL), 
washed with NaHCO3 (150 mL) and dried over MgSO4. The solvent was 
removed under reduced pressure and the residue was purified by column 
chromatography (4 : 1, hexane : ethyl acetate) to give ester 153 (7.60 g, 70% 
over two steps, E : Z = 9 : 1) as a colourless oil. 
 
Rf 0.69 (20% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.25 (2H, d, J = 8.8 Hz, ArH), 6.88 (2H, d, J = 8.7 Hz, ArH), 6.59 (1H, dq, J 
= 9.7, 1.4 Hz, H3), 4.45 (2H, s, OCH2Ar), 4.19 (2H, q, J = 7.2 Hz, OCH2CH3), 
3.81 (3H, s, ArOCH3), 3.36 – 3.31 (2H, m, H5), 2.89–2.78 (1H, m, H4), 1.87 
(3H, d, J = 1.5 Hz, =CCH3), 1.30 (3H, t, J = 7.2 Hz, OCH2CH3) and 1.04 (3H, 
d, J = 6.8 Hz, CCH3). 
 
(2S)-3-(tert-butyldimethysilyloxy)-2-methylpropanal (206)117 
 
OTBSH
O
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To a solution of Weinreb amide 174 (10.3 g, 40.3 mmol) in dichloromethane 
(100 mL) at -78 °C, was added DIBAL (82.0 mL, 82.0 mmol, 1 M in 
dichloromethane). The mixture was stirred for 3 h, quenched with aqueous 
potassium sodium tartrate (60 mL), then the mixture was stirred for a further 
2 h. The crude product was extracted with diethyl ether (3 x 100 mL), which 
was washed with brine (100 mL), dried over MgSO4 and the solvent was 
removed under reduced pressure to give crude aldehyde 206, which was used 
without further purification in the next step. 
 
Rf  0.60 (20% ethyl acetate : Hexanes); 1H NMR (300 MHz, CDCl3) δ 9.74 
(1H, d, J = 1.6 Hz, H1), 3.86 (1H, dd, J = 10.2, 5.2 Hz, H3a), 3.80 (1H, dd, J = 
10.2, 6.3 Hz, H3b), 2.60-2.47 (1H, m, H2), 1.09 (3H, d, J = 7.0 Hz, CH3), 0.87 
(9H, s, SiC(CH3)3) and 0.05 (6H, s, Si(CH3)2). 
 
(2E, 4S)-Ethyl-5-(tert-butyldimethysilyloxy)-2,4-dimethylpent-2-enoate 
(175)119 
OTBSEtO
O
 
 
To a stirring solution of activated barium hydroxide (12.1 g, 38.3 mmol) in 
THF (200 mL), triethyl-2-phosphonopropionate (12.5 mL, 72.3 mmol) was 
added. The mixture was stirred for 30 min at room temperature, and the TBS-
protected crude aldehyde 206 (40.3 mmol), in wet THF (40 : 1, THF : water, 
100 mL) was added. The mixture was stirred at room temperature for 16 h, 
after which it was filtered and washed with hexane (3 x 80 mL), followed by 
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the addition of NH4Cl (150 mL). The crude product was extracted with 
dichloromethane (3 x 100 mL), washed with NaHCO3 (150 mL) and dried 
over MgSO4. The solvent was removed under reduced pressure and the 
residue was purified by column chromatography (9 : 1, hexane : ethyl acetate) 
to give a mixture of E and Z regioisomers of 175 (8.31 g, 72% over two steps, 
E : Z = 9 : 1). 
 
Rf 0.45 (20% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
6.56 (1H, dq, J = 9.8, 1.4 Hz, H3), 4.20 (2H, q, J = 7.2 Hz, OCH2), 3.87 (1H, 
dd, J = 5.2, 10.1 Hz, H5a), 3.81 (1H, dd, J = 10.1, 6.3 Hz, H5b), 2.75-2.64 (1H, 
m, H4), 1.87 (3H, d, J = 1.3 Hz, =CCH3), 1.30 (3H, d, J = 7.3 Hz, OCH2CH3), 
1.02 (3H, d, J = 6.8 Hz, CCH3), 0.88 (9H, s, Si-C(CH3)3), and 0.05 (6H, m, 2 
× Si-CH3). 
 
(2E, 4S)-5-(para-Methoxybenzyl)-2,4-dimethylpent-2-en-1-ol (160)120 
 
OPMBHO
 
 
To a solution of PMB-protected ester 153 (6.70 g, 22.9 mmol) in 
dichloromethane (60 mL) at -78 °C, was added DIBAL (46.0 mL, 46.0 mmol, 
1 M in dichloromethane). The mixture was stirred for 3 h upon which aqueous 
potassium sodium tartrate (100 mL) was added, and the mixture was stirred 
for a further 4 h. The crude product was extracted with diethyl ether (3 x 
60 mL), which was washed with brine (60 mL), dried over Na2SO4 and the 
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solvent was removed under reduced pressure. The crude residue was purified 
using column chromatography (1 : 1, hexane : ethyl acetate) to yield alcohol 
160 (4.64 g, 81%) as a colourless oil. 
 
Rf 0.63 (50% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.28 (2H, d, J = 8.8 Hz, Ar-H), 6.91 (2H, d, J = 8.7 Hz, Ar-H), 5.26 (1H, dq, J 
= 9.2, 1.4 Hz, H3), 4.47 (2H, s, OCH2Ar), 4.00 (2H, s, H1), 3.83 (3H, s, 
ArOCH3), 3.33 (1H, dd, J = 9.2, 6.7 Hz, CH5a), 3.28 (1H, dd, J = 9.3 6.9 Hz, 
CH5b), 2.86–2.68 (1H, m, H4), 1.71 (3H, d, J = 1.3 Hz, =CCH3) and 1.01 (3H, 
d, J = 6.7 Hz, CH-CH3). 
 
(2E, 4S)-5-(tert-Butyldimethysilyloxy)-2,4-dimethylpent-2-en-1-ol (195)118 
 
OTBSHO
 
 
To a solution of TBS-protected ester 175 (6.90 g, 23.9 mmol) in 
dichloromethane (50 mL) at -78 °C, was added DIBAL (48.0 mL, 48.0 mmol, 
1 M in dichloromethane). The mixture was stirred for 3 h upon which aqueous 
potassium sodium tartrate (100 mL) was added, and the mixture was stirred 
for a further 4 h. The crude product was extracted with dichloromethane (3 x 
50 mL), which was washed with brine (50 mL), dried over MgSO4 and the 
solvent was removed under reduced pressure. The crude residue was purified 
using column chromatography (4 : 1, hexane : ethyl acetate) to yield alcohol 
195 (5.26 g, 90%) as a colourless oil.  
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Rf 0.30 (30% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
5.14 (1H, dq, J = 9.4, 1.3 Hz, H3), 3.93 (2H, d, J = 4.4 Hz, H1), 3.43 (1H, dd, 
J = 9.7, 6.1 Hz, H5a), 3.34 (1H, dd, J = 9.8, 7.1 Hz, H5b), 2.62-2.47 (1H, m, 
H4), 2.34 (1H, br s, OH), 1.65 (3H, d, J = 1.4 Hz, =CCH3), 0.92 (3H, d, J = 
6.7 Hz, CCH3), 0.86 (9H, s, Si-C(CH3)3), and 0.01 (6H, m, 2 × Si-CH3). 
 
(2E, 4R)-1-(tert-Butyldimethysilyloxy)-5-(para-methoxybenzyl)-(2, 4)-
dimethyl-pent-3-ene (154)119 
 
OPMBTBSO
 
 
To a solution of alcohol 160 (4.25 g, 16.9 mmol) in dichloromethane (60 mL) 
at room temperature, was added imidazole (1.83 g, 25.5 mmol) and TBSCl 
(3.20 g, 20.4 mmol). The mixture was stirred at room temperature for 16 h, 
and quenched with ammonium chloride (60 mL) and the product was 
extracted with dichloromethane (3 x 60 mL). The combined organic extracts 
were dried over MgSO4. The crude residue was purified using column 
chromatography (9 : 1, hexane : ethyl acetate) to afford silyl ether 154 (5.73 g, 
93%) as a colourless oil. 
 
Rf 0.48 (10% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.27 (2H, d, J = 8.6 Hz, Ar-H), 6.89 (2H, d, J = 8.7 Hz, Ar-H), 5.22 (1H, dq, J 
= 9.2, 1.3 Hz, H3), 4.44 (2H, s, OCH2Ar), 4.02 (2H, s, H1), 3.81 (3H, s, 
OCH3), 3.33 (1H, dd, J = 9.1, 6.0 Hz, CH5a), 3.24 (1H, dd, J = 9.1, 7.5 Hz, 
CH5b), 2.80–2.69 (1H, m, H4), 1.64 (3H, d, J = 1.3 Hz, =CCH3), 1.01 (3H, d, J 
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= 6.7 Hz, CH-CH3), 0.93 (9H, s, Si-C(CH3)3), and 0.08 (6H, m, 2 × Si-CH3). 
 
(2E, 4R)-5-(tert-Butyldimethysilyloxy)-1-(para-methoxybenzyl)-(2, 4)-
dimethyl-pent-3-ene (176) 
 
OTBSPMBO
 
 
To a solution of alcohol 195 (2.00 g, 8.2 mmol) in THF (50 mL), NaH (450 
mg, 11.1 mmol, 60% dispersion in mineral oil) was added at 0 ºC. After 
30 min a solution of PMBCl (1.9 mL, 13.8 mmol) in THF (20 mL) was added 
and the resulting mixture was stirred for 3 h at 0 ºC. The reaction was 
quenched with saturated aqueous NH4Cl (50 mL), and the product extracted 
with diethyl ether (3 x 50 mL). The resulting solution was dried over MgSO4, 
filtered and concentrated under reduced pressure. Purification by column 
chromatography (9 : 1 to 4 : 1, hexane : ethyl acetate) gave PMB-protected 
ether 176 (1.67 g, 56%) as a pale yellow oil. 
 
Rf 0.42 (30% ethyl acetate : petroleum ether);  1H NMR (400 MHz, CDCl3) δ 
7.26 (2H, d, J = 8.6 Hz, Ar-H), 6.86 (2H, d, J = 8.6 Hz, Ar-H), 5.19 (1H, dq, J 
= 9.3, 1.2 Hz, H3), 4.36 (2H, s, OCH2Ar), 3.85 (2H, s, H1), 3.76 (3H, s, 
OCH3), 3.49-3.33 (2H, m, CH5), 2.64–2.52 (1H, m, H4), 1.68 (3H, d, J = 1.3 
Hz, =CCH3), 0.96 (3H, d, J = 6.7 Hz, CH-CH3), 0.88 (9H, s, Si-C(CH3)3), and 
0.03 (6H, m, 2 × Si-CH3); 13C NMR (75 MHz, CDCl3) δ 159.1, 134.9, 130.9, 
129.1, 127.2, 113.7, 75.0, 72.5, 68.6, 55.3, 36.4, 32.6, 25.9, 17.7, 13.7 and -
5.2; HRMS (ES+) Calcd. For C21H40NO3Si 382.2772, found [M + NH4]+ 
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382.2770. 
 
(2S, 3E)-5-(tert-Butyldimethysilyloxy)-2,4-dimethylpent-3-en-1-ol (207)119 
 
OHTBSO
 
 
To a solution of PMB ether 154 (4.90 g, 13.4 mmol) in dichloromethane 
(100 mL) and pH 7 buffer (10 mL) at 0 °C, was added DDQ (4.20 g, 
18.0 mmol). The solution was stirred for 2 h and quenched with NaHCO3 
(1000 mL), extracted with dichloromethane (3 x 300 mL), washed with brine 
and dried over MgSO4. The solution was concentrated under reduced pressure 
and purified by column chromatography (19 : 1, hexane : ethyl acetate) to 
yield alcohol 207 (2.85 g, 87 % yield) as a colourless oil. 
 
Rf 0.25 (10% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
5.17 (1H, dq, J = 9.6, 1.4 Hz, H3), 3.96 (2H, s, H1), 3.47 (1H, dd, J = 10.4, 6.1 
Hz, CH5a), 3.36 (1H, dd, J = 10.5, 7.9 Hz, CH5b), 2.71 – 2.60 (1H, m, H4), 
1.65 (3H, d, J = 1.4 Hz, =CCH3), 0.95 (3H, d, J = 6.8 Hz, CCH3), 0.91 (9H, s, 
SiCCH3) and 0.07 (6H, s, SiCH3). 
 
(2S, 3E)-5-(para-Methoxybenzyl)-2,4-dimethylpent-3-en-1-ol (208) 
 
OHPMBO
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TBAF (8.3 mL, 8.3 mmol, 1 M in THF) was added to a solution of TBS ether 
176 (1.50 g, 4.1 mmol) in THF (15 mL) at 0 ºC. After 6 h the reaction mixture 
was quenched with saturated aqueous NH4Cl (20 mL), extracted with diethyl 
ether (3 x 20 mL) and dried over MgSO4. The resulting solution was 
concentrated under reduced pressure and purified by column chromatography 
(4 : 1, hexane : ethyl acetate) to yield alcohol 208 (923 mg, 89%) as a 
colourless oil. 
 
Rf 0.28 (20% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
7.27 (2H, d, J = 8.6 Hz, Ar-H), 6.88 (2H, d, J = 8.7 Hz, Ar-H), 5.21 (1H, dq, J 
= 9.5, 1.2 Hz, H3), 4.41 (2H, s, OCH2Ar), 3.89 (2H, s, H1), 3.81 (3H, s, 
OCH3), 3.48 (1H, dd, J = 10.4, 6.1 Hz, CH5a), 3.38 (1H, dd, J = 10.5, 7.7 Hz, 
CH5b), 2.74–2.59 (1H, m, H4), 1.72 (3H, d, J = 1.3 Hz, =CCH3) and 0.97 (3H, 
d, J = 6.7 Hz, CH-CH3). 
 
(2S, 3E)-5-(tert-Butyldimethysilyloxy)-2,4-dimethylpent-3-enal (155) 
 
HTBSO
O
 
 
Method A: 
To a solution of oxalyl chloride (156 mg, 1.23 mmol) in dichloromethane 
(5.0 mL) was cooled to -78 °C and a solution of DMSO (114 mg, 1.47 mmol) 
in dichloromethane (2.0 mL) was added dropwise over 5 min. The solution 
was left stirring for a further 10 min, upon which the alcohol 207 (150 mg, 
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614 µmol) in dichloromethane (2.0 mL) was added dropwise. The solution 
was left stirring at -78 °C for 1.5 h, prior to the addition of triethylamine 
(435 mg, 4.30 mmol) in dichloromethane (2.0 mL). The solution was warmed 
to room temperature and quenched with water (5 mL), extracted with 
dichloromethane (3 x 5 mL). The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. The residue was passed through a 
column (9 : 1, hexane : ethyl acetate) to yield aldehyde 155, which was used 
immediately without further purification. 
 
Method B: 
Dess-Martin periodinane (2.25 g, 6.84 mmol) was added to a solution of 
alcohol 207 (1.00 g, 4.10 mmol) in dichloromethane (30 mL). The solution 
stirred for 2 h then quenched with sodium thiosulfate (25 mL). The product 
was extracted with dichloromethane (3 x 30 mL) and dried over MgSO4. The 
product was purified by filtration through Celite®, and washing with excess 
petroleum ether, to give aldehyde 155, which was used immediately without 
further purification. 
 
Rf 0.55 (10% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
9.51 (1H, d, J = 1.9 Hz, H1), 5.29 (1H, dq, J = 9.1, 1.4 Hz, H3), 4.07 (2H, s, 
H5), 3.36 – 3.25 (1H, m, H2), 1.68 (3H, d, J = 1.2 Hz, =CCH3), 1.18 (3H, d, J 
= 7.0 Hz, CHCH3), 0.92 (9H, s, SiCCH3) and 0.08 (6H, s, SiCH3). 
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(2S, 3E)-5-(para-Methoxybenzyl)-2,4-dimethylpent-3-enal (173) 
 
HPMBO
O
 
 
Dess-Martin periodinane (830 mg, 2.00 mmol) was added to a solution of 
alcohol 208 (250 mg, 1.00 mmol) in dichloromethane (4 mL). The solution 
stirred for 2 h then quenched with sodium thiosulfate (5 mL). The product was 
extracted with dichloromethane (3 x 5 mL) and dried over MgSO4. The 
product was purified by filtration through Celite®, and washing with excess 
petroleum ether, to give aldehyde 173, which was used immediately without 
further purification. 
 
Rf 0.38 (10% ethyl acetate : petroleum ether); 1H NMR (400 MHz, CDCl3) δ 
9.52 (1H, d, J = 1.8 Hz, H1), 7.27 (2H, d, J = 8.6 Hz, ArH), 6.87 (2H, d, J = 
8.7 Hz, ArH), 5.30 (1H, dq, J = 9.5, 1.2 Hz, H3), 4.41 (2H, s, OCH2Ar), 3.91 
(2H, s, H5), 3.79 (3H, s, OCH3), 3.36-3.18 (1H, m, H2), 1.73 (3H, d, J = 1.4 
Hz, =CCH3) and 1.18 (3H, d, J = 6.9 Hz, CH-CH3). 
 
(2R, 3S, 4R, 5E)-Methyl 7-(tert-butyldimethylsilyl)oxy-3-hydroxy-(4, 6)-
dimethyl-2-(prop-1-en-2-yl)hept-5-enoate (162) 
 
TBSO
OH
OMe
O
 
 
 
176 
A solution of n-butyl lithium (52 ml, 0.83 mmol, 1.6 M in hexane) was added 
to a solution of diisopropylamine (110 mL, 830 µmol) in THF (5 mL) at -
78 °C. The mixture was stirred for 30 min where methyl-3,3-dimethyl acrylate  
161 (70 mg, 620 µmol) in THF (2 mL) was added. After 30 min a solution of 
aldehyde 155 (409 µmol) in THF (1 mL) was added. The mixture was left to 
stir for 1 h and quenched with NH4Cl (5 mL), the organic portions were 
extracted with diethyl ether (3 x 5 mL) and the combined organic extracts 
were dried over Na2SO4. The solution was concentrated under reduced 
pressure and purified by column chromatography (14 : 1, hexane : ethyl 
acetate) to give aldol adduct 162 (78 mg, 53%, α : γ = 4 : 1) as a colourless 
oil. 
 
Rf 0.32 (10% ethyl acetate : petroleum ether);  +21.4 (c 1.0 CHCl3); IR 
(thin film) 3450, 3442, 2970, 2926, 1714, 1651, 1447, 1280, 1180, 1015, 949, 
and 867 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.26 (1H, dq, J = 9.7, 1.4 Hz, 
H5), 5.07-5.05 (1H, m, C=CHa), 4.96–4.95 (1H, m, C=CHb), 4.00 (2H, s, H7), 
3.91 (1H, ddd, J = 7.1, 6.8, 3.3 Hz, H3), 3.70 (3H, s, OCH3), 3.21 (1H, d, J = 
6.6 Hz, H2), 2.56-2.50 (1H, m, H4), 2.43 (1H, d, J = 3.3 Hz, OH), 1.84-1.83 
(3H, m, =C-CH3), 1.60 (3H, d, J = 1.2 Hz, =C6-CH3), 1.04 (3H, d, J = 6.7 Hz, 
C4-CH3), 0.91 (9H, s, SiCCH3) and 0.07 (6H, m, SiCH3); 13C NMR (75 MHz, 
CDCl3) δ 174.2, 140.7, 134.8, 127.3, 115.1, 75.0, 68.5, 55.7, 52.1, 35.7, 30.1, 
26.0, 21.6, 15.2, 13.7 and -5.1; HRMS (ES+) calc. for C19H40O4SiN 
([M+NH4]+) 374.2721, found 374.2719. 
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(2E, 5R, 6R, 7E)-Methyl 9-(tert-butyldimethylsilyl)oxy-5-hydroxy-(3, 6, 
8)-trimethyl-nona-2, 7-dienoate (157) 
 
TBSO
OH
OMe
O
 
 
To a solution of freshly prepared ATPH 163 (6.80 mmol) in toluene (15 mL) 
at -78 °C was added a solution of methyl-3,3-dimethyl acrylate 161 (480 mg, 
4.10 mmol) in toluene (5 mL); after 15 min a solution of aldehyde 155 
(2.05 mmol) in toluene (5mL) was added. The mixture was stirred for 20 min 
upon which a solution of n-butyl lithium (2.8 mL, 4.50 mmol, 1.6 M in 
hexane) and diisopropylamine (643 µL, 4.50 mmol) in THF (15 mL) was 
added. After 30 min at -78 °C, a saturated solution of NH4Cl (30 mL) was 
added, and the mixture was filtered through Celite®. The organic portions 
were extracted with diethyl ether (3 x 30 mL) and the combined organic 
extracts were dried over Na2SO4. The solution was concentrated under 
reduced pressure and purified by column chromatography (14 : 1, hexane : 
ethyl acetate) to give aldol adduct 157 (402 mg, 55% over two steps, α : γ = 1 
: 7, d.r = 4 : 1) as a colourless oil. 
 
Rf 0.30 (10% ethyl acetate : petroleum ether);  +7.5 (c 1.1 CHCl3); IR 
(thin film) 3402, 2951, 1742, 1614, 1447, 1223, 1050 and 933 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 5.84 (1H, q, J = 1.3 Hz, H2), 5.30 (1H, dq, J = 9.9, 1.4 
Hz, H7), 4.04 (2H, s, H9), 3.70 (3H, s, OCH3), 3.53-3.47 (1H, m, H5), 2.55-
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2.49 (1H, m, H6), 2.30 (1H, dd, J = 12.8, 2.4 Hz, H4a), 1.97 (1H, dd, J = 12.0, 
5.6 Hz, H4b), 1.93 (3H, d, J = 1.3 Hz, =C3-CH3), 1.64 (3H, d, J = 1.4 Hz, C8-
CH3), 1.08 (3H, d, J = 6.8 Hz, C6-CH3), 0.91 (9H, s, SiCCH3) and 0.07 (6H, s, 
SiCH3); 13C NMR (100 MHz, CDCl3) δ 168.5, 135.6, 132.8, 126.2, 113.9, 
74.6, 70.3, 52.0, 39.1, 34.2, 31.1, 26.3, 20.9, 16.3, 12.7 and -5.2; HRMS 
(ES+) calc. for C19H40O4SiN ([M+NH4]+) 374.2721, found 374.2721. 
 
(R)-MTPA ester of 157 (171) 
 
TBSO OMe
OOO
CF3Ph
OMe
 
 
To a solution of alcohol 157 (5 mg, 14.0 µmol), DCC (5.9 mg, 38.0 µmol) and 
DMAP (2 mg) in dichloromethane (2.0 mL) at room temperature was added 
(+)-(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (6.5 mg, 38.0 µmol). 
After 6 h, the crude reaction mixture was purified directly by column 
chromatography (19 : 1, hexane : ethyl acetate) to give (R)-MTPA ester 171 
(3.6 mg, 41%). 
 
Rf  0.27 (10%, ethyl acetate : hexane); 1H NMR (400 MHz, CDCl3) δ 7.50-
7.48 (2H, m, Ar-H), 7.43-7.37 (3H, m, Ar-H), 5.75 (1H, q, J = 1.3 Hz, H2), 
5.34 (1H, dq, J = 9.8, 0.6 Hz, H7), 5.06 (1H, dt, J = 7.7, 5.8 Hz, H5), 4.03 (2H, 
s, H9), 3.66 (3H, s, OCH3), 3.48 (3H, d, J = 1.1 Hz, MTPA-OCH3), 2.79-2.77 
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(1H, m, H6), 2.21 (1H, m, H4a), 2.07 (1H, m, H4b), 2.17 (3H, d, J = 1.3 Hz, C3-
CH3), 1.74 (3H, d, J = 1.3 Hz, C8-CH3) and 1.03 (3H, d, J = 6.8 Hz, C6-CH3). 
 
(S)-MTPA ester of 157 (170) 
 
TBSO OMe
OOO
OMePh
CF3
  
 
To a solution of alcohol 157 (5 mg, 14.0 µmol), DCC (5.9 mg, 38.0 µmol) and 
DMAP (2 mg) in dichloromethane (2.0 mL) at room temperature was added 
(+)-(R)-α-methoxy-α-(trifluoromethyl)-phenylacetic acid (6.5 mg, 38.0 µmol). 
After 6 h, the crude reaction mixture was purified directly by column 
chromatography (19 : 1, hexane : ethyl acetate) to give (S)-MTPA ester 170 
(3.7 mg, 43%). 
 
Rf  0.30 (10%, ethyl acetate : hexane); 1H NMR (400 MHz, CDCl3) δ 7.49-
7.47 (2H, m, Ar-H), 7.41-7.37 (3H, m, Ar-H), 5.80 (1H, q, J = 1.1 Hz, H2), 
5.25 (1H, dq, J = 10.1, 0.8 Hz, H7), 5.10-5.07 (1H, m, H5), 3.68 (3H, s, 
OCH3), 3.51 (3H, d, J = 1.2 Hz, MTPA-OCH3), 2.73-2.71 (1H, m, H6), 2.29 
(1H, m, H4a), 2.13 (1H, m, H4b), 2.19 (3H, d, J = 1.3 Hz, C3-CH3), 1.67 (3H, 
d, J = 0.9 Hz, C8-CH3) and 0.94 (3H, d, J = 6.8 Hz, C6-CH3). 
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(2E, 5R, 6R, 7E)-Methyl 9-(para-methoxybenzyl)-5-hydroxy-(3, 6, 8)-
trimethyl-nona-2, 7-dienoate (172) 
 
PMBO
OH
OMe
O
 
 
To a solution of freshly prepared ATPH 163 (3.30 mmol) in toluene (5 mL) at 
-78 °C was added a solution of methyl-3,3-dimethyl acrylate 161 (230 mg, 
2.00 mmol) in toluene (1 mL) and a solution of aldehyde 173 (1.00 mmol) in 
toluene (1 mL) was added. The mixture was stirred for 20 min upon which a 
solution of n-butyl lithium (1.4 mL, 2.2 mmol, 1.6 M in hexane) and 
diisopropylamine (308 µL, 2.2 mmol) in THF (5 mL) was added. After 
30 min at -78 °C, a saturated solution of NH4Cl (8 mL) was added, and the 
mixture was filtered through Celite®. The organic portions were extracted 
with diethyl ether (3 x 10 mL) and the combined organic extracts were dried 
over Na2SO4. The solution was concentrated under reduced pressure and 
purified by column chromatography (14 : 1, hexane : ethyl acetate) to give 
aldol adduct 172 (184 mg, 52% over two steps, α : γ = 1 : 6, d.r = 4 : 1) as a 
colourless oil. 
 
Rf 0.35 (20% ethyl acetate : petroleum ether);  +8.2 (c 1.0 CHCl3); IR 
(thin film) 3475, 2948, 1715, 1644, 1435, 1223, 1059, 950 and 755 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.31 (2H, d, J = 8.7 Hz, Ar-H), 6.91 (2H, d, J = 
8.6 Hz, Ar-H), 5.82 (1H, q, J = 1.2 Hz, H2), 5.09 (1H, dq, J = 10.0, 1.4 Hz, 
H7), 4.49 (2H, s, OCH2PhOMe), 4.03 (2H, s, H9), 3.82 (3H, s, PhOCH3), 3.58 
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(3H, s, OCH3), 3.38-3.32 (1H, m, H5), 2.35-2.29 (1H, m, H6), 2.10 (1H, dd, J 
= 13.4, 2.3 Hz, H4a), 2.04 (3H, d, J = 1.3 Hz, =C3-CH3), 1.86 (1H, dd, J = 
13.7, 8.8 Hz, H4b), 1.61 (3H, d, J = 1.4 Hz, C8-CH3) and 1.01 (3H, d, J = 6.7 
Hz, C6-CH3); 13C NMR (100 MHz, CDCl3) δ 169.2, 159.0, 135.0, 133.9, 
131.1, 128.8, 126.2, 114.3, 113.6, 79.2, 75.1, 74.6, 53.6, 52.0, 39.1, 31.1, 
20.9, 16.3 and 12.7; HRMS (ES+) calc. for C21H34O5N ([M+NH4]+) 380.2431, 
found 380.2428. 
 
(2E, 5R, 6R, 7E)-Methyl 9-(tert-butyldimethylsilyl)oxy-5-
((triethylsilyl)oxy)-(3, 6, 8)-trimethyl-nona-2, 7-dienoate (177) 
 
TBSO
TESO
OMe
O
 
 
To solution of alcohol 157 (300 mg, 841 µmol) in dichloromethane (5 mL) at 
0 °C was added TESCl (228 µL, 1.25 mmol), imidazole (170 mg, 2.45 mmol) 
and DMAP (5.0 mg, 40.0 µmol). The reaction mixture was allowed to warm 
to room temperature then stirred for 16 h and quenched with saturated 
aqueous NH4Cl (5 mL), extracted with dichloromethane (3 x 5 mL) and dried 
over MgSO4.  The resulting solution was concentrated under reduced pressure 
and purified using column chromatography (9 : 1, hexane : ethyl acetate) to 
give silyl enol ether 177 (364 mg, 92%) as a colourless oil. 
 
Rf 0.28 (15% ethyl acetate : petroleum ether);  +19.2 (c 1.0 CHCl3); IR 
(thin film) 2950, 2929, 2850, 1732, 1617, 1435, 1225, 1082, 755 and 725 cm1; 
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1H NMR (400 MHz, CDCl3) δ 5.81 (1H, q, J = 1.3 Hz, H2), 5.22 (1H, dq, J = 
9.9, 1.3 Hz, H7), 4.14-4.08 (1H, m, H5), 4.03 (2H, s, H9), 3.63 (3H, s, OCH3), 
2.79-2.73 (1H, m, H6), 2.27-2.22 (2H, m, H4), 1.96 (3H, d, J = 1.3 Hz, =C3-
CH3), 1.64 (3H, d, J = 1.3 Hz, C8-CH3), 1.13 (3H, d, J = 6.6 Hz, C6-CH3), 
0.96-0.95 (6H, m, Si-(CH2CH3)3), 0.91 (9H, s, Si-C(CH3)3), 0.54-0.48 (9H, m, 
Si-(CH2CH3)3) and 0.07 (6H, s, Si-CH3); 13C NMR (100 MHz, CDCl3) δ 
166.6, 140.7, 132.8, 126.2, 115.6, 74.8, 70.8, 51.3, 46.9, 42.8, 32.0, 25.6, 
18.5, 16.1, 12.8, 7.8, 5.9 and -5.0; HRMS (ES+) calc. for C25H54O4Si2N 
([M+NH4]+) 488.3586, found 488.3581. 
 
(2E, 5R, 6R, 7E)-9-(tert-Butyldimethylsilyl)oxy-5-((triethylsilyl)oxy)-(3, 6, 
8)-trimethyl-nona-2, 7-dien-1-ol (178) 
 
TBSO
TESO
OH
 
 
To a solution of ester 177 (280 mg, 5.94 µmol) in dichloromethane (2 mL) at -
78 °C, was added DIBAL (1.18 mL, 1.18 mmol, 1 M dichloromethane). The 
mixture was stirred for 2 h and quenched with aqueous potassium sodium 
tartrate (5 mL), and the mixture was stirred for a further 4 h. The crude 
product was extracted with diethyl ether (3 x 5 mL), dried over Na2SO4 and 
the solvent was removed under reduced pressure. The crude residue was 
purified using coloumn chromatography (3 : 2, hexane : ethyl acetate) to yield 
alcohol 178 (234 mg, 89%) as a colourless oil.  
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Rf 0.46 (40% ethyl acetate : petroleum ether);  +10.8 (c 0.5 CHCl3); IR 
(thin film) 3418, 2951, 2921, 1457, 1008, 946 and 755 cm-1; 1H NMR (400 
MHz, CDCl3) δ 5.33-5.30 (1H, m, H2), 5.24 (1H, dq, J = 9.9, 1.3 Hz, H7), 
4.14-4.09 (1H, m, H5), 4.00 (2H, s, H9), 3.91 (2H, d, J = 6.8 Hz, H1), 2.81-
2.78 (1H, m, H6), 2.29-2.25 (2H, m, H4), 1.69 (3H, d, J = 1.3 Hz, =C3-CH3), 
1.60 (3H, d, J = 1.2 Hz, C8-CH3), 1.16 (3H, d, J = 6.8 Hz, C6-CH3), 0.95-0.94 
(6H, m, Si-(CH2CH3)3), 0.90 (9H, s, Si-C(CH3)3), 0.58-0.52 (9H, m, Si-
(CH2CH3)3) and 0.05 (6H, s, Si-CH3); 13C NMR (100 MHz, CDCl3) δ 138.9, 
133.8, 125.6, 124.2, 74.1, 71.5, 58.9, 45.9, 37.9, 29.6, 26.1, 18.5, 15.4, 12.1, 
7.3, 5.7 and -5.2; HRMS (ES+) calc. for C24H51O3Si2 ([M+H]+) 443.3371, 
found 443.3368. 
 
(2E, 5R, 6R, 7E)-9-(tert-Butyldimethylsilyl)oxy-5-((triethylsilyl)oxy)-1-
(sulfanyl-1-phenyl-1H-1, 2, 3, 4-tetrazol-5-yl)-(3, 6, 8)-trimethyl-nona-2, 
7-diene (210) 
 
TBSO
TESO
S N
N
NN
 
 
To a solution of alcohol 178 (100 mg, 225 µmol) at 0 ºC in THF 
(2 mL) was added 1-H-mercaptophenyltertrazole (60 mg, 264 µmol), 
triphenylphosphine (82 mg, 302 µmol) followed by DIAD (45 µL, 302 µmol) 
drop-wise. The reaction mixture was warmed up to room temperature and left 
to stir for 2 h before aqueous NH4Cl (2 mL) was added, upon which the 
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resulting mixture was extracted with ethyl acetate (3 x 5 mL), and dried over 
Na2SO4. The solution was concentrated under reduced pressure and purified 
by column chromatography (9 : 1, hexane : ethyl acetate) to give sulfide 210 
(108 mg, 80%) as a colourless oil. 
 
Rf 0.37 (20% ethyl acetate : petroleum ether);  +26.1 (c 0.5 CHCl3); IR 
(thin film) 3042, 2966, 2927, 2875, 1595, 1500, 1385, 1240, 1018, 950, 759, 
755 and 742 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.19-7.17 (2H, m, Ar-H), 
6.90-6.88 (3H, m, Ar-H), 5.29-5.26 (1H, m, H2), 5.19 (1H, dq, J = 9.8, 1.3 Hz, 
H7), 4.10-4.04 (1H, m, H5), 3.99 (2H, s, H9), 3.87 (2H, d, J = 7.2 Hz, H1), 
2.75-2.70 (1H, m, H6), 2.26-2.21 (2H, m, H4), 1.72 (3H, d, J = 1.2 Hz, =C3-
CH3), 1.60 (3H, d, J = 1.2 Hz, C8-CH3), 1.02 (3H, d, J = 7.0 Hz, C6-CH3), 
0.94-0.93 (6H, m, Si-(CH2CH3)3), 0.89 (9H, s, Si-C(CH3)3), 0.56-0.51 (9H, m, 
Si-(CH2CH3)3) and 0.05 (6H, s, Si-CH3); 13C NMR (100 MHz, CDCl3) δ 
154.5, 139.8, 134.1, 133.8, 129.7, 129.6, 125.2, 123.6, 119.8, 74.8, 71.8, 45.8, 
38.2, 31.9, 30.2, 25.5, 16.9, 15.4, 12.2, 7.0, 5.5 and -4.9; HRMS (ES+) calc. 
for C31H55N4O2SSi2 ([M+H]+) 603.3579, found 603.3577. 
 
(2E, 5R, 6R, 7E)-9-(tert-Butyldimethylsilyl)oxy-5-((triethylsilyl)oxy)-1-
(sulfonyl-1-phenyl-1H-1, 2, 3, 4-tetrazole)-(3, 6, 8)-trimethyl-nona-2, 7-
diene (95) 
 
TBSO
TESO
S N
N
NNO
O
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A mixture of ammonium molybdate (33 mg, 26 µmol) and hydrogen peroxide 
(47 µL, 1.2 mmol, 30% v/v) was allowed to stir at 0 ºC for 15 min. Half of the 
resulting yellow solution was added dropwise at 0 ºC to a solution of sulfide 
210 (70 mg, 116 µmol) in ethanol (1 mL). The reaction mixture was stirred 
for 1 h at room temperature before the remaining resultant oxidant was added, 
and stirred for 16 h. The reaction mixture was the diluted with ethanol (1 mL) 
then filtered. The filtrate was portioned between water (1 mL) and 
dichloromethane (2 mL) followed by extraction with dichloromethane (3 x 2 
mL). The organic phases were dried over Na2SO4, filtered and concentrated 
by reduced pressure. Purification by column chromatography (9 : 1, hexane : 
ethyl acetate) provided sulfone 95 (60 mg, 82%) as a colourless oil. 
 
Rf 0.25 (20% ethyl acetate : petroleum ether);  +21.5 (c 0.1 CHCl3); IR 
(thin film) 3049, 2955, 2927, 2870, 1498, 1449, 1354, 1015, 950, 755 and 739 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.74-7.68 (2H, m, Ar-H), 7.63-7.61 (3H, 
m, Ar-H), 5.04-4.98 (1H, m, H2), 4.94-4.88 (1H, m, H7), 4.11-4.06 (2H, m, 
H1), 3.89-3.85 (1H, m, H5), 3.40 (2H, s, H9),  2.84-2.74 (1H, m, H6), 2.58-2.51 
(2H, m, H4), 1.56 (3H, d, J = 1.3 Hz, =C3-CH3), 1.27(3H, d, J = 1.2 Hz, C8-
CH3), 1.01-0.93 (9H, m, C6-CH3 + Si-(CH2CH3)3), 0.90 (9H, s, Si-C(CH3)3), 
0.63-0.56 (9H, m, Si-(CH2CH3)3) and 0.05-0.03 (6H, m, Si-CH3); 13C NMR 
(100 MHz, CDCl3) δ 154.0, 136.8, 134.7, 133.5, 129.7, 129.7, 125.2, 123.9, 
110.0, 74.1, 71.8, 58.7, 45.9, 39.2, 30.7, 25.9, 16.8, 16.0, 12.6, 6.8, 5.2 and -
5.2; HRMS (ES+) calc. for C31H58N5O4SSi2 ([M+NH4]+) 652.3743, found 
652.3741. 
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7.6: Experimental for Chapter 4 
 
 (2E, 4S)-5-(tert-Butyldimethysilyloxy)-2, 4-dimethylpent-2-enal (209)121 
 
OTBSH
O
 
 
Method A: 
Dess-Martin periodinane (7.30 g, 17.2 mmol) was added to a solution of 
alcohol 195 (2.10 g, 8.60 mmol) in dichloromethane (50 mL). The solution 
was stirred for 2.5 h, and quenched with sodium thiosulfate (50 mL). The 
product was extracted with ethyl acetate (3 x 30 mL), and dried over MgSO4. 
The product was purified by filtration through Celite®, to give aldehyde 209 
which was used without further purification. 
 
Method B: 
To a solution of alcohol 195 (2.00 g, 8.18 mmol) in dichloromethane (100 
mL) was added MnO2 (7.10 g, 82.0 mmol) at room temperature. The resulting 
mixture was stirred for 3 h where a further MnO2 (7.10 g, 184.0 mmol) was 
added. After 3 h the mixture was filtered through Celite®, and crude aldehyde 
209 was used without further purification.  
 
Rf 0.39 (10% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
9.40 (1H, s, H1), 6.32 (1H, dq, J = 9.7, 1.3 Hz, H3), 3.59 (1H, dd, J = 9.9, 6.0 
Hz, H5a), 3.54 (1H, dd, J = 9.9, 6.5 Hz, H5b), 2.89 (1H, ddd, J = 12.6, 9.7, 6.6 
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Hz, H4), 1.77 (3H, d, J = 1.4 Hz, =C-CH3), 1.06 (3H, d, J = 6.8 Hz, -CH-
CH3), 0.87 (9H, s, Si-C(CH3)3), 0.04 (3H, s, Si-CH3) and 0.03 (3H, s, Si-CH3). 
 
(2E, 4S)-5-(para-Methoxybenzyl)-2, 4-dimethylpent-2-enal (181)122 
 
OPMBH
O
 
 
Dess-Martin periodinane (1.96 g, 4.63 mmol) was added to a solution of 
alcohol 160 (580 mg, 2.32 mmol) in dichloromethane (30 mL). The solution 
was stirred for 2 h, and quenched with sodium thiosulfate (20 mL). The 
product was extracted with ethyl acetate (3 x 20 mL), and dried over MgSO4. 
The product was purified by filtration through Celite®, and washed with 
excess petroleum ether, to give aldehyde 181 which was used without further 
purification. 
 
Rf 0.70 (20% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
9.33 (1H, s, H1), 7.16 (2H, d, J = 8.7 Hz, CH2-Ar-H), 6.81 (2H, d, J = 8.6 Hz, 
O-Ar-H), 6.27 (1H, dq, J = 13.4, 9.4 Hz, H3), 4.38 (2H, s, O-CH2-Ar), 3.74 
(3H, s, Ar-O-CH3), 3.30–3.37 (2H, m, H5), 2.89–3.00 (1H, m, H4), 1.70 (3H, 
d, J = 1.3 Hz, =C-CH3) and 1.01 (3H, d, J = 6.8 Hz, CH-CH3) 
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(3E, 5S)-6-(tert-Butyldimethysilyloxy)-3,5-dimethyl-3-hexen-1-ynylidene 
(194)123 
 
OTBS
H
 
 
Method A: 
To a solution of dry potassium tert-butoxide (530 mg, 4.75 mmol) in THF 
(20 mL) at -78 °C, was added Gilbert reagent 184 (715 mg, 4.75 mmol) in 
THF (8 mL). After 5 min a solution of crude aldehyde 209 (3.96 mmol) in 
THF (8 mL) was added and the solution was stirred at -78 °C for 16 h, 
followed by 3 h at room temperature. The reaction was quenched with water 
(80 mL), and the product was extracted with dichloromethane (3 x 50 mL), 
washed with brine (50 mL) and dried over MgSO4. The solution was 
concentrated under reduced pressure and the crude residue was purified by 
column chromatography (9 : 1, hexane : ethyl acetate) to afford alkyne 194 
(482 mg, 51% over two steps) as a colourless oil which was used immediately 
in the following reaction. 
 
Method B: 
A solution of dimethyl (1-diazo-2-oxopropyl)-phosphonate 190 (2.10 g, 
10.8 mmol), crude aldehyde 209 (3.60 mmol) and Cs2CO3 (4.80 g, 14.4 
mmol) in methanol (30 mL) was stirred at 0 ºC for 1 h, then at room 
temperature for 16 h. The reaction mixture was quenched with saturated 
aqueous NH4Cl (40 mL) and extracted with diethyl ether (3 x 40 mL). The 
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organic phase was dried with Na2SO4. Evaporation of the solvent under 
reduced pressure followed by column chromatography (9 : 1, hexane : ethyl 
acetate) yielded alkyne 194 (590 mg, 69% over two steps) as a colourless oil 
which was used immediately in the following reaction. 
 
Rf 0.61 (20% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
5.20 (1H, dq, J = 9.1, 1.4 Hz, H4), 4.00 (1H, s, H1), 3.49-3.35 (2H, m, H6), 
2.64–2.54 (1H, m, H5), 1.70 (3H, d, J = 1.4 Hz, =C-CH3), 0.97 (3H, d, J = 6.7 
Hz, -C-CH3), 0.90 (9H, s, Si-C(CH3)3) and 0.05 (6H, s, 2 x Si-CH3). 
 
(3E, 5S)-6-(para-Methoxybenzyl)-3, 5-dimethyl-3-hexen-1-ynylidene (182) 
 
OPMB
H
 
 
Method A: 
To a solution of dry potassium tert-butoxide (300 mg, 2.41 mmol) in THF 
(10 mL) at -78 °C, was added Gilbert reagent 184 (520 mg, 2.41 mmol) in 
THF (4 mL). After 5 min a solution of crude aldehyde 181 (2.0 mmol) in THF 
(4 mL) was added and the solution was stirred at -78 °C for 16 h, followed by 
3 h at room temperature. The reaction was quenched with water (50 mL), and 
the product was extracted with dichloromethane (3 x 20 mL), washed with 
brine (50 mL) and dried over MgSO4. The solution was concentrated under 
reduced pressure and the crude residue was purified by column 
chromatography (9 : 1, hexane : ethyl acetate) to afford alkyne 182 (150 mg, 
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32% over two steps) as a colourless oil which was used immediately in the 
following reaction. 
 
Method B: 
A solution of dimethyl (1-diazo-2-oxopropyl)-phosphonate 190 (1.10 g, 
5.70 mmol), aldehyde 181 (1.90 mmol) and Cs2CO3 (2.50 g, 7.60 mmol) in 
methanol (15 mL) was stirred at 0 ºC for 1 h, then at room temperature for 
16 h. The reaction mixture was quenched with saturated aqueous NH4Cl 
(20 mL) and extracted with diethyl ether (3 x 20 mL). The organic phase was 
dried with Na2SO4. Evaporation of the solvent followed by column 
chromatography (9 : 1, hexane : ethyl acetate) yielded the alkyne 182 (270 
mg, 58% over two steps) as a colourless oil which was used immediately in 
the following reaction. 
 
Rf 0.16 (20% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
7.27 (2H, d, J = 8.6 Hz, CH2-Ar-H), 6.83 (2H, d, J = 8.6 Hz, O-Ar-CH), 5.16 
(1H, dq, J = 9.2, 1.3 Hz, H3), 4.36 (2H, s, O-CH2-Ar), 3.86 (1H, s, H6), 3.70 
(3H, s, O-CH3), 3.25-3.14 (2H, m, H1), 2.69–2.62 (1H, m, H2), 1.61 (3H, d, J 
= 1.4 Hz, Me4) and 0.91 (3H, d, J = 6.7 Hz, Me2). 
 
(1E, 3E, 5S)-6-(tert-Butyldimethysilyloxy)-1-iodo-3, 5-dimethyl-1, 3-
hexadiene (193) 
 
OTBSI
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Method A: 
In a dark environment at room temperature, a solution of alkyne 194 (200 mg, 
850 µmol) in THF (7 mL) and PdCl2(PPh3)2 (33.0 mg, 43.0 µmol) was 
prepared. The mixture was stirred for 2 h and Bu3SnH (520 µL, 1.10 mmol) 
was added drop wise. The mixture was stirred for 10 min then concentrated 
under reduced pressure. Dichloromethane (8 mL) was added and the mixture 
was cooled to -78 °C, prior to the addition of a solution of iodine (400 mg) in 
dichloromethane (2 mL). After 10 min, the solution was warmed to room 
temperature and stirred for a further 2 h. The solution was concentrated under 
reduced pressure, and the crude material 193 was directly subjected to TBAF 
deprotection. 
 
Method B: 
In a dark environment a solution of crude aldehyde 209 (4.10 mmol) and 
iodoform (4.80 g, 12.3 mmol) in dioxane (100 mL) was added to a solution of 
CrCl2 (5.10 g, 41.0 mmol) in THF (100 mL) at room temperature. The 
reaction was left stirring for 16 h, upon which aqueous NaHCO3 (300 mL) 
was added and this mixture was filtered through Celite®. The product was 
then extracted with ethyl acetate (3 x 200 mL), dried over Na2SO4 and the 
crude material 193 was directly subjected to TBAF deprotection. 
 
Rf 0.76 (10% ethyl acetate/Hexanes); 1H NMR (400 MHz, CDCl3) δ 7.03 
(1H, d, J = 14.6 Hz, H2), 6.15 (1H, d, J = 14.6 Hz, H1), 5.27 (1H, d, J = 9.5 
Hz, H4), 3.45-3.41 (2H, m Hz, H6), 2.64 (1H, m, H5), 1.74 (3H, d, J = 1.3 Hz, 
=C-CH3), 0.97 (3H, d, J = 6.7 Hz, -CH-CH3), 0.88 (9H, s, Si-C(CH3)3), 0.03 
 
192 
(3H, s, Si-CH3) and 0.02 (3H, s, Si-CH3). 
 
(1E, 3E, 5S)-6-(para-Methoxybenzyl)-1-iodo-3, 5-dimethyl-1, 3-hexadiene 
(191) 
 
OPMBI
 
 
In a dark environment at room temperature, a solution of alkyne 182 (400 mg, 
1.60 mmol) in THF (10 mL) and PdCl2(PPh3)2 (68.0 mg, 97.0 µmol) was 
prepared. The mixture was stirred for 5 min and Bu3SnH (1.0 mL, 3.8 mmol) 
was added dropwise. The mixture was stirred for 10 min then concentrated 
under reduced pressure. Dichloromethane (10 mL) was added and the mixture 
was cooled to -78 °C, prior to the addition of a solution of iodine (820 mg) in 
dichloromethane (5 mL). After 10 min, the solution was warmed to room 
temperature and stirred for a further 10 min. The solution was concentrated 
under reduced pressure, and the crude material 191 was directly subjected to 
DDQ deprotection. 
 
Rf 0.54 (10% ethyl acetate : petroleum ether); 1H NMR (300 MHz, CDCl3) δ 
7.20 (2H, d, J = 8.6 Hz, ArH), 7.15 (1H, d, J = 14.7 Hz, H2), 6.83 (2H, d, J = 
8.6 Hz, ArH), 6.76 (1H, d, J = 14.7 Hz, H1), 5.13 (1H, dq, J = 9.2, 1.3 Hz, 
H4), 4.36 (2H, s, OCH2Ar), 3.70 (3H, s, OCH3), 3.25-3.14 (2H, m, H6), 2.69–
2.62 (1H, m, H5), 1.61 (3H, d, J = 1.3 Hz, =CCH3) and 0.91 (3H, d, J = 6.7 
Hz, CHCH3). 
 
 
193 
(1E, 3E, 5S)-1-Iodo-3, 5-dimethyl-1, 3-hexadiene-6-ol (192) 
 
OHI
 
 
Method A: 
TBAF (8.20 mL, 8.20 mmol, 1 M in THF) was added slowly to a solution of 
TBS-protected vinyl iodide 193 (4.10 mmol) in THF (30 mL) at 0 ºC. After 
2 h the reaction mixture was quenched with saturated aqueous NH4Cl (30 
mL), extracted with ethyl acetate (3 x 30 mL) and dried over MgSO4. The 
resulting solution was concentrated under reduced pressure and purified by 
column chromatography (19 : 1, hexane : ethyl acetate) to yield alcohol 192 
(860 mg, 83%) as a pale yellow oil. 
 
Method B: 
To a solution of PMB ether 191 (530 µmol) in dichloromethane (5 mL) and 
pH 7 buffer (0.5 mL) at 0 °C, was added DDQ (240 mg, 1.06 mmol). The 
solution was stirred for 2 h and quenched with NaHCO3 (100 mL), extracted 
with dichloromethane (3 x 30 mL and dried over MgSO4. The solution was 
concentrated under reduced pressure and purified by column chromatography 
(19 : 1, hexane : ethyl acetate) to yield alcohol 192 (64.0 mg, 79%) as a as a 
pale yellow oil. 
 
Rf 0.30 (10% ethyl acetate/Hexane);  +40.8 (c 0.7, CHCl3); IR (thin 
film) 3374, 2959, 2926, 2870, 1726, 1707, 1451, 1178, 1035, 1018, 960 and 
752 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.06 (2H, dd, J = 14.7, 0.8 Hz, H2), € 
[α]D20
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6.22 (1H, dd, J = 14.7, 0.6 Hz, H1), 5.27 (1H, dt, J = 9.6, 0.6 Hz, H4), 3.55-
3.49 (1H, m, H6a), 3.44-3.39 (1H, m, H6b), 2.78-2.67 (1H, m, H5), 1.78 (3H, d, 
J = 1.3 Hz, =C-CH3) and 0.98 (3 H, d, J = 6.7 Hz, -CH-CH3); 13C NMR (101 
MHz, CDCl3) δ 149.6, 136.5, 136.0, 74.5, 67.6, 35.7, 16.8 and 12.5; HRMS 
(ES+) calc. for C8H14IO [M+H]+ 253.0084, found 253.0079. 
 
(1E, 3E, 5S)-1-Iodo-3, 5-dimethyl-1, 3-hexadiene-6-al (179) 
 
H
O
I
 
 
Dess-Martin periodinane (1.00 g, 2.38 mmol) was added to a solution of 
alcohol 192 (300 mg, 1.20 mmol) in dichloromethane (5 mL). The solution 
was stirred for 2.5 h, and quenched with sodium thiosulfate (5 mL). The 
product was extracted with dichloromethane (3 x 5 mL), and dried over 
MgSO4. The product was purified by filtration through Celite®, and washed 
with excess dichloromethane, which was removed under vacuo, to give crude 
aldehyde 179 that was used without further purification. 
 
Rf 0.47 (10% ethyl acetate : petroleum ether); 1H NMR (400 MHz, C6D6) δ 
9.05 (1H, d, J = 1.6, H6), 6.81 (1H, dd, J = 14.7, 0.8 Hz, H2), 5.91 (1H, dd, J = 
14.7, 0.6 Hz, H1), 4.73 (1H, ddt, J = 9.2, 1.3, 0.7 Hz, H4), 2.69 (1H, ddd, J = 
9.0, 7.1, 1.8 Hz, H5), 1.19 (3H, d, J = 1.3 Hz, =C-CH3) and 0.79 (3H, d, J = 
6.9 Hz, =CH-CH3). 
 
 
195 
(1E, 3E, 5R, 6R, 8E)-Methyl 6-hydroxy-1-iodo-3, 5, 8-trimethyldeca-2, 3, 
8-trienoate (180)22a,124 
 
OH
OMeI
O
 
 
To a solution of ATPH 163 (3.95 mmol) in toluene (3 mL) at -78 °C was 
added a solution of methyl-3,3-dimethyl acrylate 161 (270 mg, 2.38 mmol) in 
toluene (1 mL); after 15 min a solution of crude aldehyde 180 (1.20 mmol) in 
toluene (1 mL) was added. The mixture was stirred for 20 min upon which a 
solution of n-butyl lithium (1.65 mL, 2.62 mmol, 1.6 M in hexane) and 
diisopropylamine (365 µL, 2.62 mmol) in THF (3 mL) was added. After 30 h 
at -78 °C, a saturated solution of NH4Cl (5 mL) was added, and the mixture 
was filtered through Celite® and washed with diethyl ether. The organic 
portions were extracted with diethyl ether (3 x 5 mL) and the combined 
organic extracts were dried over Na2SO4. The solution was concentrated 
under reduced pressure and purified by column chromatography (14 : 1, 
hexane : ethyl acetate) to give aldol adduct 180 (220 mg, 51% over two steps, 
α : γ = 1 : 7, d.r. = 3 : 1) as a pale yellow oil. 
 
Rf 0.26 (10% ethyl acetate : petroleum ether);  +17.7 (c 1.0, CHCl3); IR 
(thin film) 3475, 2948, 1715, 1644, 1435, 1223, 1151, 1059 and 950 cm-1; 1H 
NMR (400 MHz, C6D6) δ 6.92 (1H, dd, J = 14.7, 0.8 Hz, H2), 5.91 (1H, dd, J 
= 14.7, 0.7 Hz, H1), 5.80 (1H, dd, J = 2.1, 1.2 Hz, H9), 4.89 (1H, d, J = 10.0 
Hz, H4), 3.44 (3H, s, OCH3), 3.16-3.23 (1H, m, H6), 2.21-2.11 (1H, m, H5), 
€ 
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2.18 (H, d, J = 1.2 Hz, C8-CH3), 1.95 (1H, dd, J = 13.6, 2.3 Hz, H7a), 1.75 
(1H, dd, J = 13.6, 9.8 Hz, H7b), 1.31 (3H, d, J = 1.2 Hz, C3-CH3) and 0.87 
(3H, d, J = 6.7 Hz, C5-CH3); 13C NMR (100 MHz, C6D6) δ 166.6, 157.2, 
149.8, 136.5, 134.8, 118.1, 74.7, 73.1, 50.6, 46.7, 39.4, 19.0, 16.2 and 12.1; 
HRMS (ES+) calc. for C14H25IO3N [M+NH4]+ 382.0874, found 382.0869. 
 
(1E, 3E, 5R, 6R, 8E)-Methyl 6-((triethylsilyl)oxy)-1-iodo-3, 5, 8-
trimethyldeca-2, 3, 8-trienoate (196)22a,124 
 
TESO
OMeI
O
 
 
To solution of alcohol 180 (175 mg, 480 µmol) in dichloromethane (3 mL) at 
room temperature was added TESCl (105 mg, 705 µmol), imidazole (100 mg, 
1.48 mmol) and DMAP (6.0 mg). The reaction mixture was stirred for 16 h 
and quenched with saturated aqueous NH4Cl (3 mL), extracted with 
dichloromethane (3 x 5 mL) and dried over MgSO4.  The resulting solution 
was concentrated under reduced pressure and purified using column 
chromatography (9 : 1, hexane : ethyl acetate) to give silyl enol ether 196 (198 
mg, 87%) as a pale yellow oil. 
 
Rf 0.69 (10% ethyl acetate : petroleum ether);  +33.6 (c 0.5, CHCl3); IR 
(thin film) 2953, 2911, 2876, 1720, 1647, 1435, 1223, 1150, 1087, 1008, 739 
and 725 cm-1; 1H NMR (400 MHz, C6D6) δ 7.02 (1H, dd, J = 14.6, 0.7 Hz, 
H2), 5.93 (1H, d, J = 14.6 Hz, H1), 5.87 (1H, q, J = 1.1 Hz, H9), 5.12 (1H, dd, 
€ 
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J = 9.7, 0.4 Hz, H4), 3.64 (1H, dt, J = 6.6, 5.4 Hz, H6), 3.44 (3H, s, OCH3), 
2.46-2.39 (1H, m, H5), 2.25 (3H, d, J = 1.3 Hz, C8-CH3), 2.10-2.08 (1H, td, J 
= 6.10, 0.95 Hz, H7a), 2.07 (1 H, d, J = 0.8 Hz, H7b), 1.36 (3H, d, J = 1.2 Hz, 
C3-CH3), 0.96 (6H, m, Si-(CH2CH3)3), 0.89 (3H, d, J = 6.8 Hz, C5-CH3), 0.56 
(9H, m, Si-(CH2CH3)3); 13C NMR (100 MHz, C6D6) δ 166.6, 156.5, 149.9, 
137.2, 134.4, 118.7, 74.7, 74.5, 50.6, 46.9, 38.5, 19.5, 15.6, 12.1, 7.2 and 5.6; 
HRMS (ES+) calc. for C20H39IO3SiN [M+NH4]+ 496.1738, found 496.1734. 
 
(1E, 3E, 5R, 6R, 8E)-6-((Triethylsilyl)oxy)-1-iodo-3, 5, 8-trimethyldeca-2, 
3, 8-trien-1-ol (197)22a,124 
 
TESO
OHI
 
 
To a solution of ester 196 (160 mg, 345 µmol) in dichloromethane (2 mL) at -
78 °C, was added DIBAL (690 µL, 690 µmol, 1 M in dichloromethane). The 
mixture was stirred for 2 h and quenched with aqueous potassium sodium 
tartrate (5 mL) was added, and the mixture was stirred for a further 4 h. The 
crude product was extracted with diethyl ether (3 x 5 mL), dried over Na2SO4 
and the solvent was removed under reduced pressure. The crude residue was 
purified using column chromatography (4 : 1, hexane : ethyl acetate) to yield 
alcohol 197 (127 mg, 81%) as a as a pale yellow oil.   
 
Rf 0.29 (20% ethyl acetate : petroleum ether);  +18.5 (c 0.7, CHCl3); IR 
(thin film) 3342, 2955, 2911, 1457, 1003, 948, 744 and 725 cm-1; 1H NMR 
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(400 MHz, C6D6) δ 7.07 (1H, dd, J = 14.6, 0.8 Hz, H2), 5.93 (1H, dd, J = 14.6, 
0.6 Hz, H1), 5.38 (1H, ddd, J = 7.8, 5.4, 1.2 Hz, H9), 5.27 (1H, d, J = 9.8 Hz, 
H4), 3.94 (2H, d, J = 6.8 Hz, H10), 3.70-3.64 (1H, m, H6), 2.52-2.48 (1H, m, 
H5), 2.14 (2H, qd, J = 13.6, 6.2 Hz, H7), 1.51 (3H, d, J = 0.7 Hz, C8-CH3), 
1.41 (3H, d, J = 1.3 Hz, C3-CH3), 1.01-0.97 (6H, m, Si-(CH2CH3)3 + C5-CH3) 
and 0.58 (9H, m, Si-(CH2CH3)3); 13C NMR (100 MHz, C6D6) δ 150.0, 138.3, 
135.0, 133.9, 129.0, 74.7, 74.2, 59.3, 45.9, 37.8, 16.9, 15.1, 12.1, 7.3 and 5.6; 
HRMS (ES+) calc. for C19H39IO2SiN [M+NH4]+ 468.1789, found 468.1787. 
 
(1E, 3E, 5R, 6R, 8E)-6-((Triethylsilyl)oxy)-1-iodo-10-(sulfanyl-1-phenyl 
1H-1, 2, 3, 4-tetrazol-5-yl) 3, 5, 8-trimethyldeca-2, 3, 8-triene (210)22a,124 
 
TESO
S N
N
NN
I
 
 
To a solution of alcohol 197 (80 mg, 176 µmol) at 0 ºC in THF (2 mL) was 
added 1-H-mercaptophenyltertrazole (42 mg, 232 µmol), triphenylphosphine 
(61 mg, 232 µmol) followed by DIAD (32 µL, 232 µmol) dropwise. The 
reaction mixture was warmed up to room temperature and left to stir 2 h 
before aqueous NH4Cl (5 mL) was added, upon which the resulting mixture 
was extracted with ethyl acetate (3 x 5 mL), and dried over Na2SO4. The 
solution was concentrated under reduced pressure and purified by column 
chromatography (19 : 1, hexane : ethyl acetate) to give sulfide 210 (84 mg, 
79%) as a pale yellow oil. 
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Rf 0.54 (10% ethyl acetate : petroleum ether);  +58.5 (c 1.0, CHCl3); IR 
(thin film) 3068, 2955, 2911, 2875, 1597, 1500, 1384, 1234, 1092, 1015, 950, 
759, 742 and 725 cm-1; 1H NMR (400 MHz, C6D6) δ 7.19-7.17 (2H, m, Ar-
H), 7.05 (1H, dd, J = 14.6, 0.7 Hz, H2), 6.93-6.87 (3H, m, Ar-H), 5.95 (1H, 
dd, J = 14.6, 0.5 Hz, H1), 5.37 (1H, td, J = 7.9, 1.1 Hz, H9), 5.22 (1H, dt, J = 
9.8, 0.5 Hz, H4), 3.90 (2H, dq, J = 14.6, 7.9 Hz, H10), 3.62 (1H, dt, J = 6.2, 4.7 
Hz, H6), 2.46-2.240 (1H, m, H5), 2.07 (2H, ddt, J = 20.2, 13.9, 6.6 Hz, H7), 
1.58 (3H, d, J = 1.3 Hz, C8-CH3), 1.40 (3H, d, J = 1.2 Hz, C3-CH3), 0.96 (6H, 
m, Si-(CH2CH3)3), 0.92 (3H, d, J = 6.8 Hz, C5-CH3) and 0.58-0.53 (9H, m, Si-
(CH2CH3)3); 13C NMR (100 MHz, C6D6) δ 154.1, 150.0, 139.8, 138.0, 134.3, 
134.0, 129.6, 123.9, 120.8, 74.5, 74.3, 45.8, 37.7, 31.6, 16.9, 15.0, 12.1, 7.3 
and 5.6; HRMS (ASAP) calc. for C26H40ION4SSi [M+H]+ 611.1731, found 
611.1729. 
 
(1E, 3E, 5R, 6R, 8E)-6-((Triethylsilyl)oxy)-1-iodo-10-(sulfonyl-1-phenyl -
1H-1, 2, 3, 4-tetrazol-5-yl) 3, 5, 8-trimethyldeca-2, 3, 8-triene (93)22a,124 
 
TESO
S N
N
NNO
O
I
 
 
A mixture of ammonium molybdate (20 mg, 15.0 µmol) and hydrogen 
peroxide (25 µL, 650 µmol, 30% v/v) was allowed to stir at 0 ºC for 15 min. 
Half of the resulting yellow solution was added dropwise, at 0 ºC, to a 
solution of sulfide 210 (40 mg, 65 µmol) in ethanol (1 mL). The reaction 
€ 
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mixture was stirred for 1 h at room temperature before the remaining resultant 
oxidant was added, and stirred for 16 h. The reaction mixture was the diluted 
with ethanol (1 mL) then filtered. The filtrate was portioned with water (1 
mL) then extracted with dichloromethane (3 x 1 mL). The organic phases 
were dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification by column chromatography (19 : 1, hexane : ethyl acetate) 
provided sulfone 93 (33 mg, 78%) as a as a pale yellow oil. 
 
Rf 0.41 (10% ethyl acetate : petroleum ether);  +33.6 (c 0.5, CHCl3); IR 
(thin film/) 3069, 2955, 2925, 2875, 1498, 1461, 1343, 1156, 1107, 1015, 950, 
761 and 739 cm-1; 1H NMR (400 MHz, C6D6) δ 7.33-7.26 (2H, m, Ar-H), 
7.05 (1H, dd, J = 14.6, 0.8 Hz, H2), 6.87-6.85 (3H, m, Ar-H), 5.94 (2H, dd, J 
= 14.6, 0.5 Hz, H1), 5.29 (1H, td, J = 7.9, 0.9 Hz, H9), 5.22 (1H, d, J = 9.3 Hz, 
H4), 4.08 (2H, dd, J = 7.9, 3.0 Hz, H10), 3.63 (1H, td, J = 6.5, 4.1 Hz, H6), 
2.38-2.35 (1H, m, H5), 2.10 (1H, dd, J = 13.6, 6.9 Hz, H7a), 2.01 (1H, dd, J = 
13.6, 6.1 Hz, H7b), 1.50 (3H, d, J = 1.2 Hz, C8-CH3), 1.39 (3H, d, J = 1.2 Hz, 
C3-CH3), 1.01-0.89 (6H, m, Si-(CH2CH3)3), 0.86 (3H, d, J = 6.7 Hz, C5-CH3) 
and 0.60-0.48 (9H, m, Si-(CH2CH3)3); 13C NMR (100 MHz, C6D6) δ 154.0, 
149.8, 146.8, 136.6, 134.8, 133.5, 131.0, 129.4, 125.4, 111.0, 74.6, 72.6, 56.2, 
45.9, 39.2, 17.0, 16.3, 12.1, 7.2 and 6.9; HRMS (ES+) calc. for 
C26H43IO3N5SSi [M+NH4]+ 660.1895, found 660.1893. 
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